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Chapter 1
General introduction & outline of the thesis
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Head and neck squamous cell carcinoma (HNSCC) originates from mucosal surfaces of the upper 
aerodigestive tract and is the sixth most appearing type of cancer worldwide with approximately 
600,000 arising cases each year [1]. The development of new therapeutic strategies are hampered 
by its effective local invasion in functionally delicate areas. This local invasion is directly associ-
ated with high incidences of positive resection margins and poor prognosis of the patient [2]. 
Consequently, despite recent development in cancer treatment, only 40-50% of HNSCC patients 
worldwide survive longer than 5 years. Thus, to improve cancer treatment, it is of importance to 
understand what drives tumor cell invasion in HNSCC.
Infiltrating tumor cells migrate either individually without cell-cell interactions to neighboring 
cells [3] or collectively as cohesive groups when cell-cell junctions remain intact [4]. Collective 
cell migration is the dominant migration type in epithelial tumors such as HNSCC, but both cell 
migration types have been identified in reconstructions of HNSCC samples [5].
Independent of the migration type, cancer invasion occurs in close interaction with the local 
tissue environment surrounding the tumor cells including growth factors and cytokines secreted 
by stromal cells, oxygen supply and the composition of the extracellular matrix (ECM) [6]. These 
influences drive cancer invasion by acting on the cell-intrinsic properties, likely under the control 
of transcriptional programs such as the epithelial-to-mesenchymal transition (EMT) [7]. Poten-
tially, they force the cell to adapt to the environment, causing an interconversion of the tumor cell 
dissemination strategies. The ability of cells to change their mechanism of movement is termed 
plasticity [8]. However, how plasticity is spatiotemporally controlled upon challenge by the tumor 
microenvironment and whether inhibiting these factors can inhibit the plasticity progress remains 
unclear.
Chapter 2 provides an overview on growth factors and cytokines and their effects on tumor cell 
migration. By regulating cell-matrix and cell-cell adhesions, cytoskeletal dynamics and extracel-
lular matrix remodeling, growth factors and cytokines control the reciprocal interactions between 
tumor cells and their microenvironment. In addition, consequences for the plasticity of invasion 
programs and metastasis are discussed.
Growth factors are often used at one concentration to stimulate migration in a 2D model system, 
which may miss potential concentration-dependent effects on cell migration and the role of the 
3D environment. Fibroblasts, as part of the tumor stroma, secrete growth factors and cytokines 
including hepatocyte growth factor (HGF) which induces collective as well as single cell migration. 
An example of growth factor-induced tumor cell migration plasticity is described in Chapter 
3. Besides inducing migration, fibroblast-conditioned medium is able to cause a concentration-
dependent switch in migration mode, which is recapitulated by single growth factors. To 
complement biochemical analysis of entire cell populations, a novel 3D single-cell cytometry was 
developed to detect molecular markers of the EMT in tumor cell subsets. The data show EMT 
markers randomly expressed with an increasing trend in migrating cells, thus connecting EMT 
with both collective and single-cell migration modes.
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Current treatment of HNSCC includes surgery, radiotherapy and/or systemic therapy. Primary 
surgery and radiotherapy (with or without addition of systemic therapy) are the most important 
treatment modalities in curative intent treatment. Additional treatment after surgical resection is 
often required since surgery often fails to remove the tumor completely [9]. Neurovascular and 
other tissue structures provide tumor cells with abundant cues to migrate along and infiltrate 
the tissue which is often non-destructive and subclinical. Thus, regions of deep tissue invasion 
are difficult if not impossible to detect macroscopically and thereby typically escape surgical re-
moval [10]. As further confounding parameter, surgery is often performed with strict precaution 
to minimize a loss of vital structures which are required for delicate functions such as tasting, 
swallowing and speaking, causing the risk of residual disease post-surgery. As a consequence, 
choosing the resection margin represents a compromise between loss of function of the tissue 
and complete tumor removal [11]. Strategies to detect tumor invasion include advanced imaging 
such as MRI, which assists the surgeon by providing information about discriminating tumor 
from non-tumorous normal tissue. As complementary approach to MRI, molecular imaging by 
optical near-infrared fluorescence (NIRF) using fluorescent molecular probes to target cancer le-
sions shows promise to visualize tumor lesions intraoperatively with potential for high sensitivity 
and selectivity [12]. Advantage of NIRF (700-900 nm) include high tissue penetration to several 
millimeters and low auto-fluorescence, thereby providing sufficient contrast [13]. In addition, NIR 
light does not alter the surgical field since it is insensitive to the human eye and several imaging 
systems have recently become available [14]. During fluorescence-guided surgery (FGS), antibod-
ies with tumor selectivity, conjugated with a near-infrared fluorophore, are injected intravenously, 
accumulate in the lesion and can be visualized using an intra-operative imaging system [15]. 
Thereby, tumor regions can potentially be detected and resected more accurately and completely.
The identification of epitopes with an expression preferably restricted to the invasion zone is 
pertinent to selectively visualize this tumor region in HNSCC. In Chapter 4, a literature survey 
is performed and potential antigens (over-)expressed in HNSCC are tested to identify a reliable 
epitope in HNSCC which can be used for FGS. Furthermore, the technique of FGS is assessed in a 
new developed invasive HNSCC mouse model using a monoclonal antibody conjugated to a NIR 
fluorescence dye. Together, the data identified CD44v6 as a robust epitope present in invasion 
zones and the accumulation in the preclinical tumor model using a NIR-fluorescent CD44v6 tar-
geting antibody outperforms EGFR, the currently clinically explored detection epitope in HNSCC.
For early stage laryngeal as well as oropharyngeal and hypopharyngeal squamous cell carcinomas, 
carbon dioxide (CO2) laser surgery has become an established treatment modality, which enables 
precise resection margins and low complication rates [16, 17]. However, for combining laser sur-
gery with fluorescence guidance, high-power lasers may bleach fluorophores and extinguish the 
signal. Thereby it is uncertain whether CO2 laser surgery can be effectively combined with FGS.
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In Chapter 5, in vitro analyses on combining CO2 laser treatment on fluorescent tumor models 
show that laser-induced photo-bleaching is negligible since its signal is below the extent of col-
lateral thermal damage.
As summary, Chapter 6 discusses the relevance of cell invasion strategies for local tumor cell 
dissemination, the challenges of tumor cell migration plasticity on cancer treatment and perspec-
tives for targeting cancer invasion.
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Tumor cell migration, the basis for metastatic dissemination, is an adaptive process which depends 
upon coordinated interaction with the environment, influencing cell-matrix and cell-cell adhesion, 
cytoskeletal dynamics and extracellular matrix remodeling. Growth factors and cytokines, released 
within the reactive tumor microenvironment, and their intracellular effector signals strongly 
impact mechanocoupling functions in tumor cells and thereby control the mode and extent of 
tumor invasion, including collective and single-cell migration, and their interconversions. Besides 
their role in controlling tumor cell growth and survival, cytokines and growth factors thus provide 
complex orchestration of the metastatic cascade and tumor cell adaptation to environmental 
challenge. We here review the mechanisms by which growth factors and cytokines control the 
reciprocal interactions between tumor cells and their microenvironment, and the consequences 
for the efficacy and plasticity of invasion programs and metastasis.
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InTRODuCTIOn
Tumor invasion and resulting metastatic dissemination account for major morbidity and mortality 
of cancer, through the remodeling, malfunction and eventually destruction of tissues and organs. 
During metastatic dissemination, tumor cell invasion can employ a range of interconvertible mi-
gration strategies, including mesenchymal or amoeboid single migration or collective movements 
[1-4]. Mesenchymal migration, characterized by fibroblast-like elongation and spindle-shaped 
morphologies, depends upon integrin-mediated cell-matrix interactions and proteolytic remodel-
ing of the extracellular matrix (ECM), whereby cell movement and matrix remodeling form an 
integrated program [5, 6]. Amoeboid migration primarily serves cell position change without 
tissue remodeling, whereby cells lack focal adhesions, intracellular multiprotein assemblies con-
necting integrin adhesion receptors with the actin cytoskeleton, but move by low adhesion force 
and high cell deformability and maintain largely rounded, ellipsoid morphology [1, 7]. Collective 
migration occurs when cells retain cell-cell adhesions and multicellular coordination and move as 
multicellular clusters, sheets or strands [2, 3, 8].
These basic migration programs can adapt and interconvert in response to a range of cell-intrinsic 
and extracellular triggers and signals, which control cell-cell and cell matrix interactions and the 
organization of the cytoskeleton [9]. The transition between mesenchymal and amoeboid cell 
migration modes depend upon the balance between Rac and Rho signaling and signals which 
control the strength of cell-matrix interactions [9, 10]. Likewise, individual and collective migra-
tion modes are interconvertible, when junctions between cells dissociate or reform again [11, 
12]. Consequently, based on engaged cell adhesion and signaling programs, most solid tumor 
cells use both, collective as well as single cell migration mechanisms in an adaptive manner, as 
suggested by human pathology and intravital imaging studies [13].
Growth factors and cytokines released by the tumor microenvironment and tumor cells them-
selves represent central extracellular triggers which control these migration programs and thus 
regulate adaptive invasion strategies. They act in an autocrine, paracrine or endocrine fashion 
to orchestrate central cell functions, which besides cell migration further include proliferation, 
differentiation and apoptosis [14]. Growth factor and cytokine receptors, such as the epidermal 
growth factor (EGF) receptor, are found to be upregulated in invasive compared to non-invasive 
tumors, often at the invasive borders of tumors, indicating a link between growth factor signaling 
and tumor cell invasion [15, 16]. In response to receptor activation, multiple signaling pathways 
are engaged in a time- and space-controlled manner, including phosphoinositide 3-kinase (PI3K)/
Akt, Mitogen-activated protein kinases (MAPK), Janus kinase (JAK)/Signal Transducer and Activa-
tor of Transcription (STAT), Smad and small RhoGTPase signaling (Figure 1), among others, which 
cooperate and jointly define the response type, including cell migration [17, 18]. Cytokines and 
growth factors regulate the function of both tumor cells and non-transformed stromal cells, and 
induce integrated responses in both the tumor and surrounding tissue. Their function in the 
induction of proliferation, survival and cell migration is well established, including directionality, 
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efficiency, and the crossing of tissue boundaries for metastatic evasion [15, 19], yet the multiple 
roles of growth factors and cytokines in controlling tumor cell adhesion and cytoskeletal kinetics 
as well as the multiple roles in defining cellular programs to secrete and remodel extracellular 
matrix generates complex changes in both the tumor cell and the tumor stroma. Here, we review 
by which mechanisms growth factors and cytokines induce and direct tumor cell migration and 
discuss how they cooperate to induce plasticity and adaptation of cancer cell invasion and meta-
static dissemination.
GROwTh faCTOR anD CyTOkIne ReGulaTIOn Of Cell aDheSIOn
Growth factor and cytokine induced signals modulate cell-matrix and cell-cell adhesion and 
thereby control substrate specificity, cell polarity and differentiation as well as the ability to 
migrate.
figure 1 Signaling pathways involved in migration control. Growth factors and cytokines bind to either G 
protein-coupled receptors (GPCRs), cytokine receptors or receptor tyrosine kinases (RTKs) which can interact 
with integrins or cadherins. Subsequently, one or more signaling pathways are induced, driving integrated 
cell functions, including survival and proliferation in addition to migration regulation by influencing cell-matrix 
and cell-cell adhesion, cytoskeletal dynamics and the extracellular matrix (ECM) structure. Color codes denote 
downstream pathways that preferentially associate with migration or proliferation and/or survival.
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Cell-matrix adhesion
During adhesive cell migration integrins are the major adhesion receptors which mediate dynamic 
interactions between the cell and the tissue and determine the binding specificity to diverse ECM 
components [20, 21]. Cell-matrix adhesions mature by integrin clustering and focal adhesion 
formation at the leading edge of moving cells and, essential for migration, become dissembled 
at the rear of the cell [21]. As rule of thumb, optimal cell migration rates are achieved at inter-
mediate integrin adhesion level and require balanced formation and resolution of adhesions. The 
underlying integrin dynamics depend upon activation, clustering and recycling which are tightly 
regulated processes. Upon activation, integrins deliver information on cell location, environment 
and adhesive state through signaling through focal adhesion kinase (FAK) and Src-family kinases 
followed by engagement of RhoGTPases, Akt and ERK, and further mediate mechanocoupling 
and signaling underlying cell responses, such as migration, proliferation, survival or differentiation 
(Figure 1) [22, 23].
Through signaling cross-talk, integrins support growth factor signaling pathways, via FAK, MAPK 
and Akt, but can also negatively influence growth factor receptor signaling [24]. In turn, growth 
factors and cytokines regulate integrin adhesiveness and substrate specificity in migrating tumor 
cells by multiple mechanisms, including integrin expression regulation, integrin activation and 
focal adhesion turn-over (Figure 2A, B).
Integrin expression regulation
Several growth factors or cytokines control integrin expression and basic adhesion functions, 
often as part of sustained cell activation and differentiation programs. Stromal cell-derived factor 
1 (SDF-1) induces the upregulation of integrins, including αvβ3, αvβ6 and α5β1, which enhances 
adhesiveness and invasion in vitro as well as in vivo in different tumor models [25-27]. Similarly, 
transforming growth factor β3 (TGF-β3) induces β3 integrin expression in breast cancer cells 
which enhances both, collective and single-cell migration on a collagen type I matrix [28]. By 
directing the substrate recognition repertoire, growth factors and cytokines control the compat-
ibility between cell and tissue environment.
Integrin activation and adhesion
Besides ligand binding, integrins are activated by inside-out signaling pathways including PI3K, 
diacylglycerol and phospholipase C, which underlie growth factors and cytokines signaling control 
via the integrin cytoplasmic tails [29]. In pancreatic carcinoma cells, EGF induces Src-dependent 
phosphorylation of the intracellular scaffold protein p130Cas which, via Rap1, activates αvβ5 
integrin [30]. Engaging this pathway supports invasion on vitronectin and further enhances 
metastasis in vivo [30, 31]. TGF-β stimulation causes Smad-2 and Smad-3 activation, as well as 
phosphorylation of β1 integrin which induces invasion in hepatocellular carcinoma (HCC) cells 
into the stroma and blood vessels in a chicken embryo model [32]. Vascular endothelial growth 
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figure 2 Growth factor and cytokine control in cell migration. (a) Overview image indicating collective and 
single cell migration of tumor cells in an extracellular-matrix rich microenvironment including stromal cells. 
(b) Regulation of cell-matrix adhesion, including ① focal adhesion assembly and disassembly, ② recycling 
of integrins, ③ activation of integrins via inside-out signaling, and ④ expression of integrins. (C) Cell-cell 
adhesion regulation through ① cadherin-associated catenins, ② cadherin endocytosis and degradation, 
③ proteolytic cleavage of cadherins by proteases, and ④ expression of cadherins. (D) Organization of the 
cytoskeleton, by ① cell polarization and extension through actin polymerization leading to filopodia/lamel-
lipodia or bleb formation, ② actomyosin contraction, ③ microtubule organization, extension and traffick-
ing, and ④ expression of intermediate filaments. (e) Regulation of the extracellular matrix composition and 
organization by tumor cells through ① secretion and ② expression of mainly growth factors and cytokines 
activating stromal cells and matrix degrading proteases. Regulation by stromal cells through ③ secretion and 
④ expression of mainly growth factors and cytokines guiding tumor cell migration by haptotaxis/chemotaxis, 
extracellular matrix proteins, matrix cross-linking enzymes and protease inhibiting proteins leading to remod-
eling, alignment and stiffening of the ECM.
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factor (VEGF), through VEGF receptor 2 signaling, activates the PI3K-Akt pathway, co-engages 
αvβ3, α5β1, α2β1 and αvβ5 integrins for ligand binding of endothelial and melanoma cells, and 
thereby enhances both adhesion and migration [33]. Similarly, VEGF signaling through neutro-
philin 2 involves protein kinase C (PKC) activation and enhances α6β1 binding to laminin, which 
supports the elongation and migration of breast carcinoma cells [34]. Through phosphorylation 
and dephosphorylation of effector proteins, most integrin activation programs are fast, adaptive 
and support acceleration and deceleration of migration speed.
Focal adhesion regulation
Interconnected with inside-out signaling, the formation and turnover of focal adhesions are ef-
fectively regulated by growth factor and cytokine signaling, resulting in integrin adhesion regula-
tion. TGF-β, insulin-like growth factor 1 (IGF-1), EGF, VEGF-C and hepatocyte growth factor (HGF) 
all induce actin reorganization and phosphorylation of focal adhesion proteins including paxillin, 
cortactin, FAK and p130Cas in different tumor cell types, which coincides with cell spreading, 
turnover of focal adhesions, and migration [35-40].The regulation of focal adhesions is, however, 
not a prerequisite for inducing effective cell migration. In prostate cancer cells, HGF induces 
migration with only little effect on focal adhesions [41]. In highly adhesive and thus immobilized 
cells, growth factor signaling and migration induction even coincide with the lowering of cell-
matrix binding. EGF signaling leads to transient downregulation of FAK activity which weakens 
attachment to the matrix and favors cell motility in different carcinoma types [41, 42]. Thus, by 
regulating focal adhesion assembly and disassembly, growth factors and cytokines can “tune” 
cell adhesion strength and dynamics.
Subcellular integrin distribution and recycling
Endocytic recycling of integrins regulates the level of integrins available at the cell surface, which 
underlies complex control mechanisms, including growth factor and cytokine signaling. Platelet-
derived growth factor (PDGF) receptor signaling through protein kinase D induces a short-loop 
recycling of αvβ3 integrin to the leading edge of breast cancer cells, which in turn inhibits α5β1 
integrin recycling to the cell surface [43]. This promotes αvβ3-dependent cell invasion into multi-
ligand ECM [43]. Likewise, SDF-1α activates diacylglycerol kinase α which is required for β1 integ-
rin delivery to cell protrusions, and supports the spreading and invasion of breast cancer cells [44]. 
As part of a multi-step program, IGF-I stimulation disrupts molecular complexes consisting of αv 
integrin, IGF-I receptor and E-cadherin at cell-cell contacts, which allows αv integrin localization 
to substrate binding sites and partly regulates cell-cell contact adhesion, which enables invasion 
of colon cancer cells in a 3D collagen model [45].
Thus, by regulating the expression and localization kinetics of ECM-binding adhesion receptors, 
growth factors or cytokine signaling regulates cell adhesion and thereby migration of predomi-
nantly individual tumor cells.
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Cell-cell adhesion
Cell-cell adhesions are critical for cell-cell cooperation, multicellular polarity, tissue homeostasis, 
as well as collective cell movements [46, 47]. In epithelial tumor cells, cell-cell cooperation is 
mainly mediated by adherens junctions consisting of cadherin-cadherin interactions which are 
connected to actin and microtubule filaments [48, 49]. Adherens junctions are controlled by 
at least four complementary mechanisms: cadherin expression, altered function of the adapter 
proteins p120-catenin and α/β-catenin which connect cadherins to the actin cytoskeleton and 
control junction stability [50, 51]; cadherin delivery and turn-over at the plasma membrane; and 
proteolytic processing of cadherins by extracellular and intracellular proteases [52]. Each of these 
regulation mechanisms underlies control by growth factors or cytokines (Figure 2A, C).
Cadherin expression regulation
E-cadherin is highly expressed in most epithelia. Signaling pathways which induce transcription 
factors which repress E-cadherin expression directly or indirectly, including Snail, Slug, zinc fin-
ger E-box-binding homeobox (ZEB) and Twist, can modulate E-cadherin levels and accordingly 
function of the epithelium [53]. Many growth factors and cytokines induce upstream control 
of E-cadherin expression, including Akt, MAPK pathways, Smad, Notch, Wnt, hypoxia-inducible 
factor 1α and STAT3, and thereby regulate cell-cell adhesion [54]. EGF induces Snail, which 
downregulates E-cadherin in cell-cell junctions and favors mobility induction and cell detachment 
in different epithelial cancer cell types [55]. Likewise, HGF or C-X-C motif chemokine 5 (CXCL5) 
induce Snail and thereby lead to cell scattering and migration in HCC and breast cancer cells [56, 
57]. Possibly as consequence of escape of detaching cells from the primary site, growth factor-
induced repression of E-cadherin is positively associated with metastasis formation in vivo [57-
59]. Besides downregulating E-cadherin, growth factors, including bone morphogenetic protein 
4 (BMP4), TGF-β or EGF, also upregulate N-cadherin and other cadherins [60-62], which, likely 
by initiating pro-migratory signaling together with flexiblization of cell-cell adhesion, supports 
collective migration [63, 64]. The expression regulation of cell-cell adhesion proteins thus can lead 
to long-lasting reprogramming of cell-cell assemblies and their dynamics.
Intracelluar cadherin degradation
Cadherin levels at the plasma membrane are regulated by phosphorylation of the cytoplasmic 
tail, which leads to endocytosis of the cadherin complex and reduced cell-cell adhesion [65]. 
Growth factor receptors can directly interact with and phosphorylate cadherins, followed by in-
ternalization within minutes to hours [65], and further may engage Src. EGF and TGF-β signaling 
activate Cdc42-interacting protein 4 which controls Src and jointly induce E-cadherin endocytosis, 
followed by motility induction, cell scattering and invasion into 3D matrices and in vivo of breast 
cancer cells [66]. Similarly, HGF induces E-cadherin degradation through Src engagement in 
breast cancer [67] or canine kidney cells [68]. With cadherin internalization, its adaptors β-catenin 
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and p120 become released from the cell adhesion complex and activate pro-migratory signal-
ing pathways, including NFκB and the small GTPases RhoA, Rac1 and Cdc42 [69, 70]. Thereby, 
cadherin downregulation and degradation are canonical routes towards promigratory signaling, 
which converts a cohesive into dynamic epithelium or detaching and individually migrating cells 
[55, 71].
Proteolytic processing
Growth factors and cytokines regulate the expression and activation of extracellular proteases 
which cleave cadherins and thereby control intercellular adhesion strength [72]. EGF increases the 
release of matrix metalloproteinase (MMP) 9 which cleaves E-cadherin in head and neck squamous 
cell carcinoma (HNSCC) cells promoting scattering and migration [73]. Similarly, HGF induces the 
upregulation of MMP7 which cleaves E-cadherin and disrupts the E-cadherin/β-catenin complex 
in prostate and gastric cancer cells [74, 75]. By regulating both autocrine and paracrine release of 
proteases, growth factors and cytokines thus modulate cell-cell adhesions on tumor cells as well 
as neighboring cells of the tumor stroma [72, 76].
Regulation of catenins
The stability of surface cadherins is controlled by catenins which define cadherin surface position-
ing and connection to the actin cytoskeleton. Cadherin-associated catenins are, in turn, regulated 
by growth factor signaling. For example, TGF-β1 induces PI3K-dependent tyrosine phosphoryla-
tion of β-catenin which causes dissociation of the E-cadherin/catenin complex, reduces cell-cell 
adhesion and induces migration of pancreatic carcinoma cells [77]. HGF and tumor necrosis fac-
tor α (TNFα) signaling stabilize β-catenin in the cytoplasm or nucleus, which weakens E-cadherin 
complexes at the plasma membrane and cell-cell cohesion, and supports cell migration [78, 79]. If 
cadherin-based junctions are weakened, but not fully dissolved, growth factor or cytokine signal-
ing supports collective migration. In HNSCC cells EGF-induces predominantly collective migration 
which requires intact adherens junctions and the stabilizing function of p120 catenin [80]. Thus, 
growth factors and cytokines differentially regulate cell-cell adhesion stability and control the 
mode of cell migration in a cell-type dependent manner.
Modulation of other adhesion systems
Besides adherens junctions, growth factors and cytokines promote tumor cell migration by regu-
lating other, parallel cell-cell adhesion systems, particularly tight junctions [81]. EGF, via Src and 
PKCδ signaling, reduces the expression of the tight junction protein occludin in epithelial tumor 
cell lines [82] and, via MEK/ERK and PI3K/Akt signaling, induces de-localization and degrada-
tion of the tight junction proteins claudin-3 and -4 in ovarian cancer cells [83]. Consistent with 
cadherin regulation, BMP4 causes a deregulation of the epithelial cell polarization by perturbing 
the distribution of the tight junction protein zona occludens protein-1 in epithelial carcinoma cells 
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and enhances migration into a type I collagen gel [60]. Altered cadherin and tight junction regula-
tion by growth factors and cytokines likely occurs concurrently and synergizes to reduce cell-cell 
junctions and facilitated single-cell dissemination. In addition, growth factor stimulation may 
perturb intercellular communication through gap junction [84], with yet unclear consequences 
for tumor cell migration.
In summary, by impacting the steady-state cadherin functionality in cell-cell adhesion, growth 
factors and cytokines control whether tumor cells migrate in groups or as single cells.
CyTOSkeleTal DynaMICS
The polarization and the mechanical force coupling of cancer cells through adhesive cell-cell and 
cell-matrix interactions are both mediated by the actin cytoskeleton. In single-cell migration, the 
cytoskeleton undergoes a cyclic four-step process consisting of (1) protrusion of the leading edge, 
(2) adhesive cytoskeletal anchorage to substrate via adhesion sites, (3) actomyosin contraction 
along the cell body and (4) retraction of the cell rear [85]. For force generation, cytoskeletal 
systems cooperate with adhesion systems to define the type, strength and duration of cell in-
teraction with the ECM, cell polarity and migration. The small GTPases Cdc42 and Rac induce 
actin polymerization to form cell protrusions, including lamellipodia and filopodia, which push 
the leading edge forward. Actomyosin contraction, under the control of the small GTPase RhoA, 
mediates focal adhesion maturation and cell contraction. Microtubules maintain cell polarity, 
regulate vesicle trafficking and delivery of function proteins to cell-matrix interaction sites, and 
thereby support adhesion regulation and cell migration [86, 87]. Intermediate filaments includ-
ing cytokeratins and vimentin, regulate cell shape, cell-cell adhesion via desmosomes, polarity 
and cell protrusion [88, 89]. Extracellular signals including growth factor and cytokine receptor 
pathways, through PI3K/Akt, MAPK and guanine nucleotide exchange factors regulating the 
small Rho GTPases Cdc42, Rac1 and RhoA, direct the dynamics of all three cytoskeletal systems 
and thereby control cell shape, adhesion and movement (Figure 2A, D).
Cell polarization and leading edge formation
When distributed uniformly in tissues, growth factors and cytokines induce cell polarization and 
migration non-directionally (chemokinesis); when present as gradients, directional migration is 
induced (chemotaxis/haptotaxis) [90]. Growth factors and cytokines, including EGF, HGF, TGF-β 
and TNF ligand, activate the Rho GTPase Cdc42, often in cooperation with Rac, which induces 
the migration in a range of tumor cell models, including breast, breast adenocarcinoma, glioma, 
epidermoid and prostate carcinoma cells [91-94].A subset of growth factors and cytokines further 
activates RhoA, which favors rounded cell morphology and amoeboid migration in tumor cells, 
with blebs and small membrane protrusions at the cell front [9]. Examples include TGF-β, HGF 
and interleukin 6 (IL-6) stimulation in melanoma or breast cancer cells [95-97]. Thus, by regulat-
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ing the Rac/Rho balance, growth factors and cytokines determine the type of cell protrusion in 
migrating tumor cells.
Actomyosin contraction
Cell contractility is regulated by cytokines and growth factors, mainly through regulating the 
activity of RhoA and the myosin light chain (MLC), which control myosin II to intercalate between 
and contract actin filaments (Fig. 2C). EGF and HGF activate RhoA through the GTPase ADP-
ribosylation factor 1 or the tyrosine kinases Abl and Arg, respectively, followed by enhanced 
contractility and migration of individual breast cancer cells [98-100]. In cell groups, increasing 
actomyosin contractility can generate tangential forces and support the dissolution of cell-cell 
junctions. Accordingly, the scattering of single cells can be induced by TGF-β signalling, by activat-
ing MLC phosphorylation and actomyosin contractility alongside with E-cadherin endocytosis in 
breast cancer cells [66] or by HGF in non-transformed epithelial cells [101].
Microtubule organization and dynamics
Microtubule dynamics underlie the control of RhoGTPases and PI3K/Akt/GSK-3 pathways and 
upstream regulation by growth factor or cytokine [86]. Growth factors and cytokines further 
regulate motor proteins required for microtubule-dependent intracellular transport of cargo in 
vesicles. EGF and HGF control microtubule extension and protein and membrane trafficking along 
microtubules by kinesins, which supports cell protrusion, adhesion and migration in breast and 
gastric carcinoma cells [102-106]; TGF-β receptor triggering activates, via Smad7, p38 and GSK-
3β signaling, the recruitment of Adenomatous Polyposis Coli to the microtubule in the leading 
edge, which stabilizes microtubules and enhances polarization and migration in prostate cancer 
cells [107]. IL-6 induces STAT3 which regulates microtubule stability and stimulates migration and 
invasion in gastric cancer cells [105]. Thus, although most cells can still migrate when microtubule 
functions are impaired, microtubule regulation by growth factors and cytokines contributes to an 
efficient migration cycle.
Expression and function regulation of intermediate filaments
Most intermediate filaments are deregulated in tumor cells, which promotes or inhibits migration 
[88, 89, 108]. Growth factors and cytokines can influence intermediate filament expression or 
function. Vimentin, predominantly expressed by mesenchymal cells, is induced by a range of 
growth factors and cytokines, including TGF-β, EGF, HGF, C-C motif chemokine ligand 20 (CCL20) 
and TNF-α, in many epithelial cancers, as part of the epithelial-to-mesenchymal transition (EMT) 
program [73, 109-112]. Vimentin upregulation increases migration in non-transformed epithelial 
as well as cancer cells, including head and neck, breast, lung, liver and pancreas carcinoma cells, 
by multiple functions, including cell protrusion formation, destabilization of desmosomes and 
accelerated focal adhesion dynamics [88].
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Unlike vimentin, the link between keratins and tumor cell migration is less well characterized. 
Growth factors or downstream effectors, including Akt or ERK signaling, regulate the expression 
and network dynamics of keratins, which is positively associated with enhanced cell migration 
[113-116]. Growth factors and cytokines thus increase intermediate filament dynamics, either as 
cause or consequence of enhanced migration.
eCM/MICROenvIROnMenT aRChITeCTuRe
In progressing tumor lesions, the stroma undergoes significant structural and molecular remodel-
ing, which leads to increased deposition of ECM molecules as well as tissue compaction with 
stronger and longer ECM fibers and alignment parallel or perpendicular to the tumor border 
[117-119]. The ECM strongly impacts the migration type and efficiency by its dual function to (1) 
provide structural framework for resident and passenger cells and (2) by binding and immobilizing 
soluble factors which act as reservoir and information cue. Tumor cells sense both, the mechanical 
and molecular properties of the ECM, by simultaneously integrating adhesion and growth factor 
receptor signaling. Accordingly, cell migration can be guided by stiffness gradients, with migra-
tion towards more stiffer substrate (durotaxis) [120], towards the gradient of an immobilized 
ligand (haptotaxis), or towards soluble ligand (chemotaxis) [90]. Growth factors and cytokines 
display multiple, direct and indirect effects on the tissue organization and tissue-derived signaling 
with important consequences for the movement and function of tumor cells (Figure 2A, D).
ECM synthesis and remodeling
The remodeling of ECM is performed by stromal fibroblasts and other stromal cells which be-
come stimulated by growth factors and cytokines, including EGF, FGF, IL-1α, PDGF and TGF-β 
[121]. Upon stimulation with TGF-β or FGF fibroblasts downregulate secretion of matrix degrad-
ing proteinases and up-regulate tissue inhibitors of metalloproteinases to inhibit the collagen 
degradation function of extracellular MMPs, which induces collagen accumulation [122-124]. 
Growth factor signaling further impacts enzymatic cross-linking of collagen fibers with increased 
ECM stiffness as outcome [76, 117, 125, 126]. TGF-β is a strong inducer of lysyl oxidase in 
malignant mammary epithelial cells which cross-links collagen and mediates tumor cell invasion 
and proliferation [127]. The increased extracellular confinement and higher stiffness of the tumor 
stroma promotes integrin engagement and elongated movement in different tumor cell models, 
consistent with mesenchymal features [9, 128]. By guiding cells along confined space, aligned 
and bundled ECM structures further supports multicellular streaming along and cell jamming 
within the track, with conversion to collective cell migration [9, 129-131].
ECM degradation
Proteolytic degradation of ECM is an important mechanism for invading cells to widen tissue 
space. Whereas cell migration in interstitial connective tissue imposes little mechanical barriers to 
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moving cells, passage through dense tissue and particularly the basement membrane is facilitated 
by proteolytic degradation of ECM macromolecules [132-134]. A wide range of growth factors 
and cytokines regulates ECM-degrading enzyme systems, including MMPs, serine proteases and 
cathepsins [135, 136]. TGF-β, EGF, HGF, TNF-α and IL-1 induce or increase the expression of MT-1 
MMP, MMP1, MMP2, MMP9 and the serine protease uPA, all of which support tumor cell migra-
tion in 3D models and in vivo [28, 137-142]. Besides cleaving ECM proteins directly, degrading 
enzymes can release growth factors and cytokines which are bound to the ECM and thereby 
increase their biological function [143].
Thus, growth factors and cytokines have a dual function in controlling ECM composition and 
organization, by controlling cell activation and ECM deposition, and by directly binding to the 
ECM scaffold and providing topologic guidance for migrating cancer and stromal cells.
PlaSTICITy Of CanCeR Cell MIGRaTIOn In ReSPOnSe TO GROwTh 
faCTOR anD CyTOkIne SIGnalInG
By simultaneously controlling multiple components of the cell adhesion and cytoskeletal machin-
ery as well as the extracellular structure and composition, growth factors and cytokines activate 
and modulate tumor cell migration programs in an overarching, integrated manner. Besides the 
routes and efficiency, they also modulate strategies by which cells invade. Growth factor and 
cytokine stimulation which weakens cell-cell adhesion favors single cell dissemination over collec-
tive invasion; increasing cell-matrix adhesion or ECM ligand density as well as stiffness promotes 
mesenchymal movement; and lowering cell-ECM adhesion and activating RhoA rather than Rac 
signaling favors amoeboid migration strategies (Figure 3) [9, 144]. Because each migration strat-
egy conveys particular “abilities” for cells to infiltrate tissue and cross tissue barriers, this induced 
plasticity response also impacts metastatic efficacy and prognosis.
figure 3 Growth factor- and cytokine-induced plasticity in tumor cell migration. Growth factors and cytokines 
have primary effects on tumor and stroma cells influencing cell-matrix and cell-cell adhesion, cytoskeletal 
dynamics and extracellular matrix (ECM) composition and structure. This leads, depending on cell type and 
environmental context, to a plastic response in tumor cell migration of collective, mesenchymal or amoeboid 
migration.
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Induction of collective or single-cell migration
Growth factors and cytokines may induce or enhance cell movement, either as collective or 
single-cell migration modes, which depends upon the cell type and environmental context. HGF 
enhances collective migration in normal kidney epithelial cells and mammary adenocarcinoma, 
but stimulates cell detachment and mesenchymal migration in HCC [111, 145, 146]. Similarly, 
SDF-1α increases E-cadherin stability in cell-cell contacts and supports collective migration of 
colon cancer cells [147], whereas cells single-cell migration is enhanced in cholangiocarcinoma 
[148].
Epithelial-to-mesenchymal transition (EMT)
EMT is a molecular program which can be initiated by growth factors or cytokines through 
pathways including PI3K/Akt/GSK-3β, MAPK, Smad and JAK/STAT and leads to a fundamental 
reprogramming of epithelial cells [149]. EMT commonly leads to increased expression of tran-
scription factors such as Snail, Slug, Twist or ZEB which repress E-cadherin and support expression 
of N-cadherin and vimentin [150]. As a consequence, cells which undergo EMT downregulate 
their cell-cell contacts and increase their capacity for migration and 3D invasion. The strongest 
evidence for the contribution of EMT in metastasis formation is the ability of multiple EMT regula-
tors to enhance tumor cell migration, together with survival programs [54, 151]. Depending on 
its strength and duration EMT may induce a spectrum of molecular events, including complete 
EMT with entire loss of epithelial features and incomplete EMT which yields in a hybrid state 
with epithelial and mesenchymal features [152]. With induction of complete EMT, cells typi-
cally individualize and acquire elongated, spindle-like shapes [152]. However, EMT can result in 
a spectrum of migration modes, including single cell and collective migration, sometimes in the 
same cell model indicating a heterogeneous behavior within the same cell population [153, 154]. 
Moreover, there is no direct correlation between E-cadherin levels and migration mode in re-
sponse to growth factor or cytokine stimulation. TGF-β reduces expression levels and cell surface 
localization of E-cadherin, without inducing N-cadherin expression, and enhances collective sheet 
migration in colon cancer cells [147]. Similarly, TGF-β treatment although inducing complete 
EMT in murine breast cancer cells, induces a range of migration programs, including collective 
sheet migration and single cell migration on 2D surfaces and near-exclusive collective invasion 
into 3D reconstituted basement membrane [155]. Thus, growth factor or cytokine-induced EMT 
enhances both single-cell and collective migration programs in a context dependent manner.
Collective-to-single cell transition
Little is known whether and how growth factors and cytokines induce collective-to-single-cell 
dissemination by EMT-independent mechanisms. HGF, by increasing integrin-mediated adhesion 
without regulating E-cadherin, can disrupt cell-cell adhesion and induce scattering in non-
transformed MDCK cells [101]. In vivo, TGF-β1, via Smad4 and Rho/ROCK signaling, induces a 
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switch from collective to single-cell motility in breast cancer cells [156], with unclear contribution 
of EMT in this transition. Similarly, TGF-β activates Smad2 and its adaptor CITED1 and promotes 
detachment of amoeboid-migrating melanoma cells [97]. Likely, similar to EMT, EMT-independent 
mechanisms induce a spectrum of cancer cell invasion modes defined by the spectrum and mag-
nitude of growth factor and cytokine signaling.
Mesenchymal-to-amoeboid and amoeboid-to-mesenchymal transition (MAT, AMT)
In individually moving tumor cells, growth factors and cytokines can promote mesenchymal or 
amoeboid migration, and likely transitions between both modes. SDF-1α activates RhoA and 
mDia2 which induce the re-organization of filamentous actin towards bleb formation and migra-
tion in mesenchymal breast cancer cells [157]. Similarly, IL-6 receptor signaling engages JAK/Stat, 
Rho signaling and actomyosin contraction which promote a preferentially rounded, amoeboid-
moving phenotype in melanoma cells in 3D collagen and in vivo [96]. To which extent such 
single-cell plasticity supports or counteracts tumor cell transition between tissues and metastatic 
evasion remains to be clarified.
Synergistic and negative effects on cell migration and metastasis formation
Many growth factor and cytokine receptors activate similar, overlapping signaling pathways, or 
induce cross-talk between pathways to synergize or antagonize their respective downstream sig-
naling. Consequently, growth factors and cytokines can induce synergistic or antagonistic effects 
in the regulation of cell-cell and cell-matrix interaction, actomyosin contractility and resulting 
migration in tumor cells. In ovarian cancer cells HGF-induced migration requires Akt and ERK1/2 
pathways while EGF-induced migration depends on Akt and p38 pathways [158]; when applied 
simultaneously, HGF and EGF synergize and enhance invasion through reconstituted basement 
membrane [158]. IL-6 and EGF receptor signaling both occur via PI3K and MAPK pathways and 
synergize to induce migration of breast cancer cells [159]. EGF and TNF-α promote respective 
ERK or Smad signaling pathways and jointly enhance the efficacy of TGF-β in inducing EMT and 
migration of lung or pancreatic cancer cells [160, 161]. TGF-β and downstream Smad signaling 
induces the expression of PDGF which in an autocrine manner activates the PI3K/Akt pathway 
and synergistically enhances an EMT-like phenotype in melanoma cells [162]. Such cooperation 
not only may enhance the efficacy of an individual growth factor in a given environment; it 
further represents a likely mechanism of compensation upon targeted therapy against individual 
receptor systems.
Besides synergism, growth factors and cytokines can also counteract and suppress otherwise 
ongoing tumor cell migration and metastasis formation in certain experimental models. In 
HNSCC, CXCL14 strongly activates Rac1 and supports focal adhesion formation and adhesion 
to collagen, which stabilizes cell adhesion followed by cell immobilization and impaired migra-
tion [163]. IL-27 limits EMT, either by antagonizing PGE2 signaling and suppressing vimentin 
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expression, or by promoting STAT1 pathways, which ultimately maintains epithelial differentiation 
and reduces the migration of non-small cell lung cancer cells [164, 165]. Furthermore, although 
TGF-β signaling enhances collective and single cell migration of murine mammary carcinoma 
cells, interference with the TGF-β receptor, counterintuitively, promotes metastasis formation in 
chick embryos [154]. In mammary tumor cells, EGF modulates chemotactic migration towards 
an SDF-1α gradient and either enhances or decreases migration [166, 167], possibly by dose-
dependent chemokine and EGFR cross-desensitization. Similarly, interferon-γ inhibits TGF-β 
induced invasion via Smad7, which interferes with R-Smad signaling in a 3D gastric carcinoma 
model or breast cancer cells [168, 169]. Thus, the effect of growth factors and cytokines on cell 
migration is context-dependent, resulting in both induction or inhibition and diversity of the cell 
migration response. Consequently, given the plethora of mechanical and chemical signals pres-
ent in the tumor microenvironment in vivo, growth factors and cytokines likely provide complex 
orchestration of signaling networks to induce plasticity as well as unexpected outcome in tumor 
cell migration and metastasis models.
The stimulatory effects of growth factors and cytokines are typically cell-type specific, with vary-
ing sensitivity and response profile in dependence of the cell type and tumor model. In lung 
adenocarcinoma and pancreatic cancer cells, high-dose EGF and TNF-α stimulation fails to induce 
EMT, whereas TGF-β treatment leads to EMT and enhances migration across 2D substrate [102]. 
Upon direct comparison of different growth factors, TGF-β is superior and sufficient in inducing 
complete EMT, including induction of E-cadherin transcription repressors, N-cadherin, vimentin 
and fibronectin, and enhanced migration in 2D and 3D in epithelial mouse breast cancer cells in 
vitro, while EGF, IGF-1, HGF, FGF, PDGF and IL-6 cause no or partial EMT in the same cells [155]. 
Conversely, in a panel of HNSCC cell lines TGF-β stimulation and downstream Smad signaling 
elicit variable levels of EMT ranging from downregulation of E-cadherin and Cytokeratin 18 and 
upregulation of N-cadherin and vimentin to complete unresponsiveness or even up-regulation 
of epithelial markers [39]. Such variability likely reflects the intra- and interindividual differences 
of genetic and epigenetic programs in tumor cells, and contribute to tumor heterogeneity and 
molecular adaptation programs.
DISCuSSIOn
Cancer therapies involving inhibition of growth factor or cytokine receptor signaling often show 
transient efficacy in reducing tumor growth and circulating tumor cell counts, indicating the 
importance of growth factors and cytokines in tumor progression and, arguably, metastatic 
progression in patients [170-172]. However, since longitudinal histology from serial biopsies 
and circulating tumor cell analysis are often missing in clinical trials, the migratory mechanisms 
underlying the clinical efficacy of growth factor receptor targeting, such as altered tumor cell 
migration or intra- and extravasation into the blood vasculature, are poorly resolved to date. 
Furthermore, even though preclinical studies indicate that growth factors can promote migration 
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and metastasis without influencing primary tumor growth, the relative contribution of tumor cell 
migration and/or survival programs in response to growth factor signaling remains unknown [30, 
31, 173]. Thus, the translation from in vitro studies in defined environments to clinical end-points 
requires intermediate analysis by mechanistic preclinical studies, such as intravital microscopy in 
small animal models to monitor every step of the metastatic cascade before and after targeted 
therapy [174-177]. In addition, since targeting single growth factors or cytokines has been proven 
insufficient in therapy, a more global approach, such as the use of antibody arrays and (phospho-) 
proteomic analysis of invasive tumor regions will allow to identify the composition of growth 
factors and cytokines in the tumor microenvironment and to delineate signaling cross-talk. To 
this end, mathematical modeling will support multi-parametric integration of complex signaling 
and effector regulation in tumor biology. This will allow to combine varying degrees of growth 
factor signaling with the induction of plasticity of tumor cell migration in different tissue contexts 
to model both deterministic and probabilistic effects of invasion programs [178-181]. Thus, 
generating an integrated approach of cell-based in vitro analysis, preclinical mouse models, clini-
cal outcome studies and mathematical modeling will enable the dissection of plasticity of both 
invasion/dissemination and survival programs in response to growth factors and cytokines, and 
outcome after therapeutic targeting.
aCknOwleDGeMenTS
We thank Mirjam Zegers for critical reading and helpful suggestions on the manuscript. We 
gratefully acknowledge financial support by the European Research Council (617430-DEEP-
INSIGHT), NWO-Vici (918.11.626), Horizon 2020 consortium MULTIMOT (634107-2), and the 
Cancer Genomics Center.
38 | Chapter 2
RefeRenCeS
1. Lammermann, T. and M. Sixt, Mechanical modes of ‘amoeboid’ cell migration. Curr Opin Cell Biol, 
2009. 21(5): p. 636-44.
2. Rorth, P., Fellow travellers: emergent properties of collective cell migration. EMBO Rep, 2012. 13(11): p. 
984-91.
3. Friedl, P. and S. Alexander, Cancer invasion and the microenvironment: plasticity and reciprocity. Cell, 
2011. 147(5): p. 992-1009.
4. Sahai, E., Mechanisms of cancer cell invasion. Curr Opin Genet Dev, 2005. 15(1): p. 87-96.
5. Pankova, K., et al., The molecular mechanisms of transition between mesenchymal and amoeboid 
invasiveness in tumor cells. Cell Mol Life Sci, 2010. 67(1): p. 63-71.
6. Friedl, P. and K. Wolf, Proteolytic interstitial cell migration: a five-step process. Cancer Metastasis Rev, 
2009. 28(1-2): p. 129-35.
7. Friedl, P., et al., CD4+ T lymphocytes migrating in three-dimensional collagen lattices lack focal adhe-
sions and utilize beta1 integrin-independent strategies for polarization, interaction with collagen fibers 
and locomotion. Eur J Immunol, 1998. 28(8): p. 2331-43.
8. Friedl, P., Y. Hegerfeldt, and M. Tusch, Collective cell migration in morphogenesis and cancer. Int J Dev 
Biol, 2004. 48(5-6): p. 441-9.
9. Friedl, P. and K. Wolf, Plasticity of cell migration: a multiscale tuning model. J Cell Biol, 2010. 188(1): p. 
11-9.
10. Sanz-Moreno, V., et al., Rac activation and inactivation control plasticity of tumor cell movement. Cell, 
2008. 135(3): p. 510-23.
11. Hegerfeldt, Y., et al., Collective cell movement in primary melanoma explants: plasticity of cell-cell 
interaction, beta1-integrin function, and migration strategies. Cancer Res, 2002. 62(7): p. 2125-30.
12. Usui, A., et al., P-cadherin promotes ovarian cancer dissemination through tumor cell aggregation and 
tumor-peritoneum interactions. Mol Cancer Res, 2014. 12(4): p. 504-13.
13. Clark, A.G. and D.M. Vignjevic, Modes of cancer cell invasion and the role of the microenvironment. 
Curr Opin Cell Biol, 2015. 36: p. 13-22.
14. Lackie, J., A dictionary of Biomedicine. 2010, Oxford University Press.
15. Wells, A., Tumor invasion: role of growth factor-induced cell motility. Adv Cancer Res, 2000. 78: p. 
31-101.
16. Wyckoff, J., et al., A paracrine loop between tumor cells and macrophages is required for tumor cell 
migration in mammary tumors. Cancer Res, 2004. 64(19): p. 7022-7029.
17. Lemmon, M.A. and J. Schlessinger, Cell signaling by receptor tyrosine kinases. Cell, 2010. 141(7): p. 
1117-34.
18. Hembruff, S.L. and N. Cheng, Chemokine signaling in cancer: Implications on the tumor microenviron-
ment and therapeutic targeting. Cancer Ther, 2009. 7(A): p. 254-267.
19. Roussos, E.T., J.S. Condeelis, and A. Patsialou, Chemotaxis in cancer. Nat Rev Cancer, 2011. 11(8): p. 
573-87.
20. Wolfenson, H., I. Lavelin, and B. Geiger, Dynamic regulation of the structure and functions of integrin 
adhesions. Dev Cell, 2013. 24(5): p. 447-58.
21. Huttenlocher, A. and A.R. Horwitz, Integrins in cell migration. Cold Spring Harb Perspect Biol, 2011. 
3(9): p. a005074.
22. Shen, B., M.K. Delaney, and X. Du, Inside-out, outside-in, and inside-outside-in: G protein signaling in 
integrin-mediated cell adhesion, spreading, and retraction. Curr Opin Cell Biol, 2012. 24(5): p. 600-6.
2Plasticity of tumor cell invasion – governance by growth factors and cytokines | 39
23. Harburger, D.S. and D.A. Calderwood, Integrin signalling at a glance. J Cell Sci, 2009. 122(Pt 2): p. 
159-63.
24. Ivaska, J. and J. Heino, Cooperation between integrins and growth factor receptors in signaling and 
endocytosis. Annu Rev Cell Dev Biol, 2011. 27: p. 291-320.
25. Engl, T., et al., CXCR4 chemokine receptor mediates prostate tumor cell adhesion through alpha5 and 
beta3 integrins. Neoplasia, 2006. 8(4): p. 290-301.
26. Sun, Y.X., et al., Expression and activation of alpha v beta 3 integrins by SDF-1/CXC12 increases the 
aggressiveness of prostate cancer cells. Prostate, 2007. 67(1): p. 61-73.
27. Wang, B., et al., SDF-1/CXCR4 axis promotes directional migration of colorectal cancer cells through 
upregulation of integrin alphavbeta6. Carcinogenesis, 2014. 35(2): p. 282-91.
28. Lam, S., et al., Wild-type p53 inhibits pro-invasive properties of TGF-beta3 in breast cancer, in part 
through regulation of EPHB2, a new TGF-beta target gene. Breast Cancer Res Treat, 2014. 148(1): p. 
7-18.
29. Kim, C., F. Ye, and M.H. Ginsberg, Regulation of integrin activation. Annu Rev Cell Dev Biol, 2011. 27: 
p. 321-45.
30. Ricono, J.M., et al., Specific cross-talk between epidermal growth factor receptor and integrin alphav-
beta5 promotes carcinoma cell invasion and metastasis. Cancer Res, 2009. 69(4): p. 1383-91.
31. Huang, M., et al., EGFR-dependent pancreatic carcinoma cell metastasis through Rap1 activation. 
Oncogene, 2012. 31(22): p. 2783-93.
32. Fransvea, E., et al., Targeting transforming growth factor (TGF)-betaRI inhibits activation of beta1 
integrin and blocks vascular invasion in hepatocellular carcinoma. Hepatology, 2009. 49(3): p. 839-50.
33. Byzova, T.V., et al., A mechanism for modulation of cellular responses to VEGF: activation of the integ-
rins. Mol Cell, 2000. 6(4): p. 851-60.
34. Goel, H.L., et al., Neuropilin-2 regulates alpha6beta1 integrin in the formation of focal adhesions and 
signaling. J Cell Sci, 2012. 125(Pt 2): p. 497-506.
35. Liu, L., et al., Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins. 
Oncogene, 2008. 27(37): p. 4998-5010.
36. Matsumoto, K., et al., Hepatocyte growth factor/scatter factor induces tyrosine phosphorylation of 
focal adhesion kinase (p125FAK) and promotes migration and invasion by oral squamous cell carcinoma 
cells. J Biol Chem, 1994. 269(50): p. 31807-13.
37. Mezi, S., et al., Involvement of the Src-cortactin pathway in migration induced by IGF-1 and EGF in 
human breast cancer cells. Int J Oncol, 2012. 41(6): p. 2128-38.
38. Chen, H., et al., Vascular endothelial growth factor C enhances cervical cancer migration and invasion 
via activation of focal adhesion kinase. Gynecol Endocrinol, 2013. 29(1): p. 20-4.
39. Saito, D., et al., Transforming growth factor-beta1 induces epithelial-mesenchymal transition and 
integrin alpha3beta1-mediated cell migration of HSC-4 human squamous cell carcinoma cells through 
Slug. J Biochem, 2013. 153(3): p. 303-15.
40. Damiano, L., et al., p140Cap suppresses the invasive properties of highly metastatic MTLn3-EGFR cells 
via impaired cortactin phosphorylation. Oncogene, 2012. 31(5): p. 624-33.
41. Spanjaard, E., et al., Quantitative imaging of focal adhesion dynamics and their regulation by HGF and 
Rap1 signaling. Exp Cell Res, 2015. 330(2): p. 382-97.
42. Lu, Z., et al., Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephos-
phorylation and downregulation of focal adhesion kinase. Mol Cell Biol, 2001. 21(12): p. 4016-31.
43. Christoforides, C., et al., PKD controls alphavbeta3 integrin recycling and tumor cell invasive migration 
through its substrate Rabaptin-5. Dev Cell, 2012. 23(3): p. 560-72.
40 | Chapter 2
44. Rainero, E., et al., The diacylglycerol kinase alpha/atypical PKC/beta1 integrin pathway in SDF-1alpha 
mammary carcinoma invasiveness. PLoS One, 2014. 9(6): p. e97144.
45. Canonici, A., et al., Insulin-like growth factor-I receptor, E-cadherin and alpha v integrin form a dynamic 
complex under the control of alpha-catenin. Int J Cancer, 2008. 122(3): p. 572-82.
46. Friedl, P., et al., Classifying collective cancer cell invasion. Nat Cell Biol, 2012. 14(8): p. 777-83.
47. Montell, D.J., Morphogenetic cell movements: diversity from modular mechanical properties. Science, 
2008. 322(5907): p. 1502-5.
48. Cavallaro, U. and G. Christofori, Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat 
Rev Cancer, 2004. 4(2): p. 118-32.
49. Stehbens, S.J., et al., Dynamic microtubules regulate the local concentration of E-cadherin at cell-cell 
contacts. J Cell Sci, 2006. 119(Pt 9): p. 1801-11.
50. Lilien, J. and J. Balsamo, The regulation of cadherin-mediated adhesion by tyrosine phosphorylation/
dephosphorylation of beta-catenin. Curr Opin Cell Biol, 2005. 17(5): p. 459-65.
51. Ishiyama, N., et al., Dynamic and static interactions between p120 catenin and E-cadherin regulate the 
stability of cell-cell adhesion. Cell, 2010. 141(1): p. 117-28.
52. Berx, G. and F. van Roy, Involvement of members of the cadherin superfamily in cancer. Cold Spring 
Harb Perspect Biol, 2009. 1(6): p. a003129.
53. van Roy, F. and G. Berx, The cell-cell adhesion molecule E-cadherin. Cellular and Molecular Life Sciences, 
2008. 65(23): p. 3756-3788.
54. Lamouille, S., J. Xu, and R. Derynck, Molecular mechanisms of epithelial-mesenchymal transition. 
Nature Reviews Molecular Cell Biology, 2014. 15(3): p. 178-196.
55. Lu, Z., et al., Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased 
transcriptional activity of beta-catenin, and enhanced tumor cell invasion. Cancer Cell, 2003. 4(6): p. 
499-515.
56. Grotegut, S., et al., Hepatocyte growth factor induces cell scattering through MAPK/Egr-1-mediated 
upregulation of Snail. EMBO J, 2006. 25(15): p. 3534-45.
57. Hsu, Y.L., et al., Breast tumor-associated osteoblast-derived CXCL5 increases cancer progression by ERK/
MSK1/Elk-1/snail signaling pathway. Oncogene, 2013. 32(37): p. 4436-47.
58. Wang, Y., et al., Akt/Ezrin Tyr353/NF-kappaB pathway regulates EGF-induced EMT and metastasis in 
tongue squamous cell carcinoma. Br J Cancer, 2014. 110(3): p. 695-705.
59. Deckers, M., et al., The tumor suppressor Smad4 is required for transforming growth factor beta-
induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res, 
2006. 66(4): p. 2202-9.
60. Park, K.S., M.J. Dubon, and B.M. Gumbiner, N-cadherin mediates the migration of MCF-10A cells 
undergoing bone morphogenetic protein 4-mediated epithelial mesenchymal transition. Tumour Biol, 
2015. 36(5): p. 3549-56.
61. Kim, J. and S. Hwan Kim, CK2 inhibitor CX-4945 blocks TGF-beta1-induced epithelial-to-mesenchymal 
transition in A549 human lung adenocarcinoma cells. PLoS One, 2013. 8(9): p. e74342.
62. Cheng, J.C., N. Auersperg, and P.C. Leung, EGF-induced EMT and invasiveness in serous borderline 
ovarian tumor cells: a possible step in the transition to low-grade serous carcinoma cells? PLoS One, 
2012. 7(3): p. e34071.
63. Priya, R. and A.S. Yap, Making a Choice: How Cadherin Switching Controls Cell Migration. Dev Cell, 
2015. 34(4): p. 383-384.
64. Shih, W. and S. Yamada, N-cadherin as a key regulator of collective cell migration in a 3D environment. 
Cell Adh Migr, 2012. 6(6): p. 513-7.
2Plasticity of tumor cell invasion – governance by growth factors and cytokines | 41
65. Kowalczyk, A.P. and B.A. Nanes, Adherens junction turnover: regulating adhesion through cadherin 
endocytosis, degradation, and recycling. Subcell Biochem, 2012. 60: p. 197-222.
66. Rolland, Y., et al., The CDC42-interacting protein 4 controls epithelial cell cohesion and tumor dis-
semination. Dev Cell, 2014. 30(5): p. 553-68.
67. Schill, N.J., et al., Isoform 5 of PIPKIgamma regulates the endosomal trafficking and degradation of 
E-cadherin. J Cell Sci, 2014. 127(Pt 10): p. 2189-203.
68. Wang, Z., et al., Numb regulates cell-cell adhesion and polarity in response to tyrosine kinase signalling. 
EMBO J, 2009. 28(16): p. 2360-73.
69. Kourtidis, A., S.P. Ngok, and P.Z. Anastasiadis, p120 catenin: an essential regulator of cadherin stability, 
adhesion-induced signaling, and cancer progression. Prog Mol Biol Transl Sci, 2013. 116: p. 409-32.
70. Jeanes, A., C.J. Gottardi, and A.S. Yap, Cadherins and cancer: how does cadherin dysfunction promote 
tumor progression? Oncogene, 2008. 27(55): p. 6920-9.
71. Schackmann, R.C., et al., p120-catenin in cancer - mechanisms, models and opportunities for interven-
tion. J Cell Sci, 2013. 126(Pt 16): p. 3515-25.
72. Kessenbrock, K., V. Plaks, and Z. Werb, Matrix metalloproteinases: regulators of the tumor microenvi-
ronment. Cell, 2010. 141(1): p. 52-67.
73. Zuo, J.H., et al., Activation of EGFR promotes squamous carcinoma SCC10A cell migration and inva-
sion via inducing EMT-like phenotype change and MMP-9-mediated degradation of E-cadherin. J Cell 
Biochem, 2011. 112(9): p. 2508-17.
74. Davies, G., W.G. Jiang, and M.D. Mason, Matrilysin mediates extracellular cleavage of E-cadherin from 
prostate cancer cells: a key mechanism in hepatocyte growth factor/scatter factor-induced cell-cell dis-
sociation and in vitro invasion. Clin Cancer Res, 2001. 7(10): p. 3289-97.
75. Lee, K.H., et al., Association of extracellular cleavage of E-cadherin mediated by MMP-7 with HGF-
induced in vitro invasion in human stomach cancer cells. Eur Surg Res, 2007. 39(4): p. 208-15.
76. Kalluri, R. and M. Zeisberg, Fibroblasts in cancer. Nat Rev Cancer, 2006. 6(5): p. 392-401.
77. Vogelmann, R., et al., TGFbeta-induced downregulation of E-cadherin-based cell-cell adhesion depends 
on PI3-kinase and PTEN. J Cell Sci, 2005. 118(Pt 20): p. 4901-12.
78. Debelec-Butuner, B., et al., TNFalpha-mediated loss of beta-catenin/E-cadherin association and subse-
quent increase in cell migration is partially restored by NKX3.1 expression in prostate cells. PLoS One, 
2014. 9(10): p. e109868.
79. Eterno, V., et al., Adipose-derived Mesenchymal Stem Cells (ASCs) may favour breast cancer recurrence 
via HGF/c-Met signaling. Oncotarget, 2014. 5(3): p. 613-33.
80. Macpherson, I.R., et al., p120-catenin is required for the collective invasion of squamous cell carcinoma 
cells via a phosphorylation-independent mechanism. Oncogene, 2007. 26(36): p. 5214-28.
81. Thiery, J.P. and J.P. Sleeman, Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev 
Mol Cell Biol, 2006. 7(2): p. 131-42.
82. Singh, R., P. Lei, and S.T. Andreadis, PKC-delta binds to E-cadherin and mediates EGF-induced cell 
scattering. Exp Cell Res, 2009. 315(17): p. 2899-913.
83. Ogawa, M., et al., Epidermal growth factor modulates claudins and tight junctional functions in ovarian 
cancer cell lines. Histochem Cell Biol, 2012. 138(2): p. 323-38.
84. Schalper, K.A., et al., Modulation of gap junction channels and hemichannels by growth factors. Mol 
Biosyst, 2012. 8(3): p. 685-98.
85. Ridley, A.J., et al., Cell migration: integrating signals from front to back. Science, 2003. 302(5651): p. 
1704-9.
86. Etienne-Manneville, S., Microtubules in cell migration. Annu Rev Cell Dev Biol, 2013. 29: p. 471-99.
42 | Chapter 2
87. Akhshi, T.K., D. Wernike, and A. Piekny, Microtubules and actin crosstalk in cell migration and division. 
Cytoskeleton (Hoboken), 2014. 71(1): p. 1-23.
88. Leduc, C. and S. Etienne-Manneville, Intermediate filaments in cell migration and invasion: the unusual 
suspects. Curr Opin Cell Biol, 2015. 32: p. 102-12.
89. Chung, B.M., J.D. Rotty, and P.A. Coulombe, Networking galore: intermediate filaments and cell migra-
tion. Curr Opin Cell Biol, 2013. 25(5): p. 600-12.
90. Petrie, R.J., A.D. Doyle, and K.M. Yamada, Random versus directionally persistent cell migration. Nat Rev 
Mol Cell Biol, 2009. 10(8): p. 538-49.
91. Whale, A.D., et al., PAK4 kinase activity and somatic mutation promote carcinoma cell motility and 
influence inhibitor sensitivity. Oncogene, 2013. 32(16): p. 2114-20.
92. El-Sibai, M., et al., Cdc42 is required for EGF-stimulated protrusion and motility in MTLn3 carcinoma 
cells. J Cell Sci, 2007. 120(Pt 19): p. 3465-74.
93. Fortin, S.P., et al., Cdc42 and the guanine nucleotide exchange factors Ect2 and trio mediate Fn14-
induced migration and invasion of glioblastoma cells. Mol Cancer Res, 2012. 10(7): p. 958-68.
94. Hu, J., A. Mukhopadhyay, and A.W. Craig, Transducer of Cdc42-dependent actin assembly promotes 
epidermal growth factor-induced cell motility and invasiveness. J Biol Chem, 2011. 286(3): p. 2261-72.
95. Laser-Azogui, A., et al., Met-induced membrane blebbing leads to amoeboid cell motility and invasion. 
Oncogene, 2014. 33(14): p. 1788-98.
96. Sanz-Moreno, V., et al., ROCK and JAK1 signaling cooperate to control actomyosin contractility in 
tumor cells and stroma. Cancer Cell, 2011. 20(2): p. 229-45.
97. Cantelli, G., et al., TGF-beta-Induced Transcription Sustains Amoeboid Melanoma Migration and Dis-
semination. Curr Biol, 2015. 25(22): p. 2899-914.
98. Li, R., et al., Abl Kinases Regulate HGF/Met Signaling Required for Epithelial Cell Scattering, Tubulogen-
esis and Motility. PLoS One, 2015. 10(5): p. e0124960.
99. Schlienger, S., S. Campbell, and A. Claing, ARF1 regulates the Rho/MLC pathway to control EGF-
dependent breast cancer cell invasion. Mol Biol Cell, 2014. 25(1): p. 17-29.
100. Harrison, S.M., et al., LPA, HGF, and EGF utilize distinct combinations of signaling pathways to promote 
migration and invasion of MDA-MB-231 breast carcinoma cells. BMC Cancer, 2013. 13: p. 501.
101. de Rooij, J., et al., Integrin-dependent actomyosin contraction regulates epithelial cell scattering. J Cell 
Biol, 2005. 171(1): p. 153-64.
102. Oyanagi, J., et al., Epithelial-mesenchymal transition stimulates human cancer cells to extend microtu-
bule-based invasive protrusions and suppresses cell growth in collagen gel. PLoS One, 2012. 7(12): p. 
e53209.
103. Wang, F. and S.L. Lin, Knockdown of kinesin KIF11 abrogates directed migration in response to epider-
mal growth factor-mediated chemotaxis. Biochem Biophys Res Commun, 2014. 452(3): p. 642-8.
104. Takahashi, K. and K. Suzuki, Requirement of kinesin-mediated membrane transport of WAVE2 along 
microtubules for lamellipodia formation promoted by hepatocyte growth factor. Exp Cell Res, 2008. 
314(11-12): p. 2313-22.
105. Wei, Z., et al., STAT3 interacts with Skp2/p27/p21 pathway to regulate the motility and invasion of 
gastric cancer cells. Cell Signal, 2013. 25(4): p. 931-8.
106. Felkl, M., et al., Monitoring the cytoskeletal EGF response in live gastric carcinoma cells. PLoS One, 
2012. 7(9): p. e45280.
107. Ekman, M., et al., APC and Smad7 link TGFbeta type I receptors to the microtubule system to promote 
cell migration. Mol Biol Cell, 2012. 23(11): p. 2109-21.
2Plasticity of tumor cell invasion – governance by growth factors and cytokines | 43
108. Hyder, C.L., et al., Nestin regulates prostate cancer cell invasion by influencing the localisation and 
functions of FAK and integrins. J Cell Sci, 2014. 127(Pt 10): p. 2161-73.
109. Hou, K.Z., Z.Q. Fu, and H. Gong, Chemokine ligand 20 enhances progression of hepatocellular carci-
noma via epithelial-mesenchymal transition. World J Gastroenterol, 2015. 21(2): p. 475-83.
110. Maier, H.J., et al., NF-kappaB promotes epithelial-mesenchymal transition, migration and invasion of 
pancreatic carcinoma cells. Cancer Lett, 2010. 295(2): p. 214-28.
111. Ogunwobi, O.O. and C. Liu, Hepatocyte growth factor upregulation promotes carcinogenesis and 
epithelial-mesenchymal transition in hepatocellular carcinoma via Akt and COX-2 pathways. Clin Exp 
Metastasis, 2011. 28(8): p. 721-31.
112. Yoshida, K., et al., Transforming growth factor-beta transiently induces vimentin expression and invasive 
capacity in a canine mammary gland tumor cell line. Res Vet Sci, 2013. 94(3): p. 539-41.
113. Busch, T., et al., Keratin 8 phosphorylation regulates keratin reorganization and migration of epithelial 
tumor cells. J Cell Sci, 2012. 125(Pt 9): p. 2148-59.
114. Fortier, A.M., et al., Akt isoforms regulate intermediate filament protein levels in epithelial carcinoma 
cells. FEBS Lett, 2010. 584(5): p. 984-8.
115. Moch, M., et al., Measuring the regulation of keratin filament network dynamics. Proc Natl Acad Sci U 
S A, 2013. 110(26): p. 10664-9.
116. Kim, H.J., W.J. Choi, and C.H. Lee, Phosphorylation and Reorganization of Keratin Networks: Implica-
tions for Carcinogenesis and Epithelial Mesenchymal Transition. Biomol Ther (Seoul), 2015. 23(4): p. 
301-12.
117. Egeblad, M., M.G. Rasch, and V.M. Weaver, Dynamic interplay between the collagen scaffold and 
tumor evolution. Curr Opin Cell Biol, 2010. 22(5): p. 697-706.
118. Curran, C.S. and P.J. Keely, Breast tumor and stromal cell responses to TGF-beta and hypoxia in matrix 
deposition. Matrix Biol, 2013. 32(2): p. 95-105.
119. Conklin, M.W., et al., Aligned collagen is a prognostic signature for survival in human breast carcinoma. 
Am J Pathol, 2011. 178(3): p. 1221-32.
120. Plotnikov, S.V., et al., Force fluctuations within focal adhesions mediate ECM-rigidity sensing to guide 
directed cell migration. Cell, 2012. 151(7): p. 1513-27.
121. De Wever, O., et al., Stromal myofibroblasts are drivers of invasive cancer growth. International Journal 
of Cancer, 2008. 123(10): p. 2229-38.
122. Hall, M.C., et al., The comparative role of activator protein 1 and Smad factors in the regulation of 
Timp-1 and MMP-1 gene expression by transforming growth factor-beta 1. J Biol Chem, 2003. 278(12): 
p. 10304-13.
123. Leivonen, S.K., et al., TGF-beta-elicited induction of tissue inhibitor of metalloproteinases (TIMP)-3 
expression in fibroblasts involves complex interplay between Smad3, p38alpha, and ERK1/2. PLoS One, 
2013. 8(2): p. e57474.
124. Kinoshita, T., et al., Antifibrotic response of cardiac fibroblasts in hypertensive hearts through enhanced 
TIMP-1 expression by basic fibroblast growth factor. Cardiovasc Pathol, 2014. 23(2): p. 92-100.
125. Cox, T.R., et al., LOX-mediated collagen crosslinking is responsible for fibrosis-enhanced metastasis. 
Cancer Res, 2013. 73(6): p. 1721-32.
126. Levental, K.R., et al., Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell, 
2009. 139(5): p. 891-906.
127. Taylor, M.A., et al., Lysyl oxidase contributes to mechanotransduction-mediated regulation of trans-
forming growth factor-beta signaling in breast cancer cells. Neoplasia, 2011. 13(5): p. 406-18.
44 | Chapter 2
128. Ulrich, T.A., E.M. de Juan Pardo, and S. Kumar, The mechanical rigidity of the extracellular matrix 
regulates the structure, motility, and proliferation of glioma cells. Cancer Research, 2009. 69(10): p. 
4167-74.
129. Weigelin, B., G.J. Bakker, and P. Friedl, Intravital third harmonic generation microscopy of collective 
melanoma cell invasion. IntraVital, 2012. 1(1): p. 32-43.
130. Ilina, O., et al., Two-photon laser-generated microtracks in 3D collagen lattices: principles of MMP-
dependent and -independent collective cancer cell invasion. Phys Biol, 2011. 8(1): p. 015010.
131. Haeger, A., et al., Cell jamming: collective invasion of mesenchymal tumor cells imposed by tissue 
confinement. Biochim Biophys Acta, 2014. 1840(8): p. 2386-95.
132. Wolf, K., et al., Multi-step pericellular proteolysis controls the transition from individual to collective 
cancer cell invasion. Nat Cell Biol, 2007. 9(8): p. 893-904.
133. Wolf, K., et al., Physical limits of cell migration: control by ECM space and nuclear deformation and 
tuning by proteolysis and traction force. J Cell Biol, 2013. 201(7): p. 1069-84.
134. Lu, P., et al., Extracellular matrix degradation and remodeling in development and disease. Cold Spring 
Harb Perspect Biol, 2011. 3(12).
135. Matrisian, L.M. and B.L. Hogan, Growth factor-regulated proteases and extracellular matrix remodeling 
during mammalian development. Curr Top Dev Biol, 1990. 24: p. 219-59.
136. Schultz, G.S. and A. Wysocki, Interactions between extracellular matrix and growth factors in wound 
healing. Wound Repair Regen, 2009. 17(2): p. 153-62.
137. Oxmann, D., et al., Endoglin expression in metastatic breast cancer cells enhances their invasive pheno-
type. Oncogene, 2008. 27(25): p. 3567-75.
138. Lee, S.J., et al., Activation of matrix metalloproteinase-9 by TNF-alpha in human urinary bladder cancer 
HT1376 cells: the role of MAP kinase signaling pathways. Oncol Rep, 2008. 19(4): p. 1007-13.
139. Itoh, M., et al., Requirement of STAT3 activation for maximal collagenase-1 (MMP-1) induction by 
epidermal growth factor and malignant characteristics in T24 bladder cancer cells. Oncogene, 2006. 
25(8): p. 1195-204.
140. Sun, W., et al., Interleukin-6 promotes the migration and invasion of nasopharyngeal carcinoma cell 
lines and upregulates the expression of MMP-2 and MMP-9. Int J Oncol, 2014. 44(5): p. 1551-60.
141. Ozaki, I., et al., Induction of multiple matrix metalloproteinase genes in human hepatocellular carcinoma 
by hepatocyte growth factor via a transcription factor Ets-1. Hepatol Res, 2003. 27(4): p. 289-301.
142. Zhang, D. and P. Brodt, Type 1 insulin-like growth factor regulates MT1-MMP synthesis and tumor 
invasion via PI 3-kinase/Akt signaling. Oncogene, 2003. 22(7): p. 974-82.
143. Bonnans, C., J. Chou, and Z. Werb, Remodelling the extracellular matrix in development and disease. 
Nat Rev Mol Cell Biol, 2014. 15(12): p. 786-801.
144. Sanz-Moreno, V. and C.J. Marshall, The plasticity of cytoskeletal dynamics underlying neoplastic cell 
migration. Curr Opin Cell Biol, 2010. 22(5): p. 690-6.
145. Zaritsky, A., et al., Emergence of HGF/SF-induced coordinated cellular motility. PLoS One, 2012. 7(9): p. 
e44671.
146. Poujade, M., et al., Collective migration of an epithelial monolayer in response to a model wound. Proc 
Natl Acad Sci U S A, 2007. 104(41): p. 15988-93.
147. Hwang, S., et al., E-cadherin is critical for collective sheet migration and is regulated by the chemokine 
CXCL12 protein during restitution. J Biol Chem, 2012. 287(26): p. 22227-40.
148. Zhao, S., J. Wang, and C. Qin, Blockade of CXCL12/CXCR4 signaling inhibits intrahepatic cholangiocar-
cinoma progression and metastasis via inactivation of canonical Wnt pathway. J Exp Clin Cancer Res, 
2014. 33: p. 103.
2Plasticity of tumor cell invasion – governance by growth factors and cytokines | 45
149. Lamouille, S., J. Xu, and R. Derynck, Molecular mechanisms of epithelial-mesenchymal transition. Nat 
Rev Mol Cell Biol, 2014. 15(3): p. 178-96.
150. Lee, J.M., et al., The epithelial-mesenchymal transition: new insights in signaling, development, and 
disease. J Cell Biol, 2006. 172(7): p. 973-81.
151. Thiery, J.P., Epithelial-mesenchymal transitions in tumour progression. Nature Reviews Cancer, 2002. 
2(6): p. 442-454.
152. Li, H.M., et al., Ubiquitin ligase Cbl-b represses IGF-I-induced epithelial mesenchymal transition via ZEB2 
and microRNA-200c regulation in gastric cancer cells. Molecular Cancer, 2014. 13.
153. Wong, I.Y., et al., Collective and individual migration following the epithelial-mesenchymal transition. 
Nature Materials, 2014. 13(11): p. 1063-1071.
154. Matise, L.A., et al., Lack of transforming growth factor-beta signaling promotes collective cancer cell 
invasion through tumor-stromal crosstalk. Breast Cancer Res, 2012. 14(4): p. R98.
155. Waldmeier, L., et al., Py2T Murine Breast Cancer Cells, a Versatile Model of TGF beta-Induced EMT In 
Vitro and In Vivo. PLoS One, 2012. 7(11).
156. Giampieri, S., et al., Localized and reversible TGFbeta signalling switches breast cancer cells from cohe-
sive to single cell motility. Nat Cell Biol, 2009. 11(11): p. 1287-96.
157. Wyse, M.M., et al., Dia-interacting protein (DIP) imposes migratory plasticity in mDia2-dependent tumor 
cells in three-dimensional matrices. PLoS One, 2012. 7(9): p. e45085.
158. Zhou, H.Y., Y.L. Pon, and A.S. Wong, Synergistic effects of epidermal growth factor and hepatocyte 
growth factor on human ovarian cancer cell invasion and migration: role of extracellular signal-regulated 
kinase 1/2 and p38 mitogen-activated protein kinase. Endocrinology, 2007. 148(11): p. 5195-208.
159. Badache, A. and N.E. Hynes, Interleukin 6 inhibits proliferation and, in cooperation with an epidermal 
growth factor receptor autocrine loop, increases migration of T47D breast cancer cells. Cancer Res, 
2001. 61(1): p. 383-91.
160. Buonato, J.M., I.S. Lan, and M.J. Lazzara, EGF augments TGFbeta-induced epithelial-mesenchymal 
transition by promoting SHP2 binding to GAB1. J Cell Sci, 2015. 128(21): p. 3898-909.
161. Saito, A., et al., An integrated expression profiling reveals target genes of TGF-beta and TNF-alpha 
possibly mediated by microRNAs in lung cancer cells. PLoS One, 2013. 8(2): p. e56587.
162. Schlegel, N.C., et al., PI3K signalling is required for a TGFbeta-induced epithelial-mesenchymal-like 
transition (EMT-like) in human melanoma cells. Exp Dermatol, 2015. 24(1): p. 22-8.
163. Sato, K., et al., Expression of tumour-suppressing chemokine BRAK/CXCL14 reduces cell migration rate 
of HSC-3 tongue carcinoma cells and stimulates attachment to collagen and formation of elongated 
focal adhesions in vitro. Cell Biol Int, 2010. 34(5): p. 513-22.
164. Kachroo, P., et al., IL-27 inhibits epithelial-mesenchymal transition and angiogenic factor production in a 
STAT1-dominant pathway in human non-small cell lung cancer. J Exp Clin Cancer Res, 2013. 32: p. 97.
165. Ho, M.Y., et al., IL-27 directly restrains lung tumorigenicity by suppressing cyclooxygenase-2-mediated 
activities. J Immunol, 2009. 183(10): p. 6217-26.
166. Kim, B.J., et al., Cooperative roles of SDF-1alpha and EGF gradients on tumor cell migration revealed by 
a robust 3D microfluidic model. PLoS One, 2013. 8(7): p. e68422.
167. Mosadegh, B., et al., Epidermal growth factor promotes breast cancer cell chemotaxis in CXCL12 
gradients. Biotechnol Bioeng, 2008. 100(6): p. 1205-13.
168. Kuga, H., et al., Interferon-gamma suppresses transforming growth factor-beta-induced invasion of 
gastric carcinoma cells through cross-talk of Smad pathway in a three-dimensional culture model. 
Oncogene, 2003. 22(49): p. 7838-47.
46 | Chapter 2
169. Yan, X., et al., Smad7 Protein Interacts with Receptor-regulated Smads (R-Smads) to Inhibit Transform-
ing Growth Factor-beta (TGF-beta)/Smad Signaling. J Biol Chem, 2016. 291(1): p. 382-92.
170. Kalykaki, A., et al., Elimination of EGFR-expressing circulating tumor cells in patients with metastatic 
breast cancer treated with gefitinib. Cancer Chemother Pharmacol, 2014. 73(4): p. 685-93.
171. Musella, V., et al., Circulating tumor cells as a longitudinal biomarker in patients with advanced che-
morefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab. Int J Cancer, 
2015. 137(6): p. 1467-74.
172. Punnoose, E.A., et al., Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell 
lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. 
Clin Cancer Res, 2012. 18(8): p. 2391-401.
173. Sachdev, D., et al., The type I insulin-like growth factor receptor regulates cancer metastasis indepen-
dently of primary tumor growth by promoting invasion and survival. Oncogene, 2010. 29(2): p. 251-62.
174. Alexander, S. and P. Friedl, Cancer invasion and resistance: interconnected processes of disease progres-
sion and therapy failure. Trends Mol Med, 2012. 18(1): p. 13-26.
175. Alexander, S., et al., Preclinical intravital microscopy of the tumour-stroma interface: invasion, metasta-
sis, and therapy response. Curr Opin Cell Biol, 2013. 25(5): p. 659-71.
176. Conway, J.R., N.O. Carragher, and P. Timpson, Developments in preclinical cancer imaging: innovating 
the discovery of therapeutics. Nat Rev Cancer, 2014. 14(5): p. 314-28.
177. Ellenbroek, S.I. and J. van Rheenen, Imaging hallmarks of cancer in living mice. Nat Rev Cancer, 2014. 
14(6): p. 406-18.
178. Huang, B., et al., The three-way switch operation of Rac1/RhoA GTPase-based circuit controlling 
amoeboid-hybrid-mesenchymal transition. Sci Rep, 2014. 4: p. 6449.
179. Huang, B., et al., Modeling the Transitions between Collective and Solitary Migration Phenotypes in 
Cancer Metastasis. Sci Rep, 2015. 5: p. 17379.
180. Tozluoglu, M., et al., Matrix geometry determines optimal cancer cell migration strategy and modulates 
response to interventions. Nat Cell Biol, 2013. 15(7): p. 751-62.
181. te Boekhorst, V., L. Preziosi, and P. Friedl, Plastiticy of cell migration in vivo and in silico. Annu Rev Cell 
Dev Biol, 2016. 32: p. in press.


Chapter 3
Growth factor-induced plasticity of invasion 
induces eMT with amoeboid traits
Julia Odenthal1,2, Moniek Raaijmakers2, Harsha Mahabaleshwar3, 
Sebastian Sommer2, Reidar Grenman4, Robert Takes1, Peter Friedl2,5,6
1 Department of Otorhinolaryngology and Head and Neck Surgery, 
Radboudumc, Nijmegen, The Netherlands
2 Department of Cell Biology, RIMLS, Nijmegen, The Netherlands
3 National Institutes of Health, Section on Neural Developmental Dynamics, Bethesda, MD, USA
4 Department of Otorhinolaryngology-Head and Neck Surgery, Turku 
University and University Hospital, Turku, Finland
5 Genitourinary Medical Oncology, UT MD Anderson Cancer Center, Houston, TX, United States
6 Cancer Genomics Center, Utrecht, The Netherlands
Manuscript in preparation
50 | Chapter 3
Metastatic cancer progression is mediated by adaptive collective, mesenchymal and amoeboid 
invasion programs as well as molecular plasticity, including the epithelial-to-mesenchymal transi-
tion (EMT). However which cancer invasion strategies associate with EMT, and which not, remains 
poorly defined. During 3D collagen-based coculture with fibroblasts or exposure to fibroblast-
conditioned medium stimulating the HGF/c-Met axis, head-and-neck squamous cell carcinoma 
(HNSCC) spheroids developed collective invasion patterns connected by E-cadherin-positive 
cell-cell junctions which transited to single-cell dissemination with elongated, mesenchymal-like 
(<30% of detached cells) or roundish-amoeboid (>70%) movement, downregulated E-cadherin 
and notable collagenolytic migration track generation. In a cell-line dependent manner, both 
collective and individual invasion zones expressed the EMT-marker vimentin with approximately 
20% (SCC38) up to 80% (SCC58) frequency, detected by 3D single-cell cytometry. Vimentin-
positive and -negative cells were competent for collective or amoeboid migration. Neutralizing 
anti-HGF antibody or pharmacological c-Met inhibitor SU11274 eliminated single cell dissemina-
tion and reduced collective invasion, indicating differential sensitivity to targeted intervention. In 
summary, HGF induces EMT together with collective, proteolytic-amoeboid and, less frequently, 
mesenchymal invasion, indicating EMT as a probabilistic molecular program associated with any 
invasion strategy.
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InTRODuCTIOn
The invasion of cancer cells into the adjacent tissue initiates metastasis and thereby contributes 
to increased mortality of cancer patients. Invading cancer cells apply cytoskeletal activity towards 
extracellular matrix (ECM) and adapt their migration strategies to accommodate local signaling 
and tissue signatures, either as single cells without cell-cell interactions to neighboring cells [1] or 
as multicellular groups with cell-cell junctions and cytoskeletal coordination between neighboring 
cells retained [2]. Both single-cell and collective invasion modes can interconvert in response to 
cell-intrinsic or microenvironmental programs [3]. Weakening of cell-cell junctions allows cells 
to detach from a cell group and migrate individually [4-6]. Modulating cell adhesion and pro-
tease activity can support interconversions between single-cell migration modes. Mesenchymal 
movement, characterized by elongated cell morphologies, strong cell-matrix interactions and 
proteolytic ECM remodeling, can switch to amoeboid movement, with roundish yet adaptive cell 
morphology, low adhesion force and diminished proteolytic ECM processing [7-9]. Whereas col-
lective migration depends upon tissue remodeling to form multi-cellular or epithelial structures, 
mesenchymal and amoeboid migration are considered to enable efficient cancer-cell spread 
throughout interstitial tissues [4, 8, 10]. Whereas the basic mechanisms underlying individual 
and collective cell migration modes have been established in vitro and in vivo [11, 12], the micro-
environmental stimuli prompting switching of migration modes and their relation to molecular 
plasticity of cancer disease, including adhesion and cytoskeletal plasticity and the epithelial-to-
mesenchymal transition (EMT), remain poorly defined [11, 13, 14].
External triggers controlling plasticity of cell migration include ECM topology [15], promigratory 
factors released by stromal cells [13, 14] and stabilization of HIF-1α by hypoxia [5]. Activated 
fibroblasts can induce and guide tumor invasion by remodeling and aligning ECM, and this 
directs tumor cell migration by providing heterotypic cell-cell contacts and guidance by aligned 
tissue paths [16-18]. Cytokines and growth factors, including TGF-β, HGF or EGF released by the 
stroma or tumor cells themselves induces EMT, which destabilizes cell-cell adhesion and causes 
single-cell dissemination [19]. EMT is a multi-signal molecular program induced by transcription 
factors snail, slug and/or twist which downregulate E-cadherin dependent adherens junctions, 
upregulate mesenchymal markers, and stimulate cell migration [20]. Whereas EMT-dependent 
induction of mesenchymal single-cell invasion is well established [20], a range of EMT-associated 
other migration modes were predicted by in silico modeling, including collective and amoeboid 
migration and their interconversion [21, 22], awaiting wet-lab confirmation [23].
Using fibroblast-induced invasion in 3D spheroid models, we here classify the invasion plasticity 
of epithelial cancer cells from head and neck squamous cell carcinomas (HNSCC) in response 
to HGF, and identify collective and single cell invasion and their interconversions, together with 
the induction of EMT at single-cell level. The data identify EMT as overarching program in both 
collective and single-cell migration modes after stimulation with growth factors, and reveal a 
previously unappreciated HGF-induced collagenolytic amoeboid migration with EMT signature.
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MaTeRIal MeThODS
Reagents and antibodies
The following antibodies (Ab) and reagents were used for immunofluorescence: monoclonal rat 
anti-tubulin Ab (Novus Biologicals, YOL 1/34, 1/200), polyclonal rabbit anti-vimentin Ab (Biotrend, 
rp115, 1/200), polyclonal rabbit Ab directed against the C-terminal cleavage neo-epitope of 
collagen I (Col3/4, immunoGlobe, 1µg/ml), monoclonal mouse anti-E-cadherin Ab (Zymed, SHE 
78-7, 1/100), secondary Alexa Fluor 546- and 647-conjugated pre-absorbed goat anti-mouse 
or goat anti-rabbit IgG (Invitrogen, 1/200), Alexa Fluor 488-conjugated phalloidin (Invitrogen, 
1/200), DAPI (Roche, 1/1000).
For functional live-cell experiments, the following antibodies and reagents were used: monoclo-
nal mouse anti-c-Met Ab (kind gift from Raffaella Albano, Univeristy of Turin, DO-24, 5µg/ml), 
isotypic mouse IgG2a kappa (BioLegend, 1/100), secondary Alexa Fluor 647 goat anti-mouse Ab 
(Invitrogen, 1/200), propidium iodide (Sigma, 5µg/ml).
The following antibodies were used for immunoblotting: polyclonal rabbit anti-GAPDH Ab 
(Sigma, G9545, 1/1000), monoclonal rabbit anti-c-Met Ab (Abcam, EP1454Y, 1/2500), monoclo-
nal mouse anti-E-cadherin Ab (BD Biosciences, 36, 1/500), polyclonal chicken anti-vimentin Ab 
(Abcam, ab24525, 1/100) and secondary IRDye680RD- or 800CW-conjugated goat anti-rabbit, 
-mouse or –chicken Ab (Licor, 1/10000).
For 3D migration assays, the following reagents were used: epidermal growth factor (EGF, 
Thermo Fisher Scientific, PHG0311), recombinant human hepatocyte growth factor (HGF; kind 
gift from Ralph Schwall, Genentech, South San Francisco, CA), monoclonal mouse anti-HGF 
neutralizing Ab (R&D systems), c-Met inhibitor SU11274 (Selleck Chemicals), GM6001 (ilomastat, 
Calbiochem, 5µM) and dimethylsulfoxid (DMSO) for spheroid invasion assay.
Cell culture
Human UT-SCC38 cells and UT-SCC58 cells were cultured in complete growth medium con-
sisting of Dulbecco’s modified Eagle medium (DMEM, Invitrogen), supplemented with 10% 
heat-inactivated fetal calf serum (FCS, Sigma Aldrich), 100 U/ml penicillin (PAA) and 100 ug/
ml streptomycin (PAA), 2 mM L-glutamine (Invitrogen/Life Technologies), 20 mM HEPES buffer 
solution (Invitrogen/Life Technologies) and 1 mM sodium pyruvate (Invitrogen/Life technologies).
MRC5 fibroblasts (ATCC) and cancer associated fibroblasts (CAFs) derived from the UT-SCC38 
tumor (CAF553) were cultured in DMEM supplemented with 200 nm L-glutamine, 100 U/ml 
penicillin and 100 ug/ml streptomycin and 10% FCS. Conditioned medium (CM) from MCR5 
fibroblast culture was obtained 4 and again 8 days after reaching 100% confluency. CM was 
filtered (0.22 µm pore sized filter, Corning) and stored at -20°C.
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3D tumor spheroid culture
Sub-confluent cells were detached using trypsin/EDTA (Life Technologies) and aggregated to 
multicellular tumor spheroids using the hanging-drop method. Cells were suspended in DMEM 
supplemented with 10% methylcellulose solution (Sigma) and incubated as 25 µl droplets 
overnight (500 cells/drop). After overnight incubation, spheroids were harvested, washed with 
PBS and full growth medium and embedded non-pepsinized rat tail type I collagen lattices (BD 
Biosciences, final concentration: 2.5 mg/ml) in 12- or 24-well plates. For coculture experiments, 
MRC5 or CAF553 fibroblasts were added to the collagen solution (15 000 cells/100 µl) prior 
polymerization. Spheroids were allowed to invade for 72 h after incubation with full growth me-
dium, fibroblast CM in different dilution and/or the presence of rhHGF, nAb HGF, EGF, SU11274, 
DMSO and GM6001.
Immunofluorescence and imaging of spheroids
For routine immunofluorescence analysis of invasion plasticity in collagen-embedded 3D spher-
oids were fixed in 4% in phosphate buffered paraformaldehyde (PFA) at 37°C for 20 min, washed 
(PBS) and stained with DAPI and phalloidin (30 min, 20°C). For detection of intracellular proteins, 
fixed and washed samples were incubated in PBS-buffered 5% normal goat serum (NGS) and 
0.3% Triton X-100 (Sigma; 90 min, 20°C). All antibodies were dissolved in PBS containing 0.1% 
bovine serum albumin (BSA) (Aurion) and 0.3% Triton X-100 (Sigma). Unless stated otherwise, 
primary antibodies were incubated overnight at 4°C and secondary antibodies for 3 h at RT, 
followed by rigorous washing (6x 5 min) in excess PBS. Col3/4 staining was performed at 4°C.
Confocal fluorescence microscopy for up to four channels was performed by sequential confocal 
scanning keeping an inter-slice distance of 10 µm (Olympus FV100) using 10x/0.4 NA, 20x/0.5 NA 
and 40x/0.8 NA water objectives or, for up to five channels, a Leica TCS SP8 scanner equipped 
with 10x/0.4 NA air and 40x/0.85 NA water objectives.
assessment of migration mode
The types of invasion including the number of cohesive strands (>50 µm in length) and number 
of detached single cells and clusters (>50 µm diameter) was counted after 72 h of invasion 
by bright-field microscopy using 10x NA 0.20 and 20x NA 0.30 air objectives (Sentech CCD 
camera). Elongation index (length / width) was measured from time-lapse recordings every hour 
using Fiji/ImageJ (software version 1.51k, http://fiji.sc/Fiji). Cells with an elongation index <3 were 
considered “rounded” and cells with an elongation index ≥3 were considered as “elongated”.
End-point data on the invasion type of detached and moving single cells as well as MMP inhibi-
tion were validated by time-lapse microscopy. Spheroids were grown for 64h with 0, 5 or 50% 
CM and monitored (20x/0.5) under humidified conditions (Oko-lab stage incubator, Ottaviano, 
Italy; 5% CO2, 37°C) [24].
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Image quantification and data analysis
The fluorescence intensity of E-cadherin and vimentin associated with different migration types 
were quantified from 3D samples using single slices or stacks composed of 2-3 slides and nor-
malized to tubulin (Fiji/ImageJ software version 1.51k, http://fiji.sc/Fiji; Suppl. Fig. 5B, 6A). For 
E-cadherin, regions of interest (ROI) were defined manually to represent the non-invading rim of 
the spheroid, multicellular invasion strands and detached cells. For detecting vimentin at single-
cell level, ROIs were drawn around individual cells.
To measure vimentin intensities over time, round ROIs with an area of 345 pixels (SCC38) and 
275 pixels (SCC58) were positioned over nuclei based on DAPI signal. Background values from 
cell-free areas of the same images were subtracted for each specific measurement and fluores-
cence channel. and the ratios of specific signal were calculated. Normalized intensity ratios for 
vimentin/DAPI (>0.0815 = 10% for SCC38 at time point 0h and >0.1225 = 33% for SCC58 at 
time point 0h) were defined manually as threshold discriminating between vimentin-positive and 
cell-associated background values. Unspecific IgG / tubulin ratios were below threshold values.
Reverse transcription and qPCR
Total RNA was extracted from tumour spheroids or fibroblasts grown in 3D organotypic 2.5mg/
ml collagen cultures using the RNEasy mini kit (Qiagen, 74104). About 1µg of this total RNA from 
each sample was used as the input for cDNA synthesis using the RT2 First Strand kit (Qiagen, 
330401) and the reverse transcription performed according to manufacturer’s recommendations. 
The cDNA thus obtained was mixed with the RT2 SYBR Green qPCR Mastermix (Qiagen, 330503) 
and robotically loaded on to a 96 well Custom RT2 Profiler PCR Array (Qiagen, 330131), followed 
by qPCR cycling and fluorescence data collection on a Bio-Rad CFX96.
Generation of stable c-Met knockdown cells
To create MET knockdown constructs, shMET1 (GTATGTCCATGCCTTTGAA) and shMET2 (GTAT-
GTCCATGCCTTTGAA) oligonucleotide heteroduplexes were ligated in pENTR/U6 vector and sub-
sequently Gateway-cloned into pLenti6/BLOCK-iT-DEST according to the manufacturer’s protocols 
(Invitrogen). Generation of lentiviruses was done in HEK293FT cells as described previously [25]. A 
control group was transfected with a shscramble-EGFP vector (pLenti6/BLOCK-iT-DEST-EGFP) [26]. 
Cells were selected based on blastocidin resistance and knockdown efficacy was assessed with 
flow cytometry up to 4 weeks after transfection. Live cells were stained on ice and viability was 
verified with propidium iodide. Stained cells were evaluated with a FACSCalibur flow cytometer 
(BD Bioscience) and the data was analyzed with the FCS Express software (De Novo Software).
Immunoblotting
Western blot analysis of protein expression was performed using spheroids cultured in 2.5 mg/
ml collagen gels for 72 h with 0, 5 or 50% CM or whole cell lysates from cells cultured on 2D. 
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Collagen gels were washed with PBS before lysis with lysis buffer (100 mM Tris HCl pH 6.8, 4% 
SDS, 20% glycerol, 200 mM DTT, bromphenol blue) supplemented with a protease inhibitor 
cocktail (Roche). Lysates were boiled at 95°C for 10 min and then loaded on an 8% SDS-PAGE gel 
and transferred by electroblotting in transfer buffer onto PVDF membranes (Milipore). Antibody 
complexes were imaged with the Odyssey CLx scanner (Licor).
Reversed phase protein assay
The protocol provided by the MD Anderson Cancer Center for preparation of tumor lysate from 
frozen tissue was used with following modifications: SCC spheroids were cultured in 2.5 mg/ml 
collagen gels for 72 h with 0, 5 or 50% CM as described previously. Gels were quickly washed 
with PBS and immediately shock frozen in liquid nitrogen until further use. Cells were lysed in 
ice-cold lysis buffer using an electric homogenizer and analyzed at the RPPA facility at the MD 
Anderson Cancer Center.
Normalized linear data was used for the heatmap generation.
Statistical analysis
Unless stated otherwise, statistical analysis was performed using the non-parametric Mann-
Whitney test with a post-hoc correction for multiple comparisons with p≤0.05/N indicated by *, 
p<0.001/N indicated by ** and p<0.0001/N by ***. Normalized ratiometric data were statistically 
analyzed as log transformed data using a paired T test.
ReSulTS
fibroblast-induced plasticity of hnSCC cell invasion
HNSCC SCC38 and SCC58 cells, embedded as multicellular spheroids in 3D fibrillar collagen 
under FCS-containing medium conditions, developed only low-level spontaneous invasion with-
out notable single-cell detachment (Fig. 1A and Suppl. Movie 3 and 4). To stimulate invasion, 
cancer associated fibroblasts derived from the same tumor as SCC38 cells (CAF 553) or MRC5 
human lung fibroblasts were seeded in the 3D collagen matrix at the time point of spheroid 
incorporation, and both fibroblast types enhanced the efficacy of invasion (Fig. 1A, C). In contrast 
to previous evidence of exclusively collective invasion induced by fibroblasts [17, 18], both CAF 
553 and MRC5 fibroblasts induced collective invasion (Fig. 1A, black arrowheads) as well as 
detaching single-cell migration in SCC38 and SCC58 cells (Fig 1A, white arrowheads; Fig. 1C 
and Suppl. Movie 1 and 2) as seen in 3D reconstructions of HNSCC patient samples [27]. CAF 
553 cells grew poorly after passaging and failed to produce conditioned medium in quantities 
required to stimulate spheroid cultures, therefore conditioned medium from MRC5 cells was used 
for further analyses. MRC5-conditioned medium was sufficient to induce collective migration 
at low concentration and an increasing proportion of detaching cell clusters and single cells 
at higher concentration (Fig. 1B, C; Suppl. Fig. 1; Movie 3 and 4). SCC38 cells responded to 
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figure 1 Induction of plasticity of invasion in HNSCC spheroids by fibroblasts. a Overview (left) and zoomed 
(right) brightfield images showing SCC38 and SCC58 spheroids in rat tail collagen after 72 h of incubation 
with or without the presence of cancer-associated fibroblasts (CAF) or MRC5 lung fibroblasts. b Confocal 3D 
stack images of spheroids after 72 h culture with increasing concentration of MCR5 fibroblast conditioned 
medium (CM). Black arrowheads denote cohesive strands, white arrowheads detached single cells, and green 
arrows cortical actin. C Quantification of invasion modes originating from SCC spheroids incubated with 
MRC5 cells or CM. Data show box whiskers, from at least 12 spheroids from 3 independent experiments. 
Scale bars, 100 µm (overview) and 20 µm (detail).
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50% conditioned medium with near-complete individualization, whereas SCC58 cells retained a 
larger proportion of collective strands and disseminating clusters, alongside detached single cells 
(Fig. 1B, C; Suppl. Fig. 1). The spectrum of collective and single-cell invasion in response to low 
concentrations of conditioned medium (1-5%) recapitulated in both HNSCC models closely the 
spectrum of invasion modes during co-culture with fibroblasts (Fig. 1C), suggesting that soluble 
factors released by fibroblasts were sufficient to induce invasion plasticity.
hGf as non-redundant mediator of fibroblast-induced invasion plasticity
A quantitative RT-PCR screen of growth factors, cytokines and their respective receptors ex-
pressed by SCC38, CAF553 and MRC5 cells identified candidate migration-inducing cytokines 
and chemokines, including HGF, EGF and CXCL12, expressed by fibroblasts and their respective 
receptors c-Met, EGFR and CXCR7 but not CXCR4 in SCC38 cells (Fig. 2A and Suppl. Fig. 2A). 
This confirms HGF and CXCL12/SDF-1 expression in MRC5 cells or CAFs in HNSCC [28-30] and 
c-Met and CXCR7 expression in HNSCC cells [31, 32]. Both SCC38 and SCC58 cells expressed c-
Met protein (Fig. 2B) and developed a spectrum of collective and single-cell migration types when 
increasing concentrations of recombinant human HGF, at concentrations reached in body fluids 
of disease models (up 10-77 ng/ml) [33, 34], were added to the culture (Fig. 2C, D and Suppl. 
Fig. 3A). Thus HGF recapitulated the response to MRC5-conditioned medium and consistently, 
downregulation of c-Met protein in SCC38 and SCC58 cells by RNA interference (Suppl. Fig. 2B; 
60-80% reduction) was sufficient to compromise the induction of invasion by HGF, by inhibiting 
collective and fully reverting single cell migration (Fig. 2E, F). These data indicate that soluble HGF, 
through interaction with c-Met, induces plasticity of invasion. Deregulation of the HGF/c-Met 
signaling pathway is known to stimulate cancer growth, EMT and metastatic lesions in preclinical 
models and associates with metastatic progression in cancer patients [35, 36]. To test whether 
other ligand/receptor systems are able to induce similar invasion plasticity, EGF was added to 
spheroid cultures. EGF induced collective invasion at low concentrations and both collective and 
single cell migration at high dose (Suppl. Fig. 3B). Thus, HNSCC cells translate the concentration 
of extracellular HGF, EGF and fibroblast-conditioned medium by first initiating collective invasion 
figure 2 (next page) HGF as dominant inducer of invasion plasticity. a Expression of cytokine and growth 
factor receptors and their ligands measured by RT-qPCR in SCC38, CAF553 and MRC5 cells after 60 h (SCC38) 
or 36 h (fibroblasts) of culture in rat tail collagen. The horizontal line indicates the threshold cycle. Data rep-
resent the mean values and standard deviation from selected molecules from 3 independent experiments 
(see full list in Suppl. Information, Fig. 2). b Western blot analysis of SCC38 and SCC58 cells, representing 2 
independent experiments. C, D Brightfield images (C) and quantitative analysis (D) of 3D SCC spheroid culture 
incubated with CM from MRC5 cells or recombinant human hepatocyte growth factor (rhHGF) for 72 h. Data 
represent at least 9 spheroids from 3 independent experiments. P values compare invasion patterns induced 
by CM and rhHGF. e, f Brightfield images (E) and quantitative analysis of invasion plasticity of SCC control and 
c-Met shRNA expressing spheroids after stimulation with 50% CM from MRC5 cells for 72 h. Data originated 
from at least 9 spheroids from 3 independent experiments. Scale bars indicate 100 µm. Black arrowheads 
denote cohesive strands, white arrowheads detached single cells.
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and, with higher concentrations, causing a switch to single-cell dissemination. Although EGF 
induces similar plasticity in migration and mRNA was expressed in MRC5 fibroblasts, targeted 
downregulation of c-Met was sufficient to revert both single-cell and collective invasion indicat-
ing that HGF was relevant in mediating fibroblast-induced plasticity.
fibroblast-derived growth factors induce eMT diversity
We next addressed whether fibroblast-conditioned medium induces EMT in SCC38 and SCC58 
cells, similar to HGF and other growth factors in other models [37-39]. The regulation of EMT-
associated proteins was analyzed in tumor cell lysates after spheroid culture by Reverse Phase 
Protein Array (Suppl. Fig. 4A). EMT markers including E-cadherin, N-cadherin, Snail and Twist 
remained unchanged after stimulation by fibroblast-conditioned medium, whereas phosphoryla-
tion of effectors downstream of c-Met was induced, including Akt, B-Raf and Stat3 (Suppl. Fig. 
4B). Parallel Western blot analysis of E-cadherin and vimentin indicated a mild but inconsistent 
protein down- or up-regulation, respectively (Suppl. Fig. 4C). Despite the strong pro-invasive 
effects in cell subsets, we reasoned that the fraction of invading cells in spheroid cultures may 
be insufficient to significantly impact protein levels in bulk cultures and therefore performed 
validation using single-cell analysis of EMT-related proteins in situ. In control spheroids E-cadherin 
was mainly present in cell-cell junctions, however after stimulation with conditioned medium 
E-cadherin re-localized to the cytoplasm in both collective strands and detached single cells 
figure 3 (previous page) Induction of vimentin expression and association with migration modes. a Confo-
cal stack images of SCC spheroids after 72 h invasion in rat tail collagen. Scale bars indicate 100 µm (over-
view) and 20 µm (detail). Black arrows denote vimentin negative and white arrows vimentin positive cells. b 
Single-cell 3D cytometry of vimentin expression relative to tubulin (see detailed workflow in suppl. Figure 6). 
Data originate from at least 6 spheroids from 3 independent experiments. Numbers indicate vimentin positive 
percentage of cells. C Elongation index (length/width) of detached single cells plotted against the vimentin/tu-
bulin expression ratio. Numbers in cell images indicate the elongation index as example and fluorescence col-
ors represent tubulin (red) and nuclei (blue). Horizontal lines separate vimentin positive and negative events, 
vertical lines rounded from elongated cells. Data represent 20-92 cells from 3 independent experiments.
figure 4 (next page) Proteolytic movement of rounded cells after detachment from spheroid. a Stability of 
roundish cell shape after detachment. False-color representation of the elongation index over time obtained 
from time-lapse brightfield movies. b Confocal stack images of SCC spheroids incubated with 50% CM for 
72 h. Yellow arrowheads denote zones positive for collagen degradation epitope associated with detached 
single cells and white open arrowheads for collective invasion zones. C, D Brightfield images (C) and quantifi-
cation of migration modes (D) of DMSO control and GM6001 treated SCC spheroids after 72 h of incubation. 
Data represent at least 11 spheroids from 3 independent experiments. e Confocal 3D stack images of SCC 
spheroids cultured in the presence of GM6001 for 72 h. For comparison see GM6001-untreated samples in 
(B). Dotted line marks the spheroid core. f Confocal stack images of cell nuclei from detached cells in DMSO 
control and GM6001 treated spheroid culture and quantitative analysis of the smallest nuclear diameter. Yel-
low arrows denote locally deformed nuclei. Scale bars indicate 100 µm (overview) and 20 µm (detail). Black 
arrowheads show cohesive strands, white arrowheads detached single cells.
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figure 5 Prevention of invasion plasticity by interference with HGF/c-Met signaling. a, b Brightfield images 
(A) and quantification of invasion (B) of SCC spheroids incubated with 50% CM for 72 h in the presence of 
c-Met inhibitor SU211274. Data represent at least 8 spheroids from 3 independent experiments. The hori-
zontal line at 50 µm length indicates the threshold value for cohesive strands. C, D Brightfield images (C) and 
quantification of invasion (D) of SCC spheroids treated with 50% CM together with anti-HGF antibody after 
72 h. Data originated from at least 7 spheroids from 3 independent experiments. Scale bars indicate 100 µm. 
Black arrowheads show cohesive strands, white arrowheads detached single cells.
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(Suppl. Fig. 5A). Referenced against tubulin staining by semiquantitative analysis (Suppl. Fig. 
5B), E-cadherin was gradually down-regulated in collective invasion strands and minimum levels 
reached in detached cells (Suppl. Fig. 5C).
Parallel to E-cadherin downregulation, vimentin protein content referenced against tubulin stain-
ing was measured in individual cells (Suppl. Fig. 6A). In untreated spheroids of SCC38 and SCC58 
cells, vimentin was randomly expressed with a positive trend in invading cells, gradually increasing 
from collective strands to detached single cells (Fig. 3A, B). Conditioned medium intensified this 
trend and migrating cells developed consistently higher intensity compared to non-migrating cells 
(Fig. 3A, white arrowheads; B, center vs. rim/detached cells). Notably, the majority of migrating 
cells in SCC38 including tip cells in multicellular strands and detached cells and a minority in 
SCC58 cells remained vimentin-negative (Fig. 3A, C). Elongation of cells was uncorrelated with 
vimentin expression (Fig. 3C). To assess the kinetics and variability of vimentin induction spher-
oids at different time points after embedding were analyzed. In both, SCC38 and SCC58 cells, 
vimentin-positive subsets were present immediately after collagen polymerization and before 
migration was initiated (Suppl. Fig. 6B, C). This indicates that vimentin expression in cell subsets 
was intrinsic and did not depend upon contact to collagen or fibroblast-conditioned medium. 
With progressing invasion, the frequency of vimentin-positive cells remained largely unaffected 
in SCC38 cells but increased over time in SCC58 cells (Suppl. Fig. 6B, C). Thus, at single cell level, 
fibroblast-conditioned medium induces a spectrum of vimentin-positive, EMT-like, and vimentin-
negative subsets collective and single-cell invasion compartments.
Proteolytic amoeboid movement induced by fibroblast-conditioned medium
In 2D epithelial cancer cell cultures EMT induction associates with cell elongation and produces 
individualized fibroblast-like spindle-shaped morphologies in moving cells [37, 40, 41], consistent 
with EMT-mediated mesenchymal migration [42]. To invade high-density 3D fibrillar collagen with 
pore dimensions of ~ 2-10 µm², as used here, moving cells require the ability to proteolytically 
degrade the ECM [43], a typical feature of mesenchymal migration [44]. However, 70% (SCC38) 
or 90% (SCC58) of detached cells, irrespective of vimentin expression, maintained a rounded 
morphology (Fig. 3C; elongation index < 3). To verify whether cells with a rounded morphology 
developed occasional spindle-shaped periods, elongation was measured over time from time-
lapse recordings. Both cell lines retained predominantly round morphology (Fig. 4A) with visible 
cortical actin structures (Fig. 1B, yellow arrowheads) and occasional short-lived elongation periods 
(duration below 1 h; Fig. 4A; Movie 3 and 4).
Unlike amoeboid migration in leukocytes or tumor cells treated matrix metalloproteinase in-
hibitors [43, 45] or dependence on Rho/ROCK functions [46], individually moving SCC38 and 
SCC58 cells caused collagen degradation, visualized as cleavage epitope in vicinity /associated 
with multicellular strands and single cells and linear tissue tracks left behind by detached cells 
(Fig. 4B). When treated with broad-spectrum matrix metalloproteinase inhibitor GM6001, both 
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collective and single-cell migration were significantly reduced (Fig. 4C and Movie 5 and 6), and 
extracellular collagen degradation strongly diminished (Fig. 4E). Albeit diminished, residual single-
cell migration was associated with increased deformation of cell nuclei in time-lapse recordings 
of detached cells (Movie 5 and 6) and fixed samples (Fig. 4F), similar to moving leukocytes and 
tumor cells after MMP inhibition [43].
Thus, beyond its known stimulating effects on mesenchymal and collective invasion, fibroblast-
conditioned medium induces amoeboid moving cells which remodel ECM by pericellular prote-
olysis.
antagonization of invasion plasticity by hGf inhibitors
To test whether fibroblast-induced plasticity, and particularly amoeboid dissemination, can be 
prevented by pharmacologic HGF-targeting strategies, a HGF-scavenging antibody and the c-Met 
inhibitor SU11274 were applied to spheroid invasion cultures together with fibroblast-condi-
tioned medium. At low to moderate dosing, both HGF and c-Met inhibition reverted single cell 
detachment, whereas collective invasion remained largely intact (Fig. 5). With at maximum dose, 
single-cell invasion was abrogated and collective invasion strongly reduced in SCC58 cells with 
HGF blocking while in SCC38 spheroids only single cell but not collective invasion was diminished 
(Fig. 5). Notably, in contrast with direct HGF targeting, SU11274 was insufficient to reduce the 
initiation of collective invasion in both cell types, but both treatments reduced the prolongation 
of existing invasion strands (Fig. 5B, D). These data indicate that both HGF neutralization and 
downstream signaling inhibition abrogate single-cell detachment and amoeboid dissemination, 
whereas collective invasion is largely insensitive to pharmacological inhibition.
DISCuSSIOn
Using single-cell 3D cytometry of HNSCC spheroid invasion cultures, we here shed initial light 
on the interdependence of EMT-associated molecular transitions and plasticity of collective and 
single-cell cancer invasion modes in response to microenvironmental stimulation. HGF, a clinically 
relevant growth factor to mediate EMT, induces both plasticity of invasion strategies and mo-
lecular diversity with EMT and non-EMT subsets. Whereas mesenchymal-like HNSCC cell invasion 
was infrequent, HGF induced notable collective invasion and, at higher concentration, amoeboid 
single-cell dissemination, and both invasion types contained cells expressing the EMT-marker 
vimentin. These findings indicate that, in addition to previous notions associating EMT with 
mesenchymal movement [20], an EMT signature is compatible with further migration programs, 
including collective and previously unappreciated collagenolytic-amoeboid migration.
Squamous cell carcinoma invasion involves collective migration as primary strategy [27, 42], with 
fibroblasts as prominent inducers [17, 18]. Similar to HNSCC cells tested here, HGF enhances col-
lective migration in normal kidney epithelial cells, liver progenitor cells and mammary adenocarci-
noma across 2D surfaces in vitro [47-49] and of mouse mammary tumor cells and normal kidney 
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epithelial cells in ECM-based 3D models [50, 51]. Serum levels of HGF are elevated in body fluids 
of cancer patients (up to 10 ng/mL) [52] reaching concentrations which induce collective invasion 
from 3D spheroids, and local HGF levels in tumor tissue are likely higher [53]. Thus, besides its 
established function in inducing single-cell scattering [39, 54], at low concentration HGF is a 
potent inducer of collective invasion by inducing cell migration without complete downregulation 
of E-cadherin based cell-cell interactions.
Besides the type of stimulus, additional cell migration plasticity is caused by the strength of 
environmental signals. At higher HGF concentrations (above 10 ng/ml), HNSCC cells transit from 
collective to amoeboid migration, with a minor mesenchymal population in SCC38 cells, likely 
as consequence of downregulated E-cadherin combined with actin regulation. Cell rounding 
results from high actomyosin contractility and can be induced by growth factors, cytokines or 
ligand-independent receptor activation including c-Met via Rho/ROCK [13, 55]. In 3D HNSCC 
spheroid culture, initially collective invasion strands released proteolytic-amoeboid moving cells 
with diminished E-cadherin levels, cortical actin cytoskeleton without focalization to the ECM 
but collagenolytic capacity, which led to the generation of collagenolytic tracks. This differs from 
amoeboid movement of melanoma cells invading 3D collagen type I which is mediated by non-
catalytic function of MMP9 [56]. Thus, in the current model, proteolytic-amoeboid movement 
combined the features of rounded migration and MMP-dependent degradation of collageneous 
ECM environment, which deviate from otherwise non-proteolytic amoeboid migration detected 
in leukocytes and other cancer models [46, 57].
The transition from collective to amoeboid migration modes occurred as a probabilistic process 
which depended on the HNSCC type and increasing HGF/c-Met signaling strength. Similarly, the 
induction of EMT by HGF, which is well established for other cell types and mostly 2D culture 
conditions [38, 58, 59], was cell-type dependent and probabilistic when assessed by single-cell 
cytometry in situ. SCC58 cells, which are invasive and metastatic [60], developed high frequencies 
of vimentin-positive cells which invaded collectively or individually in response to HGF, whereas 
invading but non-metastatic SCC38 cells [5, 60] contained low frequency of vimentin-positive 
cells in non-invading as well as collectively and individually moving cells and no further upregula-
tion was induced by HGF. This indicates vimentin induction by HGF varies with cell type and that 
any invasion mode can harbor EMT-like and EMT-independent signaling states [61]. In collective 
invasion strands, both vimentin-positive and -negative cells retained somewhat lowered and/or 
delocalized E-cadherin along cell-cell junctions, consistent with invasive or metastatic HNSCC 
phenotype in primary tumors of patients exhibiting multicellular invasion patterns, reduced E-
cadherin content and positivity for vimentin [62-64]. The vimentin and E-cadherin double-positive 
state is consistent with partial EMT, retaining both epithelial and mesenchymal features in the 
same cell [65]. After detachment, vimentin-positive amoeboid phenotypes developed yet another 
molecular fingerprint in situ, with diminished E-cadherin but retained MMP activity and ability to 
degrade fibrillar collagen to clear the migration path. These data indicate that, besides mesen-
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chymal migration, a spectrum of collective and amoeboid migration strategies can be associated 
with EMT and further include a variable fraction of alternative, EMT-independent states.
Clinically, a subset (19%) of HNSCC patients develops an EMT phenotype with decreased E-
cadherin and increased vimentin expression in the primary lesion which increases the risk for 
distant metastasis by 2-fold compared to patients without signs of EMT [63]. This suggests that, 
with lower probability, EMT-negative cells which locally invade tissue may retain the ability metas-
tasize as in ductal or lobular breast cancer invading collectively from the primary site [66], e.g. by 
developing transient or locally very confined EMT-positive states [67, 68]. Because EMT- and non-
EMT states coexist in collective and individual migration modes, a critical progression-enhancing 
effect of HGF may result from broadening the range of migration modes and molecular diversity, 
thereby diversifying the microenvironmental coping abilities of disseminating cancer cells. Con-
sistently, the presence of single cells is detected in 3D reconstructions of HNSCC samples [27], 
and disseminated rounded single cells emanate in preclinical models of breast tumors [69] and, 
with upregulated carboanhydrase-IX, in the invasion zone of clinical HNSCC samples [5]. Thus, 
constitutive or environment-induced amoeboid migration may contribute to discrete steps of 
cancer cell invasion and metastasis.
In preclinical mouse models for epithelial cancer progression, targeting the HGF/c-Met signal-
ing pathway inhibits tumor growth and metastatic dissemination [70-73]. However, no clinically 
relevant overall survival benefit has been reported in clinical phase II and III trials in patients with 
late-stage or recurrent metastatic HNSCC disease [31, 73]. Our data suggest that both HGF neu-
tralization and c-Met inhibition diminish particularly single-cell dissemination with comparable 
efficiency, whereas collective invasion retains limited ability to resist targeted intervention. This 
indicates particular resilience of HGF-induced collective processes to withstand pharmacological 
intervention or, in a cell-context dependent manner, the function of other soluble factors released 
by MRC5 cells, such as EGF. In summary, HGF-induced molecular and functional diversification of 
migratory strategies may enhance the ability of invading cells to adapt to complex microenviron-
ments, increase the probability for escape from the primary site [74] and further differentially 
resist to pharmacotherapy.
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SuPPleMenTaRy fIGuReS
Supplementary figure 1 Induction of plasticity of invasion in HNSCC spheroids by MRC5 fibroblast condi-
tioned medium. a Overview (left) and zoomed (right) brightfield images showing SCC38 and SCC58 spher-
oids in rat tail collagen after 72 h of incubation with or without MRC5 CM. b Quantification of invasion 
modes originating from SCC spheroids incubated with MRC5 CM. For images see figure 1A. Data from at 
least 12 spheroids from 3 independent experiments. Black arrowheads denote cohesive strands, white ar-
rowheads detached single cells, and gray arrowheads detached cell clusters. Scale bars, 100 µm (overview) 
and 20 µm (detail).
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Supplementary figure 2 Expression of cytokines, growth factors and receptors and c-Met knockdown. 
a Expression of cytokine and growth factor receptors and their ligands measured by RT-qPCR in SCC38, 
CAF553 and MRC5 cells after 60 h (SCC38) or 36 h (fibroblasts) of culture in rat tail collagen. The horizon-
tal line indicates the threshold cycle. Data represent the mean values and standard deviation from selected 
molecules from 3 independent experiments. b Flow cytometry detection of extracellular c-Met in control and 
c-Met shRNA expressing SCC cells. Data represents 3 independent experiments.
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Supplementary figure 3 HGF and EGF induced plasticity of invasion. a Confocal 3D stack images of SCC 
spheroids incubated with recombinant human HGF for 72 h. b, C Brightfield images (B) and quantitative 
analysis (C) of 3D SCC spheroid culture incubated with recombinant human epidermal growth factor (EGF) for 
72 h. Data represent at least 8 spheroids from 2 independent experiments. P values compare invasion patterns 
induced by CM and EGF. Scale bars indicate 100 µm (overview) and 20 µm (detail). Black arrowheads show 
cohesive strands, white arrowheads detached single cells.
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Supplementary figure 4 Whole spheroid analysis of EMT markers. a Workflow of lysate generation from 
3D spheroids. b Reversed phase protein assay (RPPA) results and C Western blot analysis of SCC spheroids in 
collagen gel incubated with increasing concentrations of MRC5 fibroblast CM.; RPPA results represent data 
from 3 independent experiments and western blot data from 4 independent experiments.
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Supplementary figure 5 E-cadherin regulation by CM from MRC5 fibroblasts. a Confocal single slice im-
ages of SCC spheroids after 72 h invasion in rat tail collagen. Scale bars indicate 100 µm (overview) and 20 
µm (detail). Black arrows denote membranous E-cadherin and white arrows cytoplasmic E-cadherin in SCC 
cells. b, C Workflow of region 3D analysis of E-cadherin expression relative to tubulin (B) and quantitative 
analysis (C) of 3D SCC spheroid culture incubated with CM from MRC5 cells. Data originated from at least 9 
spheroids from 3 independent experiments.
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Supplementary figure 6 Vimentin expression in SCC spheroids. a Workflow of single-cell 3D cytometry of 
vimentin expression relative to tubulin. See corresponding images and results in figure 3. b, C Confocal 3D 
stack images of SCC spheroid culture incubated with 50% CM from MRC5 cells at different time points dur-
ing an incubation of 72 h (B) and quantitative analysis (C) by single-cell 3D cytometry. Scale bar indicates 100 
µm. Green line separates vimentin positive and negative cells and numbers show percentage of positive cells. 
Data represent 2 spheroids from one experiment.
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Head and neck squamous cell carcinoma (HNSCC) is an often highly invasive tumor, infiltrating 
functionally important tissue areas. Achieving complete tumor resection and preserving function-
ally relevant tissue structures depends on precise identification of tumor-free resection margins 
during surgery. Fluorescence-guided surgery (FGS), by intraoperative detection of tumor cells 
using a fluorescent tracer, may guide surgical excision and identify tumor-positive resection mar-
gins. Using a literature survey on potential surface molecules followed by immunohistochemical 
validation, we identified CD44 variant 6 (CD44v6) as a constitutively expressed antigen in the 
invasion zone of HNSCC lesions. The monoclonal anti-CD44v6 antibody BIWA was labeled with 
both a near-infrared fluorescent dye (IRDye800CW) and a radioactive label (Indium-111) and 
dual-modality imaging was applied in a locally invasive tumor mouse model. BIWA accurately 
detected human HNSCC xenografts in mice with a tumor uptake of 54 ± 11% ID/g and invasion 
regions with an accuracy of 94%. When dissected under clinical-like conditions, tumor remnants 
approximately 0.7 mm in diameter consisting of a few thousand cells were identified by fluores-
cence imaging, resulting in reliable dissection of invasive microregions. These data indicate that 
CD44v6 is a suitable target for reliable near-infrared detection and FGS of invasive HNSCC lesions 
in vivo.
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InTRODuCTIOn
Head and neck squamous cell carcinomas (HNSCCs) are invasively growing tumors in a function-
ally delicate and important area with an overall five-year survival rate below 60% 1. Surgical 
treatment of HNSCC aims to completely remove both tumor and marginal invasion zones, and 
tumor-free resection margins represent a critical prognostic parameter for reducing tumor recur-
rence and improving overall survival 2. In functionally critical areas, such as the head and neck 
region, maximizing surgical margins has to be weighed against loss of functional tissue resulting 
in compromised quality of life post surgery 3. Therefore, developments such as intraoperative 
histology and image-guided surgery aim to more accurately delineate the tumor border during 
surgery, enabling more accurate tumor resection. As complementary strategy fluorescence-guided 
surgery (FGS) aims to intraoperatively detect a fluorescent tracer after selective accumulation in 
tumor tissue and enables preclinical and clinical detection of cancer lesions eventually resulting in 
improved progression-free survival after surgery 4. Improved signal detection has been achieved 
by conjugating fluorophores in the near-infrared (NIR) range of 650-900 nm with targeting anti-
body binding extracellular epitopes preferentially expressed on tumor cells, allowing macro- and 
microscopic detection of even small tumors and tumor subregions 5. This resulted in a range of 
cancer-targeting antibodies developed for FGS surgery to validate molecular targets, establish 
conjugate safety and develop sensitive imaging devices 6-8. In clinical trials safe tracer admin-
istration and subsequent identification of cancers in the sub-millimeter resolution have been 
demonstrated 4,9-11. Potential shortcomings of FGS, however, include inhomogeneous antigen 
expression and/or tissue distribution of the antibody as well as non-specific antibody uptake in 
peritumor tissue and limited tumor detection due to high background fluorescence 4,12.
First-generation FGS of HNSCC focused on the epidermal growth factor receptor (EGFR), based 
on its prominent expression in HNSCC and efficient in vivo detection of tumors and metastasis 
in preclinical studies 13-15. A fluorescently-labeled anti-EGFR antibody (cetuximab) is clinically well 
tolerated and efficiently differentiates tumor from normal tissue 9,10. However, reliable cetuximab-
based FGS is hampered by uncertain sensitivity and specificity, as a consequence of variable 
antigen expression in tumors and high binding of cetuximab to normal tissues (tumor stroma, 
liver, skin, a.o.) 16. Thus, identifying antigens with a more tumor restricted expression remains 
pertinent to reliably and selectively visualize HNSCC tumor regions.
To reliably detect the invasion zone of HNSCC, we performed a literature survey and tested the 
presence of a range of potential antigens (over-)expressed in HNSCC including c-Met, CD44 
variant 6 (CD44v6), E-cadherin, epidermal growth factor receptor (EGFR), extracellular matrix 
metalloproteinase inducer (EMMPRIN/CD147) and epithelial cell adhesion molecule (EpCAM). We 
identify CD44v6 as candidate and apply anti-CD44v6 antibody BIWA for sensitive detection of 
the invasion margins in HNSCC in a preclinical mouse model.
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CD44v6 expression in invasive hnSCC
To identify surface markers in HNSCC patient material which reliably detect the margin of invasion 
and, hence, might be suitable for FGS, we applied comparative immunohistochemistry on hu-
man tumor samples. Candidate cell surface proteins, including c-Met, CD44v6, E-cadherin, EGFR, 
EMMPRIN and EpCAM, were identified based on a literature survey focusing on the percentage 
of positive tumors, the homogeneity of expression within the same tumor, and whether the 
protein was expressed on the epithelium or the tumor stroma (Suppl. Table 1). As further criteria 
for marker selection, extracellular cell-surface localization and expression level and variability in 
HNSCC were considered. Additionally, the availability of a monoclonal antibody with established 
low toxicity profile and imaging application in clinical trials was taken into consideration. Ap-
proximately 97% of HNSCCs were positive for CD44v6 followed by EGFR (85%) and lower 
frequencies for the other markers. CD44v6 was consistently present throughout the tumor with 
defined membrane staining, but reduced expression in keratinized or necrotizing areas in the 
tumor core (Fig. 1). EGFR and c-Met showed a strong expression throughout the tumor similar 
to CD44v6 (Fig. 1; Suppl. Fig. 1). Likewise, EMMRPIN showed reliable expression throughout 
the lesion albeit with lower intensity (Suppl. Fig. 1), whereas E-cadherin and EpCAM expression 
figure 1. Expression of CD44v6 and EGFR in primary human HNSCC samples. Tumor (T), normal epithelium 
(E), stroma (S). Dotted lines mark the tumor edge. Representative samples from 7 (CD44v6) or 5 (EGFR) inde-
pendent tumors. Scale bars indicate 1000 µm (overview) and 100 µm (zoom).
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were less reliable with notable inter-individual variability (Suppl. Fig. 1). Whereas for CD44v6 
and EMMPRIN the signal was near-exclusively tumor cell specific with only weak background 
staining from the desmoplastic stroma and adjacent epithelial structures, particularly epidermis 
and hair follicles, E-cadherin positivity resulted from both tumor-derived and non-transformed 
epithelial structures (Fig. 1; Suppl. Fig. 1). EpCAM, c-Met and EGFR were also expressed by 
stromal cells resulting in a high peri-tumor background signal (Fig. 1; Suppl. Fig. 1). The reliable 
immunohistochemical staining together with published evidence indicated CD44v6 as epitope 
with abundant expression throughout HNSCC lesions including the invasion zone. For application 
in FGS, CD44v6-targeting antibodies were previously shown to macroscopically identify CD44v6 
expressing epithelial xenograft tumors in mice, including HNSCC (Suppl. Table 1) 17-19, whereas 
its suitability for identifying the tumor margin and disseminated invasion zones remain untested. 
We therefore selected anti-CD44v6 antibody BIWA, of which the humanized form demonstrated 
safe administration in clinical trials and reliably visualized HNSCC lesions by nuclear imaging 20,21.
expression of CD44v6 in hnSCC cell lines and invasive xenograft tumors in mice
To establish an invasive HNSCC mouse model for FGS, a range of HNSCC cell lines was analyzed 
for expression of CD44v6 and growth pattern in vivo. Consistent with reliable CD44v6 expression 
in human samples, all HNSCC cell lines expressed CD44v6 at high and homogeneous levels in 
contrast to two melanoma cell lines serving as negative controls based on previous findings 
(Suppl. Fig. 2A) 22. UT-SCC58 showed a low-to-medium level of cell surface expression (50-fold 
CD44v6/IgG1 signal-to-background ratio; total range between cell lines 30 to 181), which we 
considered as a representative cell model reflecting non-overstated CD44v6 availability for realis-
tic in vivo antibody targeting. As xenograft lesions in mice, UT-SCC58 cells grew within 3-4 weeks 
to macroscopically visible tumors (Fig. 2A, B) and showed invasive growth pattern characteristics 
of differentiated HNSCC, including nest-like dissemination in the interstitial tissue (Fig. 2C1) and 
invasion along nerve fibers (Fig. 2C2). Co-staining of CD44v6 and pan-cytokeratin as epithelial 
reference marker indicated a relatively uniform expression of CD44v6 throughout the lesion (Fig. 
2D). Sub-region analysis of the tumor core, border and invasive cells, as well as scoring of CD44v6 
intensity at single cell level revealed constant expression in all tumor areas without significant 
variation (Fig. 2E, F; Suppl. Fig. 2B). Thus, UT-SCC58 xenografts recapitulate the invasive growth 
and CD44v6 expression patterns of patient samples and represent a suitable preclinical model for 
FGS of invasive and moderately CD44v6-positive HNSCC tumors.
bIwa detects CD44v6-expressing tumors in vivo
To detect small metastases and assess the biodistribution of fluorescent tracers, a cohort of UT-SCC58 
tumor-bearing mice with a lesion volume of 10-42 mm3 received 111In-DTPA-BIWA-IRDye800CW 
or 111In-DTPA-IgG1-IRDye800CW isotype-matched control antibody intravenously. Antibody uptake 
by UT-SCC58 tumors using NIR whole-body fluorescence detection reached a maximum three days 
84 | Chapter 4
figure 2. Invasive HNSCC mouse xenograft model for in vivo detection of CD44v6. a Macroscopic detection 
of a representative small and large tumor in the left cheek of two different mice. Arrowhead indicates the tu-
mor location. b Growth curve of UT-SCC58 tumors. Data show the means of 12 mice. C Central section of an 
UT-SCC58 tumor, showing multifocal invasive tumor islands in the interstitium (1) and in perineural location 
(2). Scale bars indicate 500 µm (overviews) and 100 µm (zooms). D Expression of CD44v6 and pan-cytokeratin 
(CK) in UT-SCC58 tumors. Dotted lines mark the tumor border and tumor islands. Scale bars indicate 500 µm 
(overviews) and 100 µm (zooms). e Whole-region analysis of (D). Staining intensity of CD44v6 in different 
areas analyzed at day 28 after implantation. Data show medians from 12-38 analyzed images per tumor from 
4 independent tumors. f Single cell analysis of (D). Fluorescence intensities after background substraction for 
CD44v6 and CK of the same tumors as in (E). 50 cells were analyzed per subregion and geometric symbols 
represent 5 different tumors. Core of the tumor (C), border of the tumor (B), distant cells (DC), skin (S).
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after injection (data not shown), similar to the bioavailability kinetics reported for other antibodies 
and HNSCC tumor models 19,23. 111In-DTPA-BIWA-IRDye800CW showed a most prominent signal 
originating from the tumor and weaker signal originating from the left cervical lymph node and the 
liver (Fig. 3A). In comparison, fluorescent signals from 111In-DTPA-IgG1-IRDye800CW were detected 
in the liver and weakly in the tumor (Fig. 3A). SPECT/CT images confirmed this biodistribution pro-
file, whereby one mouse also showed weak signal enrichment in the left cervical lymph node (Fig. 
3B). Biodistribution analysis revealed a mean tumor uptake of 54 ± 11% ID/g for 111In-DTPA-BIWA-
IRDye800CW compared to 5 ± 2% ID/g for IgG1 control antibody conjugate (Fig. 3C). Uptake of 
dual-labeled BIWA in other organs was considerably lower, quantified as total amount (Fig. 3C) and 
figure 3. Biodistribution of 111In-DTPA-BIWA-IRDye800CW and 111In-DTPA-IgG1-IRDye800CW control anti-
body in mice carrying HNSCC tumors in the left cheek for 28 days and 72 h after i.v. administration. a, b Near 
infrared fluorescent (NIRF) whole body images of mice n=9 (A) and corresponding micro SPECT/CT images n= 
4 (B). Tumor (T), lymph node (LN), liver (L). C Biodistribution data shown as percentage injected dose per gram 
of tissue of both dual-labeled antibodies. D Tumor-to-blood ratios obtained by ratios from (C).
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tumor-to-blood ratio (Fig. 3D). Despite yielding a positive signal (Suppl. Fig. 3A) the cervical lymph 
nodes lacked pan-cytokeratin positive tumor nests (Suppl. Fig. 3B, C) and thus were considered 
tumor-free. Most likely, false-positive detection in lymph nodes resulted from uptake of BIWA by 
macrophages via Fc-receptors, as described for other tumor models 24. Thus, systemically applied 
dual-labeled BIWA accumulates in CD44v6-expressing tumors with high selectivity.
bIwa detects invasive tumor regions
To determine whether dual-labeled BIWA is able to detect the invasive tumor margin, we performed 
sub-region immunohistochemistry and NIR fluorescence scans after systemic administration of 
111In-DTPA-BIWA-IRDye800CW. Both, the tumor core and invasion zones were macroscopically 
positive for the near-infrared signal, whereas the surrounding stroma showed a low background 
signal (Fig. 4A; Suppl. Fig. 4). Microscopic analysis revealed cell surface localization of BIWA label 
on tumor cells (Fig. 4A, white arrowheads), consistent with antigen-dependent accumulation 
after in vivo administration. Sub-region co-localization analysis of the CD44v6 NIRF signal after 
in vivo administration and pan-cytokeratin immunofluorescence showed that BIWA detected > 
85% of the CK-positive tumor cell nests (Fig. 4A, black arrowheads; Fig. 4B). Notably, occasional 
BIWA-negative tumor clusters were frequently located in direct vicinity (below ~ 250 µm distance) 
of BIWA-positive regions (Fig. 4A, open arrowheads), and thus would colocalize when viewed by 
intraoperative microscopic surgery with a sub-millimeter resolution. Including such co-localized 
events, 94% of the invasion regions were detected by 111In-DTPA-BIWA–IRDye800CW (Fig. 4B). 
No signal from IgG1 control antibody was detected in both tumor cells or the tumor stroma by 
histological scoring (Suppl. Fig. 4). Taken together, systemically applied dual-labeled BIWA detects 
all tumor regions and > 90% of invasive zones.
Preclinical fGS: sensitive detection of tumor cells
FGS experiments were performed using systemically applied BIWA-IRDye800CW detected by 
the Intraoperative QMI Spectrum fluorescence imaging system (Quest Medical Imaging), to ap-
proximate signal intensity and detection of the tumor margin under clinical-like conditions. To 
simulate incomplete tumor resection and estimate the size of minimal remnants of the resection 
margin based on the BIWA-IRDye800CW label, step-wise FGS was performed until a minimal-
residual fluorescent signal was left in situ (Fig. 5A). Subsequently, remnants were detected by 
high-sensitivity NIRF imaging followed by high-resolution immunohistochemistry to validate the 
presence and amount of tumor cells (Fig. 5A). Post-operative immunohistochemistry showed that 
NIR fluorescence-positive regions also stained positively for pan-cytokeratin (Fig. 5B), confirming 
high selectivity of CD44v6 for the detection of tumor cells. The estimated residual tumor masses, 
which could still be detected by BIWA-IRDye800CW in minimal lesions, were 0.7 – 2 mm in size 
and contained few thousand to hundred thousand cells, based on NIR scans and immunohisto-
chemistry of the residual tissue.
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figure 4. Detection of invasive tumor regions by dual-labeled BIWA 3 days after systemic administration. a 
Central, serial sections of a tumor (H&E staining, CK staining and NIRF signal). Images show invasive tumor 
islands (1, 2, dotted line) adjacent to the main tumor (3, dotted line). Tumor (T), normal epithelium (E), stroma 
(S). Black arrowheads indicate fluorescence positive islands, the transparent arrowhead a negative/weakly 
stained island. White arrowheads highlight membranous staining. Scale bars indicate 1 mm (overview) and 
100 µm (zoom). b Scoring of NIRF signal intensity for tumor core, border and invasive cells including isolated 
nests and clusters of adjacent islands. Data represent scoring of two sections per tumor in 5 mice. *Example 
shown in Suppl. Fig. 4, ** Example shown in Fig. 4A.
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figure 5. Preclinical FGS using BIWA-IRDye800CW and post-resection validation. a Experimental procedure 
of step-wise tumor resection, in situ detection and post-fixation analysis. b (1) UT-SCC58 tumors 28 days after 
implantation into mice were monitored by intraoperative fluorescence imaging (QMI Spectrum) followed by 
step-wise FGS. Dotted lines mark the mouse and tumor tissue and the arrow indicates weak fluorescent signal 
from tumor remnant in situ. Numbers show tumor-to-background ratios. (2) Post-operative high-sensitivity NIR 
fluorescence analysis of excised tissues and in situ remnant using the Odyssey CLx flatbed scanner. The scale 
bar indicates 1 mm. Further processing and re-scanning of the tumor remnant as 400- and then 7-µm thick sec-
tions. Immunofluorescence of a NIRF-positive 7 µm section of the remnant. Scale bars indicate 500 µm (over-
view) and 100 µm (zoom). The total estimated remnant tumor cells and size are shown for four experiments.
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DISCuSSIOn
We here show that systemically applied BIWA-IRDye800CW provides sensitive detection of HN-
SCC lesions under clinical fluorescence imaging conditions and allows a precise step-wise removal 
of the tumor margin with a detection limit in the submillimeter range. CD44v6 is expressed in 
HNSCC across all tumor stages, with varying trends in T stage and/or nodal status 25-28. The robust 
expression of CD44v6 across independent HNSCC lesions and most, if not all, HNSCC tumor cells 
and the availability of clinically applicable anti-CD44v6 antibody Bivatuzumab emphasize CD44v6 
as a promising antigen for reliable FGS in HNSCC cancer, enabling visualization of tumor margins 
and minimal residual lesions. Besides in primary tumors, CD44v6 is expressed in recurrent tumors 
and lymph node metastases 27,29,30, therefore administration of 111In or IRDye800CW labeled 
Bivatuzumab should enhance detection of primary as well as secondary and metastatic HNSCC 
disease. When directly compared, CD44v6 expression is approximately 8-fold higher in HNSCC 
samples compared to EGFR 31. CD44v6 is expressed only in a subset of adjacent normal epithelia 
and absent or only weakly expressed in other, non-tumor tissues 30, which minimizes background 
signal, systemic uptake and potential off-target effects. In addition, radiolabeled Bivatuzumab, 
which targets the same epitope as BIWA, was successfully applied for scintigraphic in vivo imag-
ing of HNSCC tumors in mouse models and patients with low toxicity and immunogenicity 19,32,33. 
Tumor uptake of the dual-labeled BIWA in UT-SCC58 tumors with moderate CD44v6 expression 
was comparable to that of radiolabeled anti-CD44v6 antibodies, while tumor-to-blood ratios 
even exceeded previously reported results 17,19.
Using detailed immunohistochemical analysis of CD44v6 in patient material and by in vivo tar-
geting of HNSCC xenografts by BIWA, we demonstrate that CD44v6 is strongly expressed in 
the invasion margin of tumor lesions and thus suitable for precise microscopic FGS mapping of 
invasive HNSCC. Using minimal lesion analysis, we identify high detection sensitivity of BIWA-
IRDye800CW using a clinical fluorescence imaging system detecting as little as sub-millimeter 
sized residues containing only a few thousand cells. The staining pattern was predominantly cell-
surface associated with heterogeneous targeting in the main tumor mass, potentially caused by 
heterogeneous antibody distribution 34. However, the consistent labelling of tumor borders and 
invasive cells indicated that Bivatuzumab may enable reliable intraoperative fluorescent imaging 
of both, invasion zone and small tumor remnants.
Besides HNSCC, CD44v6 is expressed in most carcinoma types, including lung, skin, cervix, breast 
and colon 30. Thus, beyond HNSCC, CD44v6 may serve for probing resection margins in a range 
of other invasive tumor types. CD44v6 targeting antibodies have achieved reliable NIR fluores-
cence enrichment in vivo in breast cancer xenografts 18, and immuno-PET imaging in a thyroid 
carcinoma model 35. Likewise, 186Re-labeled Bivatuzumab was safely administered to patients with 
early-stage breast cancer, but failed to reliably detect small lesions with low CD44v6 expression 36. 
Thus, further studies will be required to establish the application in small lesions with clinically 
variable CD44v6 expression.
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Besides application as a single agent, CD44v6 detection may be combined with EGFR detection, 
the expression of which, in contrast to CD44v6, increases in poorly differentiated carcinomas 16,30. 
Thus, combining CD44v6 and EGFR targeting may increase overall sensitivity for the detection 
of poorly differentiated carcinomas. Additional epitopes for dual- or multi-targeted FGS may 
include c-Met and EMMPRIN, based on high expression in HNSCC samples and their presence in 
the invasive front (Suppl. Table 1). In conclusion, based on its beneficial signal-to-noise ratio and 
low side effects 32 Bivatuzumab, as either NIR-fluorescence- or dual-labeled conjugate, shows 
potential to improve the outcomes of surgical treatment in HNSCC.
MaTeRIal anD MeThODS
literature survey
A systematic PubMed search was performed to identify potential cell surface markers expressed 
in the invasion region of HNSCC. The following search strategies were used for a publication 
period from 1985 to September 2015: protein name + immunohistochemistry + head and neck 
squamous cell carcinoma; protein name + imaging + head and neck squamous cell carcinoma. 
As indicator, the percentage of patients positive for the protein of interest was averaged from 
retrieved articles and, where available, differential expression within different tumor regions was 
taken into account (tumor core, tumor border, surrounding tumor stroma).
Immunohistochemistry of patient material
Tissue samples from 7 HNSCC patients were obtained from the Department of Pathology, 
Radboudumc, Nijmegen. Tumor samples were encrypted and analyzed in an anonymized man-
ner, as approved by the institutional review board and according to national law. Formalin-fixed 
and paraffin-embedded tissues were cut into sections of 4 µm, mounted onto SuperFrost 
slides (Thermo Scientific) and dried overnight at 37°C. Sections were deparaffinized in xylene, 
rehydrated in graded alcohols to water, quenched of endogenous peroxidases (0.3% H2O2, 30 
min), boiled in citrate buffer for antigen retrieval (pH 6, 13 min), pre-incubated with normal 
goat serum (20%, 30 min), washed, and incubated with primary antibody (4°C, overnight). The 
following antibodies were used: monoclonal mouse anti-human E-cadherin (SPM471, 1/300; 
Thermo Scientific), monoclonal mouse anti-human EpCAM (VU1D9, 1/200; Thermo Scientific), 
monoclonal rabbit anti-human c-Met (EP1454Y, 1/200; Epitomics), polyclonal rabbit anti-human 
EGFR (sc-03, 1/200; Santa Cruz); monoclonal mouse anti-human EMMPRIN (sc-21746, 1/200; 
Santa Cruz) and monoclonal mouse anti-human CD44v6 (VFF-18, 1/1000; AbD Serotec). After 
washing, sections were incubated with biotinylated secondary goat anti-mouse or anti-rabbit 
antibody and subsequently with the VECTASTAIN ABC reagent (Vector Laboratories) according 
to the manufacturer’s protocol. The signal was developed with diaminobenzidine and counter-
stained with hematoxylin. Sections were dehydrated in ethanol and xylene and mounted with 
Pertex (Histolab). Negative controls (buffer only) were included in each analysis. Sections were 
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imaged with an automated slide scanner with a 20x, 0.243 µm/pixels objective (Pannoramic 250 
Flash II, 3DHITECH).
Cell culture
HNSCC cell lines from primary human SCCs of cutaneous SCC (UT-SCC12A), tongue (UT-SCC16A 
and UT-SCC40), glottic larynx (UT-SCC38), supraglottic larynx (UT-SCC42B) as well as from me-
tastases of SCCs of cutaneous SCC (UT-SCC12B), tongue (UT-SCC16B) and transglottic larynx 
(UT-SCC58) were established at the University of Turku, Finland 37. Other cells used were FaDu 
cells (kind gift by the Dept. of Radiation Oncology, University of Technology Dresden) and the 
human melanoma cell lines A3755M (kind gift from Dr. Menashe Bar-Eli/Dr. Michael Davis, MD 
Anderson Cancer Center, USA) and MV3 38. All cells were cultured in Dulbecco’s modified Eagle 
medium (DMEM, Invitrogen), supplemented with 10% heat-inactivated fetal calf serum (Sigma 
Aldrich), 100 U/ml penicillin and 100 µg/ml streptomycin (both PAA), 2 mM L-glutamine, 1 mM 
sodium pyruvate (both Invitrogen/Life technologies) and 20 mM HEPES (Gibco).
flow cytometry
2 x 105 HNSCC and melanoma cells were seeded in 6-well plates two days prior to the experiment. 
Cells were detached with 4 mM ethylenediamine tetraacetic acid (EDTA) and stained on ice with 
murine anti-human CD44v6 antibody (BIWA), the humanized form of which has been applied 
clinically (bivatuzumab; BIWA-4) 19,39 or a human IgG1 istotypic control (Alpha Diagnostic Intl. 
Inc.) and a secondary goat anti-mouse/human 647 antibody (ThermoFisher Scientific). CD44v6 
expression and cell viability co-registered by lack of propidium iodide uptake were obtained by 
flow cytometry (FACS Caliber) and analyzed using the FCS Express software (version 5).
Mouse model
The animal experiments were performed in accordance with the guidelines and rules of the 
Dutch Act on animal experiments (WOD) and was approved by the Animal Welfare body of the 
Radboud University, Nijmegen (RU-DEC 2014-142). 9 x 105 UT-SCC58 cells suspended in 3 mg/
ml Matrigel (total volume 50 µl; BD Biosciences) were injected into the floor of mouth of BALB/c 
nu/nu female mice (6-8 weeks old; Charles River Laboratories). Tumors were allowed to grow for 
4-6 weeks. Tumor growth over time was measured using a caliper.
antibody conjugation
Antibodies were used as either fluorescence-only or dual-labeled conjugates carrying fluorescence 
and the radioactive isotope 111In. Human IgG1 isotypic control antibody (Alpha Diagnostic Intl. 
Inc.) was dialyzed against phosphate buffered saline (PBS) using the 10,000 Da molecular weight 
cutoff Slide-A-Lyzer MINI Dialysis device (Thermo Scientific) to remove azide and other additives. 
To generate NIR fluorescent conjugates, BIWA (1 mg) was incubated with a 3-fold excess of 
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IRDye800CW-N-hydroxysuccinamide (NHS) in 0.1 M sodium carbonate buffer (pH 8.5) for 1 h 
at room temperature (RT). For fluorescence guided surgery experiments, BIWA was only labeled 
with IRDye800CW-NHS. The final concentration of the antibody and the molecular substitution 
ratio were determined spectrophotometrically (Ultrospec 2000 spectrophotometer, Pharmacia 
Biotech) yielding an antibody:fluorophore ratio of 1:2. BIWA-IRDye800CW was stored in the dark 
at 4°C.
For dual-labeling, IRDye800CW-labeled antibodies were conjugated with the chelator p-
isothiocyanatobenzyl-diethylenetriaminepentaacetic acid (ITC-DTPA) with a 10-fold excess in 0.1 
M sodium carbonate buffer (pH 9.5) for 1 h at RT. The solution was dialyzed for 1 week against 
0.25 M ammonium acetate (pH 5.5) using a Slide-A-Lyzer cassette with a molecular weight cutoff 
of 20,000 Da (Thermo Scientific). The final concentration of the antibody and the molecular 
substitution ratio of the fluorescent dye were determined spectrophotometrically (Ultrospec 2000 
spectrophotometer, Pharmacia Biotech) yielding a ratio of 1.4. DTPA-BIWA-IRDye800CW and 
DTPA-IgG1-IRDye800CW were stored in the dark at 4°C until further use.
For radiolabeling, DTPA-BIWA-IRDye800CW and DTPA-IgG1-IRDye800CW were incubated with 
0.05 MBq of 111In (Mallinckrodt) per microgram of antibody in two volumes of 0.5 M 2-(N-mor-
pholino)ethansulfonic acid (MES) buffer (pH 5.5). For SPECT/CT studies antibodies were labeled 
with 1.5 MBq of 111In per microgram of antibody. After incubation of 20 min at RT 50 mM EDTA 
was added to a final concentration of 5 mM to chelate unincorporated 111In. Labeling efficiency 
was determined by instant thin-layer chromatography on silica gel strips (Agilent Technologies) 
using 0.15 M citrate buffer, pH 6.0 as the mobile phase. For all preparations, the radiochemical 
purity of 111In-DTPA-BIWA-IRDye800CW and 111In-DTPA-IgG1-IRDye800CW exceeded 95%.
Unperturbed immunoreactivity of the antibody conjugates was confirmed as described 40 with 
minor modifications. A serial dilution of UT-SCC58 cells was incubated with radiolabeled antibody 
conjugate (333 Bq equivalent to 6.7 ng antibody per dilution in DMEM medium) for 30 min at 
37°C. To determine nonspecific binding, an excess of unlabeled antibody conjugate was added 
to a duplicate of the lowest cell concentration. Unbound antibody was removed by washing with 
DMEM and samples were analyzed in a γ-counter (Wizard; Pharmacia-LKB). For all preparations, 
the immunoreactive fraction of available antibody exceeded 85%.
SPeCT/CT and fluorescence whole body imaging
Mice bearing UT-SCC58 tumors in the left cheek were injected into the tail vein with either 10 
µg of the dual-labeled antibody 111In-DTPA-BIWA-IRDye800CW or 111In-DTPA-IgG1-IRDye800CW. 
Three days after injection the distribution of the tracer was determined with a U-SPECT II SPECT/
CT scanner (MILabs, Utrecht, The Netherlands) in four mice using a 1.0-mm-diameter multipinhole 
mouse/rat collimator (2x 25 min with 44 bed positions). Images were reconstructed by ordered-
subset maximization expectation using the MILabs reconstruction software (U-SPECT-Rec, Milabs, 
Utrecht, The Netherlands) with the following settings: selection of the lower 111In photopeak 
4Targeting CD44v6 for fluorescence-guided surgery in head and neck squamous cell carcinoma | 93
(152-183 keV), corrected for two backgrounds (135-151 keV and 184-211 keV), pixel based 
OSEM, voxel size 0.4 mm3 and 1 iteration over 16 subsets. After SPECT imaging, all mice were 
euthanized and whole-body fluorescence images were acquired (IVIS Lumina imaging system, 
Caliper Life Science) using the following settings: F/Stop - 2, excitation filter - 745 nm, emission 
filter - ICG, field of view - C, 675 nm autofluorescence and background correction, recording 
time of 1 min and medium binning factor. Images were processed with the IVIS Lumina software.
biodistribution analysis
Three days after intravenous administration of the antibodies and whole-body imaging, the 
biodistribution of 111In-DTPA-BIWA-IRDye800CW and 111In-DTPA-IgG1-IRDye800CW in body 
fluids and excised organs of mice were determined. Blood was collected by heart puncture and 
tissue samples of the tumor lesion, superficial cervical lymph nodes, muscle, heart, lung, spleen, 
pancreas, kidney, liver, stomach and duodenum were collected, weighed and the radioactivity 
was measured in a well type γ counter (Wallac 2480 wizard, Perkin Elmer). Radioactivity uptake in 
each tissue was calculated as the percentage of the injected dose per gram of tissue.
Immunohistochemistry of mouse tumors and cervical lymph nodes
Frozen tumor sections (7 µm) were fixed in ice-cold methanol (10 min), washed and pre-incubated 
with normal goat serum (5%, in 1% BSA, 1 h) followed by incubation with primary antibody 
(overnight, 4°C). Formalin-fixed cervical lymph nodes and tumors were embedded in paraffin, 
sectioned (7 µm), mounted onto SuperFrost slides (Thermo Scientific), dried overnight (37°C), 
deparaffinized in xylene and rehydrated in graded alcohols to water. Sections were stained with 
hematoxylin eosin (H&E) or boiled in EDTA/Tris buffer (pH 9, 15 min) for antigen retrieval and pre-
incubated with normal goat serum (5%, in 1% BSA, 1h) followed by incubation with antibody 
(overnight, 4°C). The following antibodies were used: polyclonal rabbit anti-human and mouse 
pan-cytokeratin (CK) (ab9377, 1/100; Abcam); monoclonal murine anti-human CD44v6 (BIWA, 
5µg/ml; kind gift from V. Orian-Rousseau, Karlsruhe Institute of Technology, Germany). After 
washing, sections were incubated with secondary goat anti-rabbit Alexa Fluor 546 and goat 
anti-mouse/human Alexa Fluor 647 antibody (Invitrogen) for 2h at RT and counter stained with 
DAPI (Sigma). Negative controls were obtained by IgG isotype staining and tumor tissue served 
as positive controls for lymph node staining. Fluorescence on tissue sections was imaged using a 
10x NA 0.25 objective (DMI6000B slide scanner, Leica) and H&E staining using a 20x 0.243 µm/
pixels objective (Pannoramic 250 Flash scanner, 3DHITECH).
Digital image analysis was performed using Fiji (software version 1.51k, https://imagej.net/Fiji). 
Fluorescence intensity of CD44v6 and CK were coregistered for tissue subregions from images 
containing skin, local invasion, the core or the border of the tumor and each subregion was 
manually segmented based on topology, DAPI and CK signal. Mean CD44v6 and CK fluorescence 
intensities in individual cells were obtained using same region of interest, using an area of 51 
94 | Chapter 4
µm2 to sufficiently represent the size of single cells. Fluorescence intensities were normalized 
by subtracting the mean intensity from five background measurements from tumor-free tissue 
regions.
nIR imaging and analysis of mouse tumors and lymph nodes
Fresh-frozen tumor tissue from mice after i.v. administration of 111In-DTPA-BIWA-IRDye800CW 
or 111In-DTPA-IgG1-IRDye800CW were sectioned (7 µm) and two positions with at least 400 µm 
distance were scanned for NIR fluorescence intensity (settings: slide, intensity 2, resolution 21 µm, 
highest quality; Odyssey CLx, LI-COR Biosciences). Regions of interest identified by fluorescence 
detection from the Odyssey scans were re-sampled with high resolution by NIR imaging (20x NA 
0.8; mono setting, 5 sec acquisition time; Nuance-XR, PerkinElmer). Further subsampling and 
validation of fluorescence-positive regions obtained by Odyssey scanning were obtained by H&E 
and CK staining.
fluorescence-guided surgery
UT-SCC58 tumor-bearing mice after 28 days of growth in the left cheek received 10 µg of 
BIWA-IRDye800CW by tail vein injection. Three days later whole-body fluorescence was detected 
under isoflurane anesthesia followed by euthanasia. For intraoperative fluorescence detection, 
the tumor-containing cheek including surrounding fluorescence-negative tissue was surgically 
isolated and monitored in real-time using the Spectrum camera system (Quest medical imaging, 
Wieringerwerf) under clinically used imaging conditions. To match step-wise tumor resection 
conditions, sequential removal of the lesion guided by fluorescence was performed, until a weak 
but nonetheless positive signal in situ was obtained, reflecting a minimal tumor residue. Tumor-
to-background signals were analyzed using Fiji (software version 1.51k, https://imagej.net/Fiji). 
For verification of fluorescence, all freshly excised tissue samples including the residual lesion in 
the cheek in situ were subjected to high-sensitivity NIR scanning (instrument settings as described 
above; Odyssey CLx, LI-COR Biosciences) as native whole-mounts, followed by fixation (10% 
formalin, over night, RT, in the dark). Images were used to estimate the remnant tumor size. To 
detect both antibody distribution and topology of the resected lesions, the cheeks were sliced 
into 400 µm thick sections (Vibratome VT 1000 S, Leica), scanned again for fluorescence (Odyssey 
CLx), embedded in paraffin, sliced into 7 µm thick sections and scanned for NIR fluorescence 
(Odyssey). Subsequently, samples were stained for CK and DAPI or H&E and the amount of tumor 
cells in the remnant was estimated by counting the tumor cells of one central slide multiplied by 
the volume of cytokeratin positive sections, taking into account that each nucleus is present on 
every 1.7 section based on a mean diameter of a tumor cell nucleus of 12.3 µm (averaged from 
50 UT-SCC58 cell nuclei).
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Statistics
Statistical analysis was performed using the non-parametric Mann-Whitney test with a post-hoc 
correction for multiple comparisons (p≤0.05/N).
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Supplementary figure 1. In situ detection of candidate targets for FGS in human HNSCC tumors. a Repre-
sentative primary HNSCC lesion showing expression of c-Met, EMMPRIN (weak expression), E-cadherin and 
EpCAM. Tumor (T), normal epithelium (E), stroma (S). Scale bars indicate 1000 µm (overview) and 100 µm 
(zoom). b Scoring of expression level in 4-7 primary HNSCC lesions based on immunohistochemical staining.
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Supplementary figure 2. Expression of CD44v6 in HNSCC and other cell lines cultured in vitro and UT-
SCC58 tumors in vivo. a Surface expression of CD44v6 in 9 HNSCC and 2 melanoma cell lines maintained 
in liquid culture, detected by flow cytometry for IgG1 control (black lines) and CD44v6 (red lines). Numbers 
indicate the geometric mean. b Immunofluorescence whole-region analysis of Fig. 4D. Co-localization of 
CD44v6 and pan-cytokeratin (CK) staining in different areas in UT-SCC58 tumors analyzed at day 28 after 
implantation. Data show the medians from 12-38 analyzed images per tumor from 4 independent tumors.
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Supplementary figure 3. Radioactive and fluorescence detection in cervial lymph nodes. a Biodistribtion 
expressed as percentage injected dose of 111In-DTPA-BIWA-IRDye800CW and 111In-DTPA-IgG1-IRDye800CW 
in right and left cervical lymph nodes (LN). b Central section and NIRF signal of a left cervical LN of a mouse 
injected with dual-labeled BIWA. Dotted line marks the LN edge. Scale bars indicate 500 µm (overview) and 
50 µm (zoom). C Detection of CK in left cervical LNs. Scale bars indicate 500 µm.
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Supplementary figure 4. HE staining and NIRF signals in tumors injected with dual-labeled BIWA and IgG1 
isotypic control. Central, serial sections of mouse cheeks (H&E staining and NIRF signal) indicating the tumor 
border (dotted line; T), normal epithelium (E) and stroma (S); Left zoomed images: (1) tumor border and (2) 
false positive NIRF signal. Right zoomed images: (1) positive signal from tumor cells and (2) negative back-
ground from tumor stroma. Arrowheads indicate membranous staining. Scale bars indicate 2 mm (overview) 
and 100 µm (zoom).
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Surgical treatment of cancer requires tumor excision with emphasis on function preservation 
which is achieved in (early stage) laryngeal cancer by transoral carbon dioxide (CO2) laser surgery. 
Whereas conventional laser surgery is restricted by the surgeon’s visual recognition of tumor tissue, 
new approaches based on fluorescence-guided surgery (FGS) improve the detection of the tumor 
and its margin. However, it is unclear whether fluorophores are compatible with high-power 
laser application or whether precision is compromised by laser-induced bleaching of the dye. We 
applied topology-controlled 3D laser resection of fluorescent tumors in vitro and laser-induced 
autofluorescence analysis ex vivo. Laser-induced bleaching of fluorescent dyes in the visible 
and near-infrared light spectrum (650-900 nm) ranges below the resolution range of operation 
microscopes. Furthermore, specific fluorescent signals in an FGS mouse model is 104 higher than 
laser induced autofluorescence in mouse tissue. Laser-induced lateral photobleaching is negligible 
indicating a path forward for fluorescence-guided laser surgery in head and neck cancer.
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InTRODuCTIOn
The use of the carbon dioxide (CO2) laser in transoral surgery of the larynx was first described 
in 1972 (1). During the following decades it has become an established treatment modality for 
the transoral resection of early stage laryngeal as well as oropharyngeal and hypopharyngeal 
squamous cell carcinomas. With comparable oncological outcomes, its advantage over open 
partial laryngectomy is considered to result from lower complication rates and faster recovery (2-4).
The objective of surgical oncological treatment is to achieve adequate surgical margins which are 
free of tumor cell infiltration. In an anatomically and functionally delicate structure such as the lar-
ynx this is challenging to achieve, due to the choice of small margins to preserve as much tissue as 
possible. In the search of techniques that could be helpful in optimizing surgical outcomes, a new, 
evolving technique is the use of fluorescence as guidance during surgery with the potential use for 
all areas in head and neck squamous cell carcinoma (HNSCC) (5). During this fluorescence-guided 
surgery (FGS), autofluorescence of the tumor in the visible light range can be used as guidance (6), 
and much improved signals have been achieved by conjugating fluorophores in the near-infrared 
(NIR) range of 650-900 nm to targeting antibodies which bind extracellular epitopes preferentially 
expressed on tumor cells (5). NIR-FGS allows biomarker-based demarcation of the tumor margin, 
potentially detecting tumor residues and invasive regions which remain undetected otherwise.
CO2 laser surgery is usually applied through a microscope and this type of surgery could poten-
tially be combined with FGS with NIR fluorophores. However, when performing laser surgery, 
thermal damage and photobleaching is caused to the tissue which also might interfere with 
the fluorophore signal (7, 8). To combine NIR-guided tumor detection with transoral laser surgery 
(TOLS), the compatibility of both approaches has to be established, particularly whether CO2 laser 
ablation may negatively affect fluorophore signals. Thus, the purpose of the current study was 
to test whether CO2 laser ablation has an effect on fluorophore signals, potentially hampering its 
application in TOLS.
MaTeRIal anD MeThODS
Cell culture
Mouse mammary tumor (MMT) cells expressing nuclear EGFP coupled to histone-2B (H2B) (9) were 
used as a proxy for an epithelial solid tumor type. The cells were maintained in RPMI 1640 growth 
medium (Invitrogen) supplemented with 10% heat-inactivated fetal calf serum (Sigma Aldrich), 
100 U/ml penicillin and 100 µg/ml streptomycin (PAA).
HNSCC cell line UT-SCC58 was a kind gift from Reidar Grenman, University of Turku, Finland (10) 
and cells were cultured in Dulbecco’s modified Eagle medium (DMEM, Invitrogen), supplemented 
with 10% heat-inactivated fetal calf serum (Sigma Aldrich), 100 U/ml penicillin and 100 µg/ml 
streptomycin (PAA), 2 mM L-glutamine, 1 mM sodium pyruvate (both Invitrogen/Life technolo-
gies) and 20 mM HEPES (Gibco).
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To generate SCC58-H2B-GFP cells, lentiviral particles, produced in HEK293T cells using the Vi-
ralPower expression system (Life technologies, containing pLenti6.2v5-H2B-GFP (Clontech) were 
used followed by blasticidin selection (5 µg/ml) and cell sorting for GFP-expressing cells (FACS Aria 
SORP, Becton Dickinson).
antibody conjugation
NIR fluorescent conjugation to murine anti-CD44v6 IgG1 antibody (BIWA), the humanized form 
of which (Bivatuzumab, BIWA-4) has been applied in human clinical trials was performed. In 
short, BIWA was incubated with a 3-fold excess of IRDye800CW-N-hydroxysuccinamide (NHS) in 
0.1 M sodium carbonate buffer (pH 8.5) for 1 h at room temperature (RT). The final concentration 
of the antibody and the molecular substitution ratio were determined spectrophotometrically 
(Ultrospec 2000 spectrophotometer, Pharmacia Biotech) yielding an antibody:fluorophore ratio 
of 1:2. BIWA-IRDye800CW was stored in the dark at 4°C.
Unperturbed immunoreactivity of the antibody conjugates was confirmed as described (11).
3D tumor spheroid culture and CO2 laser treatment
Sub-confluent cells were detached using trypsin/EDTA (SCC58-H2B-GFP) or EDTA (MMT-H2B-GFP) 
(Life Technologies) and aggregated to multicellular tumor spheroids using the hanging-drop meth-
od. Cells were suspended in DMEM or RPMI medium supplemented with 10% methylcellulose 
solution (Sigma) and incubated as 30 µl droplets (50,000 cells/drop). After overnight incubation, 
spheroids were harvested, washed with PBS, washed again in full growth medium, and embedded 
in non-pepsinized rat tail type I collagen lattices (BD Biosciences, final concentration: 5 mg/ml) on 
a layer of rat tail type I collagen in 12-well plates. Spheroids were allowed to invade 3D collagen 
scaffolds in vitro for 72 h. To reach equilibrium saturation in SCC58-H2B-GFP spheroids, 5 µg/ml of 
the antibody BIWA-IRDye800CW was added to the growth medium at time point 0. After removal 
of the medium, spheroids were burned with a CO2 laser (SHARPLAN, Laser vision) using a single 
pulse, 2W for 0.1, 0.5 or 1 sec (MMT-H2B-GFP), for 0.5 sec (SCC58-H2B-GFP) or cut with a scalpel.
Spheroids imaging and analysis
After partial laser dissection of spheroids, which aimed to remove approximately one third to 
half of the tumor mass, the remaining portion was analyzed by epifluorescence or confocal 
microscopy. MMT-H2B-GFP spheroids were imaged by sequential confocal scanning keeping an 
inter-slice distance of 10 µm (Olympus FV100) using a 20x/0.5 NA water objective. NIR and GFP 
imaging of SCC58 spheroids was performed with the Nuance XR (PerkinElmer; 20x NA 0.8; mono 
setting, 5 sec acquisition time for NIR).
Digital image analysis was performed using Fiji (software version 1.51k, https://imagej.net/Fiji). Rect-
angle regions of interest crossing the resection margin were defined (blue rectangle in figure 1B) and 
the intensities of the reflectance and fluorescent signals were obtained in perpendicular direction 
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to the resection margin (figure 1C, arrow). Resection margins from laser cuts were irregular due to 
debris. Thus, the slope of reflectance and fluorescent intensity signal were gradual over distances of 
100 µm and varied from sample to sample. Therefore, intensities were normalized to define cutting 
edges for inter-sample comparison, as follows: the edge between tissue-free background and the 
onset of signal was defined as inner margin (0% value). Then the region approximating maximum 
fluorescence intensity was identified to denote unperturbed tissue (100% value). To avoid errors 
caused by debris, the tissue region representing 50% of the maximum of the fluorescence chan-
nel was defined as reference point, thus representing the zone of clearly detectable fluorescence 
(figure 1D, blue dotted line). The distance of bleaching was obtained as distance between the inner 
margin of the reflectance channel to the location of 50% GFP intensity (MMT-H2B-GFP). Because 
IR-Dye800CW detection using the Nuance imaging system did not enable reflection signals, the 
H2B-GFP signal was used as reference for SCC58 cells, as H2B-GFP largely withstood exposure to 
laser irradiation and showed only negligible bleaching below 50 µm in extension.
animal experiments
The animal experiments were performed in accordance with the guidelines and rules of the 
Dutch Act on animal experiments (WOD) and was approved by the Animal Welfare body of the 
Radboud University, Nijmegen (RU-DEC 2014-142). A laryngeal tumor mouse model is ethically 
and logistically not possible to perform, thus 9 x 105 UT-SCC58 cells suspended in 3 mg/ml 
Matrigel (BD Biosciences; total volume 50 µl) were injected via an intraoral approach into the left 
floor of mouth of BALB/c nu/nu female mice (Charles River Laboratories; 6-8 weeks old). Tumors 
were allowed to grow for 4-6 weeks which led to tumor extension in the floor of mouth and the 
left cheek. Tumor growth over time was measured using a caliper. UT-SCC58 cells were chosen as 
they resemble the Immunohistochemical invasion and growth pattern of human HNSCC.
Mice bearing UT-SCC58 tumors in the left cheek were injected into the tail vein with 10 µg of 
BIWA-IRDye800CW. Three days after injection mice were euthanized and whole-body fluores-
cence images were acquired (IVIS Lumina imaging system, Caliper Life Science) using the fol-
lowing settings: F/Stop - 2, excitation filter - 745 nm, emission filter – ICG (810-875 nm), field 
of view - C, 675 nm autofluorescence and background correction, recording time of 1 min and 
medium binning factor.
To further test whether laser application could create false-positive events by autofluorescence 
induction, mouse skin was burned with a CO2 laser (SHARPLAN, Laser vision) using the following 
settings: single pulse, 2 or 5W for 0.1, 0.5 or 1 sec. Mouse floor-of-mouth tissue was burned 
with a single pulse, 2W for 0.5 sec and the wound was washed with PBS. Subsequently, the 
fluorescence was detected by whole-body imaging (IVIS Lumina; settings as described above). 
Images were processed with the IVIS Lumina software. For NIR intensities, regions of interest (ROI) 
were defined manually to represent laser-treated tissue. Background values from tissue free areas 
of the same images were subtracted for each specific measurement.
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Statistics
Statistical analysis was performed using GraphPad Prism (version 5). Non-parametric Mann-
Whitney test with a two-tailed p value and a conficence interval of 95% was chosen. In addition, 
a post-hoc correction for multiple comparisons (p ≤ 0.05/3) was used for data shown in figure 1.
ReSulTS
Stability of fluorophores after CO2 laser treatment
The effects from lasers on tissues have been well-described, causing a very fine carbonization 
zone, a necrotic zone and cell debris including a denaturing of collagen (7). To mimic this effect 
and study the influence of CO2 laser application on fluorescence in a tumor-like model, GFP 
fluorescent tumor spheroids were embedded in a 3D collagen lattice (Figure 1A). Spheroids were 
allowed to invade into the collagen for 72 h and subsequently treatment was performed with 
a single pulse of a CO2 laser (Figure 1B) or cut in half with a scalpel as control. Analysis of the 
cutting edge (Figure 1 C, D) indicated a non-significant shift of the genetically encoded, histone-
bound GFP fluorescent signals to the reflection signal caused by fibrillar collagen and with lower 
intensities cells (Figure 1E). This shift was independent of the duration of the single CO2 laser 
shot. Thus, the ablation of genetically encoded fluorescence in the green visible light range by a 
CO2 laser occurred within the spatial range of collateral thermal damage in patients which lies on 
average between 150 - 160 µm (12, 13).
To analyze a fluorophore in the NIR range, spheroids were stained with the anti-CD44v6 antibody 
BIWA conjugated to the NIR dye IRDye800CW. Spheroids were then cut with a scalpel or burned 
with a CO2 laser (Figure 2A). Fluorescent images showed an equal distribution of the antibody 
throughout the spheroid prior to laser ablation (Figure 2B). This distribution was not influenced 
after cutting with a scalpel or a CO2 laser, with identical position of NIR fluorescence to the 
histone-tagged GFP signal, which has been shown to be the same as the collagen signal (Figure 
1E), in either cutting method (Figure 2C). Thus, CO2 laser application does not lead to significant 
ablation of cell-surface bound NIR fluorescence.
Interference of CO2 laser-dependent autofluorescence and nIR fluorescence
Burning wounds caused by lasers induce autofluorescence of the tissue (14). Consequently, we 
tested whether the resulting autofluorescence can produce false-positive results during surgery 
(Figure 3). Single pulse shots with 2 or 5 W causing roundish wounds in the mouse skin caused 
autofluorescence in the NIR fluorescent range (810-875 nm) with increasing intensities depend-
ing on laser power and pulse duration (Figure 3A). However, the in vivo fluorescent signal from an 
oral tumor targeted with BIWA-IRDye800CW was approximately 104 times higher as the caused 
autofluorescence (Figure 3B). Since autofluorescence is tissue-specific (15), autofluorescence origi-
nating from the floor-of-mouth was also compared. A treatment with 2W for 0.5 sec was not 
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figure 1 Stability of genetically encoded H2B-EGFP and DsRed2 after CO2 laser treatment. a Experimental 
setup. b Brightfield image of MMT-H2B-GFP spheroids incubated in rat tail type I collagen for 72h before (left) 
and after (right) treatment with a CO2 laser. C Confocal image showing the burned edge of an MMT-H2B-GFP 
spheroids marked in A. Numbers indicate time of CO2 laser shot. D Plot profiles show analysis of area in (B). 
The blue dotted line indicates the edge according to reflection signal. e Graph shows analysis of plot profiles 
from 1-8 spheroids. Scale bars indicate 100 µm.
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figure 2 Stability of near infrared fluorescent (NIRF) antibody (BIWA-IRDye800CW) after CO2 laser treatment. 
a Scheme of experimental setup. Arrowheads indicate cutting edge, blue rectangle marks area of analysis. 
b Brightfield and fluorescent images showing SCC58-H2B-GFP spheroids before and after treatment. BIWA-
IRDye800CW (red) and H2B-GFP (green) signals were detected by epifluorescence microscopy. Scale bar in-
dicates 100 µm, arrowheads mark cutting edge. C Analysis of B as shown in figure 1 from 4 spheroids. Blue 
rectangle marks area of analysis.
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detected at the same image settings as the oral tumor (Figure 3B) and washing the wound did 
not influence the autofluorescence signal. Differences in the autofluorescence signals from the 
mouse skin and the floor-of-mouth are likely due to variations in tissue structure(15, 16) and tissue 
preparation. In conclusion, CO2 laser-dependent autofluorescence is unlikely to interfere with 
strong NIR signals.
DISCuSSIOn
In this study we provide proof of principle for a combination of NIR fluorescence imaging and 
CO2 laser ablation in a 3D in vitro system. The occurring error range of fluorescent signal in the 
visible light range after laser ablation ranges within resolution limits of state-of-the-art opera-
tion microscopes. Furthermore, near-infrared fluorescence was not damaged by the CO2 laser 
which, however, requires confirmation under clinical conditions. Taken together, the bleached 
corridor ranges below the extent of collateral thermal damage induced by a CO2 laser which 
ranges between 0.15 and <0.3 mm (12, 13, 17), thus enabling a combination of both CO2 laser and 
fluorescence-guided surgery.
Fluorescence-guided surgery using NIR dyes has recently been introduced in HNSCC patients 
showing efficient tumor detection (18) and permitting visualization of microscopic lesions (19), thus 
potentially assisting the surgeon in more accurately defining tumor deposits and borders. Indeed, 
a first approach of fluorescent-guided laser surgery has been applied in a soft tissue sarcoma 
model using a Nd:YAG laser system which ablated far-red fluorescent tumor tissue with minimal 
disruption of adjacent tissue improving recurrence-free survival in mice (20).
figure 3 Autofluorescence of burned wounds. a Brightfield and NIR fluorescence image of a mouse skin 
burned with a CO2 laser. b NIR fluorescence whole body image of a mice with a growing HNSCC tumor in the 
left cheek 72 h after i.v. administration of BIWA-IRDye800CW (left). Tumor (T), liver (L). Images with the same 
settings of a mouse floor-of-mouth burned with a CO2 laser (right). Arrowheads indicate burning wounds. C 
The graphs show an analysis of autofluorescence signals before and after washing the wound; n=3. Fl. Int. – 
fluorescence intensity in (p/sec/cm²/sr)/(µW/cm²).
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In addition, we confirm that laser wounds induce autofluorescence (14) in the NIR light range, 
but show that the unspecific fluorescent signal was 100 - 10,000 times below the specific signal 
emitted by the tumor after in vivo application of an IRDye800CW conjugated anti-CD44v6 an-
tibody. Direct autofluorescence of tumor tissue has been used in TOLS using a D-light system to 
identify positive superficial margins in patients without mentioning difficulties with laser-induced 
autofluorescence (6). Thus, although autofluorescence-induced false-positive signals are unlikely 
in a fluorescence-guided laser surgery approach, caution should be taken for weak signals. Such 
weaker signals are expected for smaller tumors or tumors expressing less of the target epitope.
Taking together, first in vitro and preclinical data suggest that fluorescence-guided laser surgery is 
an effective and promising technique in improving transoral laser surgery of laryngeal cancer but 
potentially of other tumors as well.
auThORS COnTRIbuTIOn
J.O. designed and carried out the experiments, analyzed the data and wrote the manuscript. P.F. 
designed the experiments, supervised the work and wrote the manuscript. R.T. supervised the 
work and wrote the manuscript.
aCknOwleDGeMenTS
We gratefully acknowledge Silvia van Vugt-Eijkhout and Corien Janssen for expert technical assis-
tance and Véronique Orian-Rousseau for providing the BIWA antibody and Bianca Lemmers-van 
de Weem and co-workers at the Central Animal Facility for assistance with animal experiments. 
P.F. was supported by NWO-VICI (918.11.626), the European Research Council (ERC-CoG DEEP-
INSIGHT, Project No. 617430) and the Cancer Genomics Center, The Netherlands.
5Compatibility of CO2 laser surgery and fluorescence detection in head and neck cancer cells | 121
RefeRenCeS
1. Strong MS, Jako GJ. Laser surgery in the larynx. Early clinical experience with continuous CO 2 laser. Ann 
Otol Rhinol Laryngol 1972;81(6):791-8.
2. Rodrigo JP, Suarez C, Silver CE, et al. Transoral laser surgery for supraglottic cancer. Head Neck 
2008;30(5):658-66.
3. Ambrosch P. The role of laser microsurgery in the treatment of laryngeal cancer. Curr Opin Otolaryngol 
Head Neck Surg 2007;15(2):82-8.
4. Canis M, Martin A, Ihler F, et al. Transoral laser microsurgery in treatment of pT2 and pT3 glottic 
laryngeal squamous cell carcinoma - results of 391 patients. Head Neck 2014;36(6):859-66.
5. Zhang RR, Schroeder AB, Grudzinski JJ, et al. Beyond the margins: real-time detection of cancer using 
targeted fluorophores. Nat Rev Clin Oncol 2017;14(6):347-364.
6. Succo G, Garofalo P, Fantini M, Monticone V, Abbona GC, Crosetti E. Direct autofluorescence during CO2 
laser surgery of the larynx: can it really help the surgeon? Acta Otorhinolaryngol Ital 2014;34(3):174-83.
7. Sigston EA, Longano A, Strzelecki AT, Williams BR. Surgical margins in head and neck squamous cell 
carcinoma: Effect of heat artifact on immunohistochemistry as a future tool for assessment. Head Neck 
2016;38(9):1401-6.
8. Diaspro A. Nanoscopy and multidimensional optical fluorescence microscopy. Boca Raton: CRC Press/
Taylor & Francis Group; 2010.
9. Tsuji K, Yamauchi K, Yang M, et al. Dual-color imaging of nuclear-cytoplasmic dynamics, viability, and 
proliferation of cancer cells in the portal vein area. Cancer Res 2006;66(1):303-6.
10. Paluszczak J, Wisniewska D, Kostrzewska-Poczekaj M, et al. Prognostic significance of the methylation 
of Wnt pathway antagonists-CXXC4, DACT2, and the inhibitors of sonic hedgehog signaling-ZIC1, 
ZIC4, and HHIP in head and neck squamous cell carcinomas. Clin Oral Investig 2017;21(5):1777-1788.
11. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA, Jr. Determination of the immunoreactive fraction of 
radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. Journal 
of immunological methods 1984;72(1):77-89.
12. Bailey AP, Lancerotto L, Gridley C, et al. Greater surgical precision of a flexible carbon dioxide laser fiber com-
pared to monopolar electrosurgery in porcine myometrium. J Minim Invasive Gynecol 2014;21(6):1103-9.
13. Suter VG, Altermatt HJ, Dietrich T, Warnakulasuriya S, Bornstein MM. Pulsed versus continuous wave 
CO2 laser excisions of 100 oral fibrous hyperplasias: a randomized controlled clinical and histopatho-
logical study. Lasers Surg Med 2014;46(5):396-404.
14. Giordano PA, Prosperi E, Bottiroli G. Primary fluorescence of rat muscle after CO2 laser thermal injury. 
Lasers Surg Med 1984;4(3):271-8.
15. Stelzle F, Knipfer C, Adler W, et al. Tissue discrimination by uncorrected autofluorescence spectra: a 
proof-of-principle study for tissue-specific laser surgery. Sensors (Basel) 2013;13(10):13717-31.
16. Monici M. Cell and tissue autofluorescence research and diagnostic applications. Biotechnol Annu Rev 
2005;11:227-56.
17. Fitzpatrick RE, Ruiz-Esparza J, Goldman MP. The depth of thermal necrosis using the CO2 laser: a com-
parison of the superpulsed mode and conventional mode. J Dermatol Surg Oncol 1991;17(4):340-4.
18. de Boer E, Warram JM, Tucker MD, et al. In Vivo Fluorescence Immunohistochemistry: Localization of 
Fluorescently Labeled Cetuximab in Squamous Cell Carcinomas. Scientific reports 2015;5:10169.
19. van Dam GM, Themelis G, Crane LM, et al. Intraoperative tumor-specific fluorescence imaging in ovarian 
cancer by folate receptor-alpha targeting: first in-human results. Nature medicine 2011;17(10):1315-9.
20. Lazarides AL, Whitley MJ, Strasfeld DB, et al. A Fluorescence-Guided Laser Ablation System for Removal 
of Residual Cancer in a Mouse Model of Soft Tissue Sarcoma. Theranostics 2016;6(2):155-66.

Chapter 6
General discussion and future directions

6General discussion and future directions | 125
Head and neck squamous cell carcinomas (HNSCCs) are located in a functionally critical region 
including the naso-, oro- and hypopharynx, larynx, oral and nasal cavity. This heterogeneous 
group of tumors are characterized by intense local invasion which hampers effective treatment, 
consequently leading to a high frequency of local recurrence [1, 2]. In this thesis, new mechanism 
of local invasion and strategies to target this invasion are provided. Using an innovative 3D in 
vitro model for HNSCC invasion, growth factors have been identified as regulators of tumor cell 
migration plasticity. This finding may have a predictive value in targeting growth factor signaling 
in tumor progression. Collective invasion, as one type of growth factor-induced tumor cell migra-
tion, has been visualized using intraoperative fluorescence imaging in an HNSCC mouse model 
potentially contributing to the improvement of radical surgery.
COlleCTIve MIGRaTIOn aS hnSCC InvaSIOn MeChanISM
Migrating cells can move either individually or as cohesive groups. During collective migration, 
cadherin-based junctions enable the maintenance of collective polarization, mechanocoupling 
and cytoskeletal kinetics of cohesive groups [3]. In cancer development, collective invasion differs 
from single cell migration which includes pro-survival signals due to cell-cell contacts and local 
growth factor or cytokine secretion, protection against immune responses and a passive move-
ment of non-migratory cells. Highlighting the importance of collectivity is the growing evidence 
that epithelial cancer metastasis involves the traveling of tumor cell clusters into blood vessels 
followed by collective organ colonization [4, 5].
The primary strategy of squamous cell carcinoma invasion is collective migration [3]. Three-dimen-
sional reconstruction of human oral tongue SCCs, multi-photon imaging of an oral tongue SCC 
mouse model and immunohistochemistry results of the oral HNSCC mouse model, as presented 
in Chapter 4, show multicellular groups at the invasive front [6, 7]. These findings support the 
presence of collective invasion strategies in HNSCC. Furthermore, buds of primary tumor masses 
have been observed in immunohistochemical analysis to frequently penetrate lymphatic vessels 
[6, 8], and these nests coincide with similar immunohistochemically detected collective invasion 
zones shown in this thesis. As further clinically relevant complication, local collective invasion in 
the soft tissue of the head and neck area accounts for difficult-to-detect tissue contamination 
with tumor cells and hence incomplete tumor removal. As a consequence, collective migration is 
one aspect of invasion which needs more examination in HNSCC.
Fibroblasts have been shown to guide collective invasion in epithelial cells [9-11]. However, in the 
HNSCC models used for this thesis, fibroblast guided invasion is negligible, as low concentrations 
of both hepatocyte growth factor (HGF) and epidermal growth factor (EGF) efficiently stimulate 
collective migration despite the absence of fibroblasts. Both growth factors signal via MAPK and 
Akt signaling pathways [12], which are also activated by other growth factors and cytokines. 
Thus, low levels other growth factors or cytokines likely induce collective invasion as well [13]. In 
conclusion, comparable to breast and colon cancer [14, 15], HNSCC predominantly invades by 
collective strategies likely stimulated by growth factors and cytokines.
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aMOebOID DISSeMInaTIOn aS hnSCC InvaSIOn MeChanISM
On the basis of morphology, kinetics and function, amoeboid and mesenchymal movement have 
been defined in vivo as the two types of single cell migration. Amoeboid dissemination is an 
emerging avenue in cancer research [15] and although it is difficult to appreciate in histological 
sections, live cell culture and intravital imaging reveal amoeboid migration in carcinoma cells 
[16, 17]. In HNSCC, rounded cells with amoeboid-like nuclear deformation were detected in 
hypoxic regions of clinical samples, suggesting a collective-to-amoeboid transition under oxygen 
deprivation [18]. Furthermore, amoeboid migration has been detected in vivo in breast cancer 
mouse models by intravital microscopy [19], indicating that this migration type is a frequent mode 
across tumor types.
In Chapter 3, multicellular spheroid culture stimulation with high growth factors concentrations 
downregulates E-cadherin and stimulates disseminating single migrating cells with a roundish-
amoeboid movement. As particular subtype identified in this thesis, amoeboid moving HNSCC 
cells were proteolytic and generated migration tracks in the collagen. Furthermore, migration 
was largely dependent on proteinases since matrix metalloproteinase inhibition almost blocked 
migration. Thus, amoeboid cancer cell movement may occur as cell-intrinsic, hypoxia- or growth 
factor-induced variants, including HGF and transforming growth factor-β (TGF-β) in melanoma, 
breast and HNSCC cells [18, 20, 21].
In addition, whereas collective migration depends upon tissue remodeling to form multi-cellular 
or epithelial structures, mesenchymal and amoeboid migration are considered to enable efficient 
cancer-cell spread throughout interstitial tissues with amoeboid migration being the fastest 
migration type [22-24]. Consistently, in HNSCC, reduced expression or loss of the epithelial 
marker E-cadherin is associated with lymph node metastasis, tumor stage, poor differentiation 
and infiltrative margin [25-27]. Together, these findings lead to the concept that detachment of 
tumor cells is more efficient in migration and leads to poorer prognosis. However, the relevance 
of amoeboid migration in driving metastasis warrants further exploration [15, 17].
PlaSTICITy Of hnSCC InvaSIOn
Cell migration plasticity is defined as the conversion from one migration mode to another. It can 
be triggered in vitro by several mechanism including matrix confinement as shown in transition 
from mesenchymal to collective migration with increasing collagen density [28] or the transition 
from collective to amoeboid migration under hypoxic conditions [18]. Mechanisms by which 
growth factors or cytokines induce plasticity are summarized in Chapter 2. In Chapter 3, HGF 
released by fibroblasts is identified as potent inducer of simultaneous collective and single cell 
migration in HNSCC spheroids. Furthermore, fibroblast conditioned medium induces a concen-
tration-dependent transition from collective to single cells with single cells or clusters detaching 
from collective strands.
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Given that each migration mode has unique advantages and potential shortcomings for tumor 
cell spreading, plasticity induction is thought to facilitate the possibilities for escape in a hetero-
geneous tumor microenvironment. The concept that tumor cell migration plasticity might be the 
most efficient strategy in vivo is supported by mathematical models. The ECM is characterized 
by structural heterogeneity [29] while chemical gradients are present simultaneously [30, 31]. 
In such heterogeneous conditions, in silico amoeboid-mesenchymal migration plasticity is most 
efficient [32]. Accordingly, amoeboid cells can benefit from the presence of a small number of 
paths created by slower migrating proteolytic cells [32]. Thus, as also shown in this thesis, in vitro 
systems studying tumor invasion should take into account the complexity of the microenviroment 
by combining 3D structural and chemical heterogeneities.
Similar to the models described in this thesis, patient samples of HNSCC show detached het-
erogeneous groups of single cells and clusters reaching hundreds of cells at the invasive zone 
[6]. These findings highlight remarkable variance of invasion mechanisms present in the same 
tumor, including differences in cluster size and heterogeneous morphology including spheroidal, 
amoeboid, branching or stretching features [6]. In conclusion, migration plasticity is part of tumor 
heterogeneity resulting in a major challenge to overcome in cancer treatment.
COOPeRaTIOn Of MOleCulaR PlaSTICITy anD InvaSIOn PlaSTICITy
The results of this thesis indicate that amoeboid movement can be associated with epithelial-
mesenchymal transition (EMT), a well-established molecular program driving cancer progression, 
metastasis and therapy resistance [33]. EMT inducers such as Twist or Snail can initiate invasion 
and metastasis in animal models and correlate with poor prognosis [18, 34-36]. E-cadherin, as 
epithelial marker, decreases at invasive regions in HNSCC patient samples [25] as well as other 
cancers. Cells expressing EMT markers have been localized to the periphery of the tumor where 
they are in closer contact to growth factors of the tumor environment [37, 38]. This phenotype is 
reflected in SCC58 cells in our spheroid model in which E-cadherin was gradually down-regulated 
in collective invasion strands and reached minimum levels in detached cells while vimentin was 
more prominent in invasive cells. These similarities suggest that during cancer development the 
transition from an epithelial to a mesenchymal state must not be absolute and independent from 
one another, but that it is instead a continuous spectrum of both properties. Thus, plasticity of 
invasion programs and EMT may partially overlap, likely in response to environmental cues [25, 
35, 38]. As outcome, this epithelial plasticity might then lead to single cell and/or collective cell 
migration and each migration mode may harbor EMT-like and EMT-independent signaling states. 
However, besides induction by defined triggers, EMT may also occur as ‘random’ process in small 
cell subsets, as reflected in the SCC38 cell line in Chapter 3. Similarly, vimentin or snail are often 
found in subsets of tumor cells in HNSCC patient samples [39, 40], reflecting EMT as a ‘random’ 
process.
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EMT induction in cancer appears to have clinical significance, potentially offering new drug targets, 
e.g. by neutralizing factors which induce EMT. As seen in Chapter 3, HGF induces cell migration, 
destabilizes cell-cell adhesions and regulates vimentin expression. Inhibition of HGF signaling in 
vitro readily reduces single cell migration and markedly reduced collective migration as outcome. 
Likewise, TGF-β is known to induce EMT and migration in several tumor models, and inhibition of 
the signaling in a rat mammary carcinoma model inhibited single cell migration whereas collective 
migration and subsequent lymphatic metastasis were maintained [23]. Together, these results 
suggest that growth factor induced collective migration is particularly resistant to treatment, 
asking for complementary targeted approaches for collective processes in cancer.
fluOReSCenCe-GuIDeD SuRGeRy
The importance of resection margins varies between cancer types. While positive surgical margins 
in kidney cancer patients are not associated with an increased risk for local recurrence or metasta-
sis [41], incomplete resection is an important risk factor limiting the prognosis of HNSCC [42, 43] 
and pancreatic cancer patients [44]. This indicates the importance of radical surgery in HNSCC. 
Thus, new technologies, such as intraoperative fluorescence imaging, show the potential to 
improve tumor detection and outcomes of curative surgery. Indeed, animal models of pancreatic 
and colorectal cancer have shown better tumor resections, detection of small satellite tumors 
and longer disease-free survival [45, 46]. Chapter 4 describes the dissection of orthotopic HNSCC 
tumors under clinic-like conditions using a commonly used operation microscope. Here, tumor 
remnants of approximately 0.7 mm in diameter consisting of a few thousand cells were reliable 
detected by near-infrared fluorescence, allowing precise dissection of invasive microregions. 
Other fluorescence imaging systems were able to visualize and resect tumors of comparable sizes 
in vivo and in patients which were otherwise not detected under standard conditions [47, 48]. 
Thus, fluorescence-guided surgery (FGS) shows promise to detect the invasion zones and improve 
outcomes of HNSCC surgery. However, a significant part of HNSCC invasion consists of small 
cluster and even single cells [6]. Although small strands or clusters were detected by the CD44v6 
targeting antibody fluorescence imaging, this method may be insufficiently sensitive to detect 
such small lesions under clinical conditions. Thus, despite efficient detection of the collective inva-
sion zone, single cell dissemination beyond the resection margin may remain a potential threat 
for optimal results of surgical procedures. Importantly, although successfully applied in animal 
models, FGS still has to prove its contribution to recurrence-free and overall survival in patients.
CD44v6 aS TaRGeT In hnSCC
The consistent expression of CD44v6 across heterogeneous HNSCC lesions and most, if not all, 
HNSCC tumor cells emphasize CD44v6 as a promising antigen for reliable FGS in HNSCC cancer. 
In addition, the availability of clinically applicable anti-CD44v6 antibody Bivatuzumab enables 
visualization of tumor margins and minimal residual lesions (Chapter 4). Targeting CD44v6 in 
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other cancer types has been shown to inhibit proliferation and migration in vitro and in vivo and 
seems to have a role in c-Met and vascular endothelial growth factor receptor signaling [49-51]. 
Thus CD44v6 could potentially be used in cancer therapy after surgery. However, despite its 
high and homogeneous expression in HNSCC patients, the association with CD44v6 and disease 
outcome is contradictory and depends on the tumor site [52-54]. In addition, inhibiting CD44 
and its variants shows only a minor function in migration and invasion in cancer cells in 3D in 
vitro models [55, 56]. Thus, besides its use for intraoperative detecting of the tumor margin, 
therapeutic targeting of CD44v6 in HNSCC might require careful selection among patient groups.
COnCluSIOn
The work presented in this thesis identifies collective invasion as important target for reducing the 
emergence of local tumor infiltration into healthy tissue and improving the determination of the 
optimal resection margin for curative surgery. Fluorescence imaging, because of its high sensitivity 
and real-time capabilities has great potential to improve surgical outcomes. Strategies include the 
targeting of proteins such as CD44v6 which are highly expressed in collective invasion which is 
characteristic for HNSCC. Subsequently, since growth factors or cytokines are major contributors 
in driving collective tumor invasion as well as migration plasticity with cell detachment, they 
form an interesting target in post-surgical treatment (Figure 1). Thus, FGS could improve surgical 
outcomes and reduce the need for adjuvant treatment with its additional toxicity and costs. 
In this way it can add to better oncologic as well as functional outcomes and therefore also 
figure 1. Growth factor induced cell migration plasticity and potential targets for fluorescence-guided sur-
gery and/or interference of cell migration processes.
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more cost-effective treatment. As FGS cannot detect small volumes of detaching cells it could 
be combined with other novel treatments such as immunotherapy (Figure 1). Such combinations 
have been shown to decrease metastatic recurrence in animal models of pancreatic cancer, breast 
cancer or soft tissue sarcoma [57-59] and are informed by mechanistic cell biological studies as in 
this thesis. This dual approach could enable minimally invasive, function-preserving surgery and 
destruction of microscopic tumor deposits.
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Head and neck squamous cell carcinoma (HNSCC) arises from the mucosal surfaces of the up-
per aerodigestive tract. Despite efforts in improving both surgical and non-surgical treatment, 
outcomes have barely improved with 40-50% of patients developing lethal recurrences and 
metastasis. Characteristic for HNSCC is its local invasion in the often functionally important soft 
tissues of the head and neck. Therefore, in case of surgical treatment, the resection margins are 
often inadequate and/or the functional consequences of treatment are significant. Inadequate 
margins require further surgery or post-operative (chemo-) radiotherapy. This additional oncologic 
treatment adds to the toxicity and impact on quality of life. Thus, to improve cancer treatment, 
it is important to understand the basis of HNSCC tumor cell invasion and to optimize surgical 
outcomes.
Analysis of HNSCC tumors have identified growth factor and cytokine signaling as potential 
targets which contribute to carcinogenesis and invasion. By acting on the cell intrinsic proper-
ties, likely under the control of transcriptional programs such as the epithelial-to-mesenchymal 
transition (EMT), growth factors and cytokines can induce all known forms of cell migration. 
These are individual cell movements without cell-cell interactions to neighboring cells or collec-
tive migration, where cells move as cohesive groups with cell-cell junction remaining intact. In 
addition to the induction of cell migration, growth factors and cytokines are also able to cause an 
interconversion of the tumor cell dissemination strategies, termed plasticity of invasion. However, 
how invasion plasticity is spatiotemporally controlled upon challenge by the tumor microenviron-
ment and whether inhibiting these factors can prohibit the plasticity progress remains unclear.
A general introduction and outline of the thesis are given in Chapter 1.
In Chapter 2 we group current concepts and functional consequences of growth factor and 
cytokine signaling control in key “modules” of single-cell and collective invasion programs. By 
focusing on the best-documented examples that support the concepts, influences on cell-matrix 
adhesion, cell-cell interaction, cytoskeletal dynamics and remodeling of the extracellular matrix 
are described. Individual and combined effects of growth factors and cytokines contribute to 
the reprogramming and plasticity of cancer invasion programs as typically detected in the tumor 
microenvironment. To better understand the mechanisms of invasion plasticity and potential 
intervention points, combining cell-based in vitro analysis, preclinical mouse models, clinical 
outcome studies and mathematical modeling is necessary to dissect the cooperation of growth 
factors and cytokines and improve outcome by therapeutic targeting.
Fibroblasts, as part of the tumor stroma, secrete growth factors and cytokines. In Chapter 3, 
the presence of fibroblasts induce collective as well as single cell migration at the same time in 
HNSCC cells in a 3D collagen spheroid invasion assay. Hepatocyte growth factor (HGF) was identi-
fied as main contributor of fibroblast conditioned medium to induce this invasion. In addition, 
increasing concentrations of fibroblast conditioned medium, HGF or epidermal growth factor 
(EGF) promoted collective-to-single cell transition. The majority of detaching cells developed 
amoeboid migration and, uncharacteristically for amoeboid migration, degraded the collagen 
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which was dependent on matrix metalloproteinases. To complement biochemical analysis of 
entire cell populations, novel 3D single-cell cytometry was developed to detect molecular markers 
of the EMT in tumor cell subsets. Both collective and individual invasion zones expressed the 
EMT-marker vimentin with approximately 20% up to 80% frequency, depending on the cell line. 
Inhibition of HGF signaling eliminated single cell dissemination and reduced collective invasion, 
indicating differential sensitivity to targeted intervention. Thus, HGF induces EMT together with 
collective, proteolytic-amoeboid and, less frequently, mesenchymal invasion. This indicates EMT 
as a probabilistic molecular program, in association with any invasion strategy.
As most promising strategy to improve surgical outcomes, image-guided surgery (FGS) aiming 
to identify the tumor margin shows great potential to guide and improve the precision of surgi-
cal excision. For FGS, antibodies with tumor selectivity become conjugated with a near-infrared 
fluorophore, are injected intravenously and accumulate in the lesion of the patient. They can 
be visualized subsequently by using an intra-operative imaging system. However, the type of 
biomarkers and detection strategies are under development and by combining fluorescence 
guidance with other types of surgery, such as CO2 laser surgery, high-power lasers may bleach 
fluorophores and extinguish the signal. Thereby, it is uncertain whether CO2 laser surgery can be 
effectively combined with FGS.
In Chapter 4 we demonstrate the suitability for FGS in a preclinical model of invasive HNSCC. 
Based on a literature survey on potential surface molecules followed by immunohistochemical 
and functional validation, we here identify CD44v6 as antigen reliably expressed in the invasion 
zone of HNSCC lesions. The monoclonal anti-CD44v6 antibody BIWA was used for near-infrared 
fluorescent detection in a series of human HNSCC cells and a locally invasive tumor mouse model. 
BIWA accurately detected human HNSCC xenografts in mice with excellent signal-to-noise ratio 
and low uptake in the tumor-free margin and other organs. This was sufficient to resolve tumor 
portions below 1 mm consisting of a few thousand cells under clinical-like resection conditions. 
The data indicate CD44v6 as a suitable target for reliable near-infrared detection of invasive 
margins in HNSCC lesions in vivo.
In Chapter 5 we demonstrate that the irradiation by a CO2 laser does not interfere significantly 
with the fluorescence signal in the visible and near-infrared light spectrum in vitro. Furthermore, 
specific fluorescent signals in a FGS mouse model was 1000-times stronger than laser induced 
auto-fluorescence in mouse tissue. These findings indicate a compatibility of CO2 laser surgery 
and FGS.
Chapter 6 discusses the relevance of cell invasion strategies for local tumor cell dissemination, 
the challenges of tumor cell migration plasticity on cancer treatment and the perspectives for 
targeting cancer invasion by surgical and molecular therapy.
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SaMenvaTTInG
Het hoofd-hals plaveiselcelcarcinoom (HHPCC) ontstaat uit de mucosale oppervlakte van de 
bovenste aerodigestieve kanaal. Ondanks recente verbeteringen in chirurgische technieken en 
doelgerichte behandelmethodes, zijn de behandelresultaten nauwelijks verbeterd en 40-50% 
van de patiënten ontwikkelt lethale recidieven en/of metastasen. Kenmerkend voor HHPCC is 
de lokale invasie in het, vaak functioneel belangrijke, zachte weefsel van het hoofd en de hals. 
Daarom zijn de resectiemarges na een chirurgische behandeling vaak ontoereikend en / of zijn 
de functionele gevolgen van de behandeling aanzienlijk. Ontoereikende marges vereisen extra 
chirurgie of postoperative (chemo-) radiotherapie, wat bijdraagt aan de toxiciteit van oncologi-
sche behandelingen en de impact ervan op de kwaliteit van leven. Om de behandeling van deze 
kanker te verbeteren is het dus van belang de basis van tumorcel invasie in HHPCC te begrijpen 
en om de uitkomst van de chirurgische behandelingen te verbeteren.
Analyse van HHPCC tumoren heeft de signaaltransductie van groeifactoren en cytokines ge-
identificeerd als potentieel doelwit die bijdragen aan carcinogenese en invasie. Ze werken op 
transcriptionele programma’s zoals de epitheliale-mesenchymale transitie (EMT) en kunnen zo 
alle bekende vormen van celmigratie induceren. Dit zijn zowel de individuele celbewegingen, 
waarbij er geen interactie is met naburige cellen, als collectieve migratie, waarbij cellen zich 
verplaatsen als cohesieve groepen met intacte cel-cel contacten. Naast het induceren van invasie, 
kunnen groeifactoren en cytokinen ook een conversie van de strategie van tumorcel verspreiding 
veroorzaken, hetgeen de plasticiteit van invasie wordt genoemd. Hoe de plasticiteit van invasie 
echter spatiotemporeel wordt gecontroleerd door de micro-omgeving van de tumor en of het 
remmen van deze factoren de voortgang van de plasticiteit kan remmen, blijft onduidelijk.
Een algemene inleiding en schets van de scriptie worden gegeven in hoofdstuk 1.
In hoofdstuk 2 worden de huidige concepten en functionele consequenties van de signaaltransductie 
van groeifactoren en cytokines gegroepeerd in functionele “modules” die bepalend zijn in de keuze 
tussen een individueel, of een collectief invasieprogramma. We onderscheiden hier de invloed op cel-
matrix adhesie, cel-cel interactie, cytoskelet dynamiek en remodellering van de extracellulaire matrix 
op basis van goed gedocumenteerde voorbeelden. Dit hoofdstuk beschrijft verder hoe individuele 
en gecombineerde effecten van groeifactoren en cytokines cellen kunnen herprogrammeren en zo 
de plasticiteit van kankerinvasie veroorzaken. Om de mechanismen van de plasticiteit van invasie en 
potentiële interventiepunten beter te begrijpen, is het combineren van op cellen gebaseerde in vitro 
analyse, preklinische muismodellen, klinische studies en mathematische modellering noodzakelijk. 
Zo kan in de toekomst door specifieke therapie de uitkomst verbeterd worden.
Groeifactoren en cytokines worden geproduceerd door fibroblasten die zich in de tumor om-
geving bevinden. hoofdstuk 3 beschrijft hoe er met behulp van een 3D-collageen-spheroïde 
invasie test wordt gedemonstreerd dat de aanwezigheid van fibroblasten zowel collectieve als en-
kelvoudige celmigratie in HHPCC cellen bewerkstelligt. We identificeren Hepatocyte groeifactor 
144 | Appendix
(HGF) als de belangrijkste factor waarmee fibroblasten de migratie van HHPCC cellen reguleert 
en laten zien dat toenemende concentraties van fibroblast geconditioneerd medium, HGF of 
epidermale groeifactor (EGF), een overgang van collectief naar individuele celmigratie induceert. 
De meeste individueel migrerende cellen ontwikkelden amoeboide migratie. Echter, deze cellen 
waren nog steeds in staat om collageen af te breken, en waren voor migratie afhankelijk van 
matrix-metalloproteïnasen, wat ongebruikelijk is voor amoeboide migratie. Om de biochemische 
analyse van volledige celpopulaties aan te vullen, werd een nieuwe 3D-celcytometrie ontwikkeld 
om moleculaire markers van EMT in subsets van tumorcellen te detecteren. Zowel collectieve als 
individuele invasiegebieden brachten de mesenchymale marker vimentine tot expressie met een 
frequentie van ongeveer 20 tot 80%, afhankelijk van de cellijn. Remming van de HGF signaal-
transductie route elimineerde de verspreiding van individuele cellen en verminderde collectieve 
invasie, wat een verschil in gevoeligheid voor gerichte interventie aangeeft. HGF induceert dus 
EMT samen met collectieve, proteolytisch-amoeboïde en somsmesenchymale invasie, wat EMT 
aanduidt als een mogelijk moleculair programma dat betrokken is bij elke invasiestrategie.
Fluorescentie gestuurde chirurgie (FGS) met als doel de tumormarge te identificeren is de meest 
veelbelovende strategie ter verbetering van routine klinische chirurgie. Tijdens FGS worden 
tumor- specifieke antilichamen geconjugeerd met een nabij-infrarood fluorofoor en intraveneus 
geïnjecteerd. Zij accumuleren in de tumor laesie en kunnen worden gevisualiseerd met behulp van 
een intraoperatief beeldvormingssysteem. Tumor-specifieke antilichamen en detectiestrategieën 
zijn echter nog in ontwikkeling en door het combineren van fluorescentie met bijvoorbeeld CO2 
laserchirurgie, kunnen fluoroforen verbleken en het signaal uitdoven. Daardoor is het belangrijk 
de effectiviteit van CO2 laserchirurgie in combinatie met FGS te onderzoeken.
Op basis van een literatuuronderzoek naar potentiële oppervlaktemoleculen gevolgd door 
immunohistochemische en functionele validatie, identificeren wij in hoofdstuk 4 CD44v6 als 
antigeen dat op betrouwbare wijze tot expressie wordt gebracht in de invasiezone van HHPCC 
tumoren. Monoklonaal anti-CD44v6 antilichaam BIWA werd gebruikt voor nabij-infrarood fluo-
rescentiedetectie in een reeks menselijke HHPCC cellen en een lokaal invasief tumor muismodel. 
BIWA detecteerde nauwkeurig menselijke HHPCC xenotransplantaten in muizen met een uitste-
kende signaal - ruis verhouding en lage opname in het weefsel rond de tumor en andere organen. 
Dit was voldoende om tumorgedeelten kleiner dan 1 mm, bestaande uit een paar duizend cellen, 
onder klinische condities zichtbaar weer te geven. De gegevens duiden aan dat CD44v6 een 
geschikt doelwit is voor betrouwbare detectie van invasieve regio’s in HHPCC tumoren in vivo.
In hoofdstuk 5 laten wij zien dat de bestraling door de CO2 laser in vitro niet significant in-
terfereert met het fluorescentiesignaal in het zichtbare en nabij-infrarode lichtspectrum. Verder 
waren specifieke fluorescentiesignalen in een FGS muismodel 1000 keer sterker dan door laser 
geïnduceerde auto-fluorescentie in muizenweefsel. Deze bevindingen duiden op compatibiliteit 
van CO2 laserchirurgie en FGS.
SSamenvatting | 145
hoofdstuk 6 bespreekt de relevantie van celinvasie strategieën voor de verspreiding van lokale 
tumor cellen, de uitdagingen van de plasticiteit van tumorcelmigratie bij de behandeling van kanker 
en perspectieven voor het doelgericht bestrijden van kanker door chirurgische en moleculaire 
therapie.
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ZuSaMMenfaSSunG
Kopf-Hals-Plattenepithelkarzinome (head and neck squamous cell carcinoma, HNSCC) sind eine 
Gruppe von Tumoren, die ihren Ursprung in den Schleimhautoberflächen des oberen Aerodiges-
tivtraktes haben. Trotz jüngster Bemühungen entwickeln noch immer 40 – 50% der Patienten 
tödliche Rezidive und Metastasen. Eine Ursache dafür ist die hohe lokale Invasion in das umlie-
gende Gewebe, was zur Behandlung oft radikale Operationen erfordert. Diese führen häufig zu 
einem Verlust von gesundem, funktionalem Gewebe mit klinisch relevanten Komplikationen und/
oder einer unvollständigem Entfernung des Tumors. Um die Krebsbehandlung zu verbessern ist 
es daher wichtig, die Grundlagen der Tumorzellinvasion von Kopf-Hals-Plattenepithelkarzinomen 
zu verstehen und die chirurgischen Eingriffe zu optimieren.
Studien von Kopf-Hals-Plattenepithelkarzinomen haben Signalwege von Wachstumsfaktoren 
und Zytokinen identifiziert die zur Karzinogenese und Invasion beitragen. In der Tumorzelle 
beeinflussen sie Transkriptionsprogramme wie die Epithelial-mesenchymale Transition (EMT) und 
können so alle bekannten Formen von Zellmigration induzieren. Dazu gehört die Wanderung von 
Einzelzellen, die keine Verbindung mit benachbarten Zellen eingehen oder kollektive Wanderung, 
bei der sich Zellen als zusammenhängende Gruppen mit Zell-Zell-Adhäsionen fortbewegen. 
Zusätzlich zu der Induktion von Invasion können Wachstumsfaktoren und Zytokine eine Interkon-
version der Tumorzellwanderung verursachen, die sogenannte Plastizität der Invasion. Wie jedoch 
diese Invasionsplastizität durch die Umgebung des Tumors räumlich und zeitlich kontrolliert wird 
und ob die Hemmung von Wachstumsfaktor- und Zytokinsignalwegen die Plastizität hemmen 
kann, bleibt ungeklärt.
kapitel 1 gibt eine Einführung in die Thematik und stellt die Gliederung der Arbeit vor.
In kapitel 2 werden die aktuellen Konzepte und funktionalen Konsequenzen der Signaltrans-
duktion von Wachstumsfaktoren und Zytokinen in funktionelle „Module“ gruppiert, die ent-
scheidend sind für die Wahl zwischen einem individuellen oder kollektiven Invasionsprogrammes. 
Anhand gut dokumentierter Beispiele, die diese Konzepte unterstützen, werden Einflüsse auf 
Zell-Matrix-Adhäsion, Zell-Zell-Interaktion, Zytoskelettdynamik und die Veränderung der ex-
trazellulären Matrix beschrieben. Um die Mechanismen der Invasionsplastizität und möglicher 
Interventionsziele besser zu verstehen, ist eine Kombination aus zellbasierten In-vitro-Studien, 
präklinischen Mausmodellen, klinischer Studien und mathematischen Modellen notwendig. 
Dann kann das Zusammenwirken von Wachstumsfaktoren und Zytokinen analysiert werden und 
spezifische Therapie zur Krebsbehandlung herausgearbeitet werden.
Fibroblasten sezernieren als Teil des Tumorstromas Wachstumsfaktoren und Zytokine. kapitel 3 
beschreibt die gleichzeitige Induzierung kollektiver Migration sowie Einzelzellmigration durch 
Fibroblasten in HNSCC-Zellen in einem 3D Kollagen-Sphäroid-Invasionsmodell. In Fibroblasten-
konditioniertem Medium verursacht hauptsächlich Hepatozyten-Wachstumsfaktor (hepatocyte 
growth factor, HGF) diese Invasion. Darüber hinaus sorgt eine ansteigende Konzentration von 
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Fibroblasten-konditioniertem Medium, HGF oder dem epidermalen Wachstumsfaktor für einen 
Übergang von kollektiver zur Einzelzellwanderung. Die Mehrheit der sich ablösenden Zellen 
entwickelte eine runde, amöboide Wanderung. Jedoch untypisch für amöboide Wanderung de-
gradierten diese Zellen das Kollagen und waren somit abhängig von Matrix-Metalloproteinasen. 
Um die biochemische Analyse ganzer Zellpopulationen zu vertiefen, wurde eine neuartige 3D-
Einzelzellzytometrie entwickelt. So konnten molekulare Marker der EMT in Tumorzellsubpopula-
tionen nachgewiesen werden. Der EMT-Marker Vimentin wurde sowohl in kollektiv als auch die 
individuell wandernde Zellen exprimiert mit einer Häufigkeit von etwa 20% bis zu 80% in Abhän-
gigkeit von der verwendeten Zelllinie. Die Hemmung von HGF beseitigte die Einzelzellwanderung 
und konnte die kollektive Invasion jedoch nur reduzieren. Dies deutet auf einen Unterschied in der 
Empfindlichkeit gegenüber einer gezielten Intervention hin. HGF induziert daher EMT zusammen 
mit kollektiver, proteolytisch-amöboider und weniger häufig mesenchymaler Invasion, was darauf 
hindeutet, dass EMT ein molekulares Programm ist, das mit jeder Invasionsstrategie assoziiert ist.
Als eine vielversprechende Strategie zur Verbesserung der klinischen Routine der Krebsbehand-
lung erweist sich die Fluoreszenz-gesteuerte Chirurgie, mit dem Ziel, den Tumor und Tumorrand 
zu identifizieren und sichtbar zu machen. Sie hat damit ein großes Potenzial, die Präzision der 
chirurgischen Exzision zu steuern und zu verbessern. Während der Fluoreszenz-gesteuerten 
Chirurgie werden tumorgerichtete Antikörper, die mit einem Nahinfrarot-Fluorophor konjugiert 
sind, intravenös injiziert, welche sich dann in der Läsion ansammeln und unter Verwendung eines 
intraoperativen Bildgebungssystems sichtbar gemacht werden können. Die Art der Biomarker und 
Detektionsstrategien sind jedoch in der Entwicklung und bei Kombinationen von Fluoreszenz-
gesteuerter Chirurgie mit anderen Operationsarten, wie die CO2-Laserchirurgie, könnte der Laser 
Fluorophore bleichen und das Signal schwächen. Daher ist es unsicher, ob CO2-Laserchirurgie 
effektiv mit Fluoreszenz-gesteuerter Chirurgie kombiniert werden kann.
Basierend auf einer Literaturstudie zu möglichen Oberflächenmolekülen, gefolgt von einer 
immunhistochemischen und funktionellen Validierung, wird in kapitel 4 CD44v6 als Antigen 
identifiziert, welches in der Invasionszone von HNSCC-Tumoren zuverlässig exprimiert wird. Der 
monoklonale Anti-CD44v6 Antikörper BIWA wurde für den nahinfrarot-Fluoreszenznachweis in 
einer Reihe von humanen HNSCC-Zellen und einem lokal invasiven präklinischen Krebsmodell 
verwendet. BIWA konnte humane HNSCC-Xenotransplantate in Mäusen mit ausgezeichnetem 
Signal-Rausch-Verhältnis und geringer Aufnahme im krebsfreien Gewebe und anderen Organen 
genau nachweisen. Das Signal war ausreichend um Tumorgewebe unter 1 mm Durchmesser, wel-
ches aus einigen tausend Zellen bestand, unter klinisch ähnlichen Bedingungen zu detektieren. 
Diese Daten deuten somit darauf hin, dass CD44v6 für eine zuverlässige Nahinfrarotdetektion 
von invasiven Rändern von HNSCC-Tumoren ein geeignetes Zielobjekt ist.
In kapitel 5 wird gezeigt, dass die Bestrahlung mit einem CO2-Laser das Fluoreszenzsignal im 
sichtbaren und nah-infraroten Lichtspektrum in vitro nicht signifikant stört. Darüber hinaus war das 
spezifische Fluoreszenzsignal in einem Fluoreszenz-gesteuerten Chirurgie Mausmodell tausendmal 
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stärker als die Laser-induzierte Autofluoreszenz im Mausgewebe. Diese Ergebnisse weisen darauf 
hin, dass die CO2-Laserchirurgie mit Fluoreszenz-gesteuerter Chirurgie kompatibel ist.
Die Bedeutung von Zellinvasionsstrategien für die lokale Tumorzelldissemination, die Herausfor-
derungen der Tumorzellmigrationsplastizität in der Krebsbehandlung und Perspektiven für die 
gezielte Behandlung von Krebs durch chirurgische und molekulare Therapie werden in kapitel 6 
diskutiert.
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